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Improving The Usage Of Unnatural Amino Acids In Proteins: Thioamides And
Other Biophysical Probes
Abstract
Methods for genetically and synthetically manipulating protein composition enable a greater flexibility in
the study of protein dynamics and function. However, current techniques for incorporating biophysical
probes in the form of unnatural amino acids (Uaas) can suffer from poor yield, limited selectivity for the
desired probe, and an insufficient understanding of the impact that the probe has on protein structure and
function. Each of the studies discussed herein addresses one or more of these shortcomings in an effort
to improve the usage of Uaas in biochemistry. We have shown that using inteins as traceless, cleavable
purification tags enables the separation of full length Uaa containing proteins from their corresponding
truncation products. This method has been used to incorporate Uaas in previously unattainable positions
in a variety of proteins using a myriad of Uaas, inteins, and purification tags. In other applications, we
have used E. coli aminoacyl transferase (AaT) to selectively modify the N-termini of proteins with Uaas to
be used in native chemical ligation or “click” chemistry reactions. Finally, we have previously used
backbone thioamide modifications to enable biophysical studies of proteins by taking advantage of their
properties as fluorescence quenchers. However, the impact of thioamides on the stability of proteins rich
in secondary and tertiary structure has yet to be understood in detail. In this work, we have conducted the
most comprehensive studies to date on the effect of thioamides on the structure and thermostability of
the full-length proteins, using calmodulin and the B1 domain of protein G. We have found that the
thioamide can have destabilizing, neutral, or even stabilizing effects depending on the position of
substitution within alpha-helical and beta-sheet folds. Moreover, the advances we have made in thioamide
peptide synthesis and protein ligation will enable us to install thioamides with increased efficiency,
permitting the first syntheses of proteins with multiple thioamides. In general, by working at the interface
of several protein modification technologies, we have developed rigorous methodologies for the
incorporation of side chain and backbone modifications while scrutinizing the effects that these
modifications may have on protein structure and stability.
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ABSTRACT
IMPROVING THE USAGE OF UNNATURAL AMINO ACIDS IN PROTEINS: THIOAMIDES AND
OTHER BIOPHYSICAL PROBES
Christopher R. Walters
E. James Petersson

Methods for genetically and synthetically manipulating protein composition enable
a greater flexibility in the study of protein dynamics and function. However, current
techniques for incorporating biophysical probes in the form of unnatural amino acids
(Uaas) can suffer from poor yield, limited selectivity for the desired probe, and an
insufficient understanding of the impact that the probe has on protein structure and
function. Each of the studies discussed herein addresses one or more of these
shortcomings in an effort to improve the usage of Uaas in biochemistry. We have shown
that using inteins as traceless, cleavable purification tags enables the separation of full
length Uaa containing proteins from their corresponding truncation products. This method
has been used to incorporate Uaas in previously unattainable positions in a variety of
proteins using a myriad of Uaas, inteins, and purification tags. In other applications, we
have used E. coli aminoacyl transferase (AaT) to selectively modify the N-termini of
proteins with Uaas to be used in native chemical ligation or “click” chemistry reactions.
Finally, we have previously used backbone thioamide modifications to enable biophysical
studies of proteins by taking advantage of their properties as fluorescence quenchers.
However, the impact of thioamides on the stability of proteins rich in secondary and tertiary
structure has yet to be understood in detail. In this work, we have conducted the most
comprehensive studies to date on the effect of thioamides on the structure and
vii

thermostability of the full-length proteins, using calmodulin and the B1 domain of protein
G. We have found that the thioamide can have destabilizing, neutral, or even stabilizing
effects depending on the position of substitution within alpha-helical and beta-sheet folds.
Moreover, the advances we have made in thioamide peptide synthesis and protein ligation
will enable us to install thioamides with increased efficiency, permitting the first syntheses
of proteins with multiple thioamides. In general, by working at the interface of several
protein modification technologies, we have developed rigorous methodologies for the
incorporation of side chain and backbone modifications while scrutinizing the effects that
these modifications may have on protein structure and stability.
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CHAPTER 1:
INTRODUCTION TO CURRENT PROTEIN MODIFICATION TECHNIQUES AND
SYNTHESIS OF THIOAMIDE CONTAINING PROTEINS

1

Section 1.1 - Introduction to Protein Structure and Function
The structural and functional characterization of macromolecules such as
DNA, RNA, and proteins has vastly expanded our understanding of fundamental
cellular processes in biology. Genetic information is stored and transmitted by DNA
and RNA, whereas proteins carry out nearly all of the chemical transformations
and functional tasks necessary for cells to maintain homeostasis.1, 2 Proteins are
sequences of amino acids strung together linearly, which can arrange into larger,
complex structural motifs. According to the Anfinsen hypothesis3, protein
architectures (i.e. folds or conformations), are encoded by the identity of the amino
acids in the protein sequence. The amino acid sequence can drive this folding
event through local and global amino acid interactions in the form of intricate
hydrogen bonding networks, removal of hydrophobic groups from bulk solvent
(water), van der Waals forces, salt bridges, covalent bonds (e.g. disulfide bonds),
and even weak electronic interactions (nàπ*).4-6 Helical and sheet-like motifs,
(dubbed secondary structure) resulting from these interactions can arrange into a
vast array of architectures (tertiary and quaternary structure) that enable a
functional task or chemical reaction to be carried out by the protein. The folding
process itself is fast (microseconds to hours in vitro) due to the low free-energy
changes and small activation barriers often associated with individual folding
steps.7,
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Additionally, local interactions of amino acids essentially limit the

conformational space a protein can explore. These two factors enable small
thermodynamically favorable folding events to “funnel” the protein to a global
energy minimum generally corresponding to its folded state (Figure 1-1).
2

Generic Protein
Folding Landscape

Figure 1-1: Global protein folding landscape depicting the distinct intermediate states that occur as the
9
protein is ‘funneled’ to its native conformation. Figure adapted from work by Splettstoesser.

Although the widely accepted dogma from Anfinsen postulated that a single
sequence specified a single fold for a protein, many proteins that toggle between
multiple folded structures have been described in the literature.5,

10-12

This

discrepancy, along with the general complexity of protein structure, makes
predicting the structure and function of proteins based upon sequence alone a
complex task. One must also consider that proteins are dynamic macromolecules
that change their conformations based upon their bulk chemical environment
(cellular environment or in vitro buffer conditions) or ligands to which they are
covalently or electrostatically bound. These factors make mapping the dynamic
processes and nano-scale movements of proteins, a challenging problem in
biology and chemistry.
There are a nearly unfathomable number of proteins that exist in nature.
Yet, for the proteins that have been isolated, structural and dynamic details are
constantly in flux, largely due to the continual advancements in methods used to
study macromolecules. These studies have implications for human health, as
3

misfolded and aggregated proteins are the underlying cause of many inherited,
neurodegenerative, and infectious diseases. These diseases include, but are not
limited to: Cruzfeldt-Jakob disease, Alzheimer’s disease, Parkinson’s disease,
Bovine spongiform encephalopathy (mad cow disease) and Amyotrophic lateral
sclerosis.13

Figure 1-2: The folding and misfolding landscape that can lead to disease state aggregated protein
14
structures in the diseases described above. Figure adapted from work by Stefani.

Understanding the structural and dynamic characteristics of proteins can
not only provide understanding as to how proteins misfold, but also insight into the
design of therapeutic molecules for disease treatment and prevention. Additionally,
protein targets in cancers and pathogenic diseases require a detailed
understanding of the protein’s architecture to design molecules with highspecificity to only that protein target. Finally, understanding the link between
sequence, structure, dynamics, and function will allow scientists to engineer

4

proteins for biocatalysis in synthetic applications, and in the future design de novo
proteins for applications of their choosing.
Section 1.2 - Techniques to Observe Protein Structure, Function, and
Dynamics
As mentioned previously, a protein’s fold can vary with chemical
environment. Therefore, techniques for studying protein structure and dynamics
should allow for mimicry of the native cellular environment as much as possible.
Small disruptions to the chemical environment such as changes in salt
concentration, solvent, pH, and concentration of the protein itself may induce nonnative folds.6 To achieve atomic resolution of protein structures, X-ray
crystallography and nuclear magnetic resonance (NMR) spectroscopy have been
used to great effect. Indeed, as of 2017, more than 130,000 high-resolution
structures of proteins have been deposited online in the protein data bank (PDB).15
Yet, only proteins that can effectively crystallize can be studied by X-ray diffraction,
making it difficult to obtain structures of proteins that contain highly flexible,
dynamic regions. Crystallography also inherently limits these studies to static
snapshots of the protein that lack dynamic information and implicit hydrogen atom
assignments.16 However, NMR can often be used in the determination of structural
and dynamic information of an ensemble of protein conformations in solution,
without the need for crystal lattices. For precise structure determination, NMR
requires the isotopic labeling of proteins with
impractical on large scales.17,

18

13

C and

15

N isotopes, which can be

NMR also generally has limitations in the

molecular weight of proteins that can be studied in solution (<40 kilodaltons), as
5

large isotopically labeled proteins lead to distorted signals due to long rotational
tumbling times, thereby making the reconstitution of protein structures difficult.19
For higher molecular weight structures and protein complexes, electron
microscopy (EM) could also theoretically be used to determine protein structure.2022

Yet, atomic resolution in EM is still difficult to achieve, with technical limitations

enabling a threshold of 3-4 Å resolution.23
In vitro studies are empowering in understanding protein function, structure,
and dynamics. However, developing in vitro methods that can be recapitulated in
vivo may provide even more valuable tools for studying protein folding and
dynamics in more meaningful contexts.24 Most notably, fluorescence studies of
proteins can enable an array of biophysical experiments not accessible by X-ray
crystallography, NMR, or EM. These experiments are at the sacrifice of lower
structural resolution, but can be performed on much lower concentrations of
protein (≤ 1 µM), giving them a distinct advantage over X-ray diffraction and NMR.
Only three naturally occurring amino acids are fluorescent: Phe, Tyr, and
Trp. However, the low quantum yield and near-UV absorbance properties of these
amino acids makes them of limited utility in studying proteins in cells.25, 26 One
major class of fluorescent probes are fluorescent proteins, established with the
isolation of green fluorescent protein (GFP) from the jellyfish Aequorea Victoria.27
The protein is 240 amino acids in length and forms an 11-strand β-barrell that
contains the chromophore 4-(p-hydroxybenzylidene)-imidazolidin-5-one. This
chromophore forms post-translationally from a Ser-Tyr-Gly tripeptide motif that is
only fluorescent within the folded core of GFP. As a fluorescent probe for
6

is often constrained by the chemistry necessary to install a fluorescent probe, the size of
biophysical studies,
GFP can be genetically encoded at the C- or N-terminus of
the probe, or the location of the probe’s installation on the protein. Development of

any protein without
themodifications
need for
specialized
or additional
fluorescent
for proteins
has yielded atranslational
broad suite of probesmachinery
and methods
that are as structurally and spectroscopically diverse as the applications for which they

reagents. GFP was first recombinantly expressed in E. coli in 1992 and saw its first
were designed.

in vivo use in the female germ cells of Drosophila to study the role of the exu protein
in oogenesis in FLUORESCENCE
1994.28, 29 AS A MINIMALLY PERTURBING METHOD FOR
MONITORING PROTEIN DYNAMICS

Gly67

Tyr66

HO

O

O

N

N
N
H

OH

Ser65

4-(p-hydroxybenzylidene)imidazolidin-5-one
chromophore

Green Fluorescent
Protein

Figure 1-3: GFP (left) showing its characteristic β-barrel structure and chromophore (right) formed from
Ser65, Tyr66 and Gly67.

Since then, GFP has seen remarkable improvements and modifications
Figure 1.1: Chromophore Size. Space-filling renderings of several chromophores, based on either crystal
including different
emission and excitation wavelengths, enhanced brightness, pH
structures or ab initio calculations. The green fluorescent protein (GFP) was rendered from PDB ID 1GFL9.

30-33
benzylated SNAP tag protein wasvariants.
rendered from PDB
ID 3L00
(S. Schmitt,
B. Mollwitz,
F. Pojer,been
M.
resistance, andThephotoactivatable
There
have
even
split GFP
4
tags attached to two protein targets where
assembly of the chromophore

containing β-barrel only occurs when two proteins of interest (POIs) bearing the
tag come into contact with one another.34 This has been used to great effect in
mapping neuronal networks in response to stimuli in Drosophila.35 As an in vitro
probe, GFP has been used in a variety of techniques that include Förster
resonance energy transfer (FRET) with other GFP variants, fluorescence
correlation spectroscopy, fluorescence recovery after photobleaching, and even
super-resolution techniques, such as stimulated emission depletion microscopy
7

and photoactivated localization microscopy.36-38 For all the gains in understanding
of biological processes GFP has provided, its usage is inherently limited by its size.
Fusing GFP to a protein of interest could disrupt the processes one wishes to
observe, especially when the protein is of similar or smaller in size than the GFP.
This size also makes it difficult to monitor smaller dynamic movements of the
protein that may be captured in high-resolution techniques like NMR. Additionally,
photostability of GFP is an issue; GFP readily photobleaches, making small
molecule fluorophores that have better photostability more desirable.
Genetically encoded proteins that can be covalently linked with fluorescent
small molecules can provide an alternative to fluorescent proteins. Several
modified enzymatic tags have been developed to this end, with SNAP-tag, CLIPtag, and HALO-tag being the most widely used. SNAP-tag is a mutant of the
enzyme O6-alkylguanine-DNA alkyltransferase that can recognize and covalently
link to benzylguanine groups with high specificity.39 Similarly, CLIP-tag uses a
modified enzyme to covalently bond with benzylcytosine substrates.39 HALO-tag
utilizes a mutant haloalkane dehalogenase to covalently link to an alkyl chloride
substrate.40 Here, any synthetic, small molecule fluorophore can be chosen by the
user, provided that they can be synthesized as benzylguanine, benzylcytosine, or
alkyl chloride derivatives. This allows for fluorescently tagged proteins with a larger
range of spectrochemical properties, but these proteins are again large in size (~20
kDa) and may influence the dynamics, fold, and function of the proteins they are
attached to.
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Figure 1-4: SNAP-Tag (left) and CLIP-Tag (right) attached to a protein of interest (POI). Labeling reactions
proceed through covalent modification of a Cys residue with fluorescently tagged (red stars)
benzylguanosine and benzylcytosine substrates, respectively.

The restrictions of these fluorescent and taggable proteins that arise from
their size can be overcome by finding methods to modify single or multiple amino
acids as local “tags” to enable tracking of smaller dynamic movements. By making
changes at specified amino acid locations, one can potentially minimize the nonnative perturbations these probes have on protein structure. Modifications at amino
acids also enable site-specific molecular contacts to be mapped in protein-ligand,
intermolecular protein-protein, and intramolecular protein domain interactions.41
The remaining portion of this introduction will focus on the site-specific
incorporation of canonical and non-canonical mutations to proteins and how these
modifications have enabled a wide array of protein engineering, therapeutic
development, and biophysical structure/function studies of POIs.
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Section 1.3 – Amino Acid Modifications and Chemoselective Reactions for
the Labeling and Biophysical Studies of Proteins
Modifications to the side chains and backbones of amino acids is one of the
most powerful and widely used strategies available to protein scientists.
Technologies enabling chemical changes to side chains give access to sitespecifically installed post-translational modifications (PTMs), biophysical probes,
affinity tags, and many other modifications.24 These changes can enable the study
of protein folding as it relates to disease, protein-protein interactions in proteomics
applications, protein engineering, and various other applications. This section
briefly summarizes the types of side chain modifications that are of use to the
biochemical community, with a focus on those that enable biophysical studies of
protein folding and misfolding phenomena.
Post-translational Modifications
PTMs are modifications that can be transferred to side chains containing
functional groups either co-translationally or after the protein is released from the
ribosome. These modifications can be as small as methyl groups or as large as
small proteins and have been found to occur on the side-chains Arg, Asn, Cys,
Gln, Glu, His, Lys, Pro, Ser, Thr, Trp, and Tyr.42 The most common PTMs are (in
order of occurrence) phosphorylation (Ser, Thr, Tyr, His, Lys, and Arg), acetylation
(N-terminus, Lys), N-linked glycosylation (Asn), amidation (N-terminus, Asp, Glu,
and Cys), hydroxylation (Lys or Pro), methylation (Arg or Lys), O-linked
glycosylation (Ser or Thr), ubiquitylation (Lys), and sulfation (Tyr).42 These
modifications often control the enzymatic activity of central metabolic enzymes,
10

highlighting their functional importance in regular cellular processes. The
installation of site-specific PTMs both in vitro and in vivo has enabled researchers
to map the functional relevance of single or multiply modified proteins without
complications from undesired off-target PTMs. These studies include the
interactions of histones with chromatin, nuclear transport processes via GTPase
acetylation, and the ubiquitylation processes of many other proteins, along with a
myriad of other studies.43 Additionally, amino acids bearing non-hydrolyzable
mimics of PTMs have been used to decipher cell signaling pathways.44 PTMs are
naturally occurring modifications that can inform about enzymatic and cellular
processes in general, but an additional repertoire of amino acid side chain variants
are necessary if one wishes to deconvolute specific, complex biochemical
interactions in detail.
Fluorescent Amino Acids
One class of Uaas that can assist in the tracking of protein trafficking and
protein-protein interactions are fluorescent amino acids. These amino acids
contain, in general, polyaromatic side chains with varying fluorescent properties.
To date, several classes of fluorescent molecule cores have been synthesized as
amino acids and incorporated into proteins such as: coumarins, phenylalanine
derivatives, acridones, naphthalenes, dansyls, and others.24 Fluorescent amino
acid scaffolds can be chemically modified to enhance the properties desired for a
chosen experimental technique. Properties of interest are the wavelength of
excitation and emission maxima, extinction coefficient (ε), quantum yield (Φ),
11

fluorescence lifetime, pH dependent fluorescence and in the case of dansyl and
naphthalene derived scaffolds, solvatochromatic shift.45-47
Canonical Fluorescent Amino Acids
HO
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Trp

Tyr

Unnatural Fluorescent Amino Acids
N
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O

CN

O
O

O S O
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DansA

HN

NC
HN

HN

Anap

Acd

Cnf

TrpCN

Figure 1-5: Top: Fluorescent canonical amino acid side chains phenylalanine (Phe), tyrosine (Tyr), and
tryptophan (Trp). Bottom: A non-exhaustive list of example fluorescent unnatural amino acids including (7methoxy-coumarin-4-yl)-alanine (Mcm), dansyl alanine (DansA), 6-propionyl-2-(N,N-dimethyl)aminonapthalene (Anap), acridon-2-ylalanine (Acd), 4-cyano-phenylalanine (Cnf), and 5-cyano-tryptophan
(TRPCN).

Fluorescent Uaas generally have more ideal properties for biophysical
studies than the naturally occurring fluorescent amino acids Phe, Tyr, or Trp.
Furthermore, the sidechains are often small enough that it is unlikely they will
provide the perturbations to protein structure that are more commonly associated
with fluorescent proteins. One can use fluorescence quenching studies such as
Förster resonance energy transfer (FRET) or photoinduced electron transfer (PeT)
to obtain distance dependent measurements between side-chains, enabling
intramolecular and intermolecular contacts to be deconvoluted using minimal
modifications to the protein.48 Other applications of fluorescent amino acids include
12

metal-binding studies and cellular and subcellular localization studies through the
use of fluorescence microscopy.49 However, many of these fluorescent Uaas have
short excitation wavelengths, making them non-ideal for uses in vivo as UV
irradiation can damage cells.50 Yet, derivatization of fluorescent amino acid cores
and improved rational design of fluorescent molecules means there is sufficient
variety such that one can often choose an amino acid with properties appropriate
for the application at hand.
Photocrosslinking Amino Acids
Sidechains bearing UV-activatable photocrosslinkers may be valuable in
identifying protein binding partners and determining a residue’s role in proteinprotein or protein-ligand interactions. In total, cohorts of UV-crosslinking studies
can generally inform on the global topographical positioning of protein-protein
interactions. The light triggered reaction allows for temporal and spatial control of
the reaction, providing several advantages over chemical crosslinking methods.41
Several classes of photocrosslinkers are available, with the most common being
p-benzoyl-phenylalanine (Bpa), which can trap protein-protein or protein-ligand
interactions through insertion of the benzophenone diradical into C-H bonds in both
proteins and DNA.51, 52 Additionally, aziridine containing lysine, phenylalanine, and
methionine-like residues, along with p-azidophenylalanine (Azf), can eliminate
nitrogen in a phototriggered process to form a carbene or nitrene intermediate,
which can insert into C-H, N-H, or O-H bonds.41 These photocrosslinking amino
acids have been used in detailing protein-DNA binding sites in chromatin-histone
13

interactions, showing contacts between the active mitochondrial protein
translocation gate (TOM complex) and its translocating substrates, as well as
giving quantitative readouts on a host of histone modifications that controlled
chromosome hypercondensation during mitosis.53-55 The broad usage of
photocrosslinking amino acids amongst varied protein-protein and protein-DNA
substrates shows their versatility in biochemical studies. However, the resulting
covalent linkage between the two interacting molecules is irreversible, making
binding-dissociation studies unfeasible. As with many of the fluorescent probes,
these amino acids require near-UV light to generate the radical crosslinking
species, making them difficult to use in vivo due to cellular toxicity. Despite this
limitation,

there

have

still

been

several

studies

performed

where

photocrosslinkning has been done in vivo using short irradiation times.56, 57
Photocrosslinking Amino Acids
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Figure 1-7: Commonly used photocrosslinking amino acids for covalently linking intermolecular or
intramolecular contacts of proteins. From left to right: p-benzoyl-phenylalnine (Bpa), p-azidophenylalanine
(Azf), 4’-(3-trifluoromethyl)-3H-diazirin-3-ylphenylalanine (TmdPhe), photo-methionine (PhotoMet), and
photo-lysine (PhotoLys).
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Each of the aforementioned amino acid derivatives (PTMs, fluorophores,
and photocrosslinkers) have stand-alone functional groups enabling the probing of
biochemical phenomena. However, size and functional group identity may make
the cotranslational introduction of these amino acids difficult (see Section 1.3 on
genetic code expansion). Additionally, it may be useful to temporally or spatially
control the addition of a modification to the side-chain of an amino acid embedded
in a protein to capture a desired process or biomolecular interaction. The
burgeoning field of chemoselective reactions for protein labeling has provided a
host of new techniques enabling the post-translational insertion of virtually any
probe for these types of applications.
Cysteine Mediated Labeling of Proteins
One strategy for installing unnatural functionalities on side-chains of amino
acids is cysteine (Cys) mediated conjugation. Site-selective modification can be
achieved by genetically encoding a Cys residue at virtually any position within a
protein. Linkages to the Cys sulfur can be performed by disulfide formation with
the target modification or through simple alkylation via a SN2 reaction with an alkyl
halide.58 However, these reactions may be difficult to control and may lead to off
target labeling of protein substrates, especially when a protein contains multiple
Cys residues. Cys can also be converted to dehydroalanine through treatment with
α,α’-dibromo-adipyl(bis)amide.59 This dehydroalanine can then be selectively
labeled with alkyl halides through a radical initiated process.60 This is a versatile
method for post-translationally modifying the protein but leads to racemization of
the target amino acid site.
15
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Figure 1-8: Site selective modifications of cysteine residues as discussed in the text. The modification (red
star) can be an array of fluorophores, affinity handles (e.g. biotin), and in alkylation, disulfide, and
dehydroalanine labeling reactions, post-translational modification mimics.

Cys residues are sufficiently ‘soft’ nucleophiles that they can undergo 1,4conjugate addition with α, β-unsaturated carbonyls. The most widely used method
for labeling Cys is the Michael addition of the Cys sulfur to a maleimide, which can
contain the desired biochemical or biophysical probe linked to the maleimide
nitrogen.61 Cys-maleimide reactions have been used in the conjugation of
therapeutic small molecules to antibodies, fluorescent dyes to proteins for
16

fluorescent tracking, and biotin to proteins of interest for streptavidin pull-down
studies.61 Additionally, Pentelute and coworkers have devised nucleophilic
aromatic substitution reactions using polyfluorinated aromatic probe molecules as
a selective Cys labeling method in Phe-Cys-Pro-Phe labeling tags.62 Buchwald
and Pentelute have even ambitiously pioneered the palladium based crosscoupling of the Cys thiol to aryl halides.63 However, in each of these strategies, it
is difficult to control site-specific Cys conjugation in proteins that contain other
native Cys residues. Additionally, the Cys residue must be sufficiently solvent
accessible for an encounter with the target labeling molecule. Since Cys has a low
natural occurrence in proteins64, may perturb the structure of the protein at point
mutant insertion points65, or cause unwanted disulfide formation, other more
selective protein conjugation reactions have been developed.
Chemoselective Reactions Using Non-native Functional Groups
Chemoselective reactions using Uaas must meet the following criteria: 1)
the functionality installed in the protein and the probe must react with one another
selectively in the presence of all other chemical functionalities observed under
physiological conditions, 2) the reaction products contain a covalent linkage that is
stable, and 3) byproducts or reagents used in the reaction must not interfere with
the function of the biomolecule or the processes to be studied.24 If these criteria
are met, a single chemical reaction can theoretically be used for labeling a diverse
set of biomolecules with virtually any probe both in vitro and in vivo.58 Additional
criteria that may be desired for individual applications are fast kinetic rates of the
labeling reaction, low cytotoxicity for in cellulo studies, and few equivalents of
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probe molecule necessary for complete labeling, among others. Owing to their high
chemoselectivity in the presence of all other biologically relevant functional groups,
these reactions are more colloquially referred to as ‘click’ chemistry reactions, a
term coined by B. Sharpless in 1998.66
Perhaps the most powerful and popular development in chemoselective
reactions came when azide-alkyne [3+2] cycloadditions were first applied to
biological systems (see Figure 1-9). First described in the mid-20th century, this
cycloaddition required high temperature and pressure to form the triazole
product.67, 68 However, in 2002, the catalysis of this reaction by copper(I) salts
using terminal alkynes and azides was first described for the selective formation
of 1,4-disubstituted 1,2,3-triazoles.69-71 Azides and alkynes are generally stable
under physiological conditions, are not found in biochemical systems, and are
synthetically accessible when functionalizing probe molecules. The Cu(I)
catalyzed reaction is also faster in water than in organic solvents, however for
cellular applications, Cu(I) has shown high cytotoxicity in both mammalian and
bacterial cells due to the copper mediated generation of reactive oxygen
species.72, 73 Unfortunately, azide-alkyne cycloaddition rates decrease to unusable
levels when limiting the amount of copper catalyst, making the reduction of Cu(I)
species not a viable strategy for limiting toxicity when labeling proteins in cellulo.74
However, many water soluble Cu(I) ligands, such as tris[(1-hydroxypropyl-1H1,2,3-triazol-4-yl)methyl]amine (THPTA), have been applied to this methodology
to increase reaction rates and limit the amount of free copper necessary for the
reaction to occur.75 In fact, routine Cu(I) mediated ‘click’ reactions often have rate
18

constants of the magnitude of 105 M-1 s-1. However, in many cases cytotoxicity is
still an issue and the copper salt may also induce off target pathway activation that
may interfere with physiologically relevant studies. Nonetheless, the landmark
development in the use of Huisgen cycloaddition reactions is one of the most
effective chemoselective reactions for the in vitro labeling of biomolecules, where
toxicity is not a factor. Indeed, these labeling reactions have spanned a variety of
substrates on viruses, proteins, lipid membranes, and nucleic acids.24
To circumvent the need for copper in ‘click’ chemistry reactions, Bertozzi
and coworkers used a strained alkyne (difluorooctyne) to chemoselectively react
with a terminal azide.76, 77 The destabilization of the alkyne through ring-strain and
the electronic induction of the geminal difluorine motif provide the driving force for
the reaction. Other octynes, including dibenzocyclooctynes (DBCO) and
biarylazacyclooctynes (BARAC), have been used in these “strain promoted
alkyne-azide cycloadditions (SPAAC).” However, these reactions are generally
slower than the Cu(I) mediated reactions by several orders of magnitude (k = ~0.2
M-1 s-1) and the synthesis of octyne containing probes for labeling proteins can
often be challenging.78,

79

Thus, alternative cycloaddition reactions have been

investigated for their use in ‘click’ chemistry.
Although many other variations on these cycloaddition reactions have been
used for chemoselective labeling of biomolecules, the fastest strain-promoted,
metal free reaction to date is the strained alkene/alkyne-tetrazine reaction. These
inverse-electron-demand Diels-Alder [4+2] cycloadditions can have rate constants
on the order of 103-104 M-1 s-1 in the cases of substrates such as norborenes and
19

trans-cyclooctenes. They produce a stable 1,4-dihydropyridizine and are
‘bioorthogonal’ to physiological alkenes.80-82 These versatile probes have now
been used to both image and modify proteins in bacteria and mammalian cells with
no apparent cytotoxicity.83,

84

Indeed, other smaller, strained alkenes, such as

methylcyclopropene derivatives, have also been used in tetrazine Diels-Alder
reactions.85 The development of faster cycloadditions that are biocompatible will
enable the usage of these probes in even more diverse settings in the future.
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Figure 1-9: Selected ‘click’ chemistry reactions. Top: Copper catalyzed Huisgen cycloaddition between
protein containing an azide and an alkyne containing probe molecule. Tris[(1-hydroxypropyl-1H-1,2,3triazol-4-yl)methyl]amine (THPTA) is used as a water soluble ligand to for the copper catalyst. Middle: Strain
promoted alkyne-azide cycloaddition (SPAAC) between a protein-azide and biarylazacyclooctyne (BARAC).
Bottom: Inverse-electron-demand Diels-Alder cycloaddition between a protein containing a transcyclooctene modified side chain and a tetrazine containing probe molecule.
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Although the focus of this section was the use of cycloaddition reactions as
chemoselective labeling methods, there have been a host of other reactions
suitable for bioconjugation. Aldehydes and ketones have been used in conjunction
with amines and hydroxylamines for reversible labeling of proteins through imine
and oxime formation.86 Additionally, aldehydes have also been used in PictetSpengler rearrangements with tryptamine bearing probes.87,

88

The aldehyde

moiety has even found use in linking proteins to phosphonium ylide containing
probes through Wittig reactions.89 In another vein, terminal azides, a functionality
that has most often been used in cycloaddition reactions, can also be treated with
phosphine reagents to undergo Staudinger reactions. The most effective example
is when the azide is treated with a phosphine reagent to form an aza-ylide, which
can subsequently rearrange to give an amide-linked bioconjugation that is free
from the phosphine-oxide byproduct.90 This reaction has been dubbed the
“traceless” Staudinger ligation. Finally, even organometallic cross coupling has
found use in the labeling of proteins with probe molecules.91 In one such example,
a protein containing a p-iodophenylalanine was reacted with a fluorescent boronic
acid derivative to label proteins on the surface of E. coli. This Suzuki-Miyaura
reaction can be performed in aqueous buffer at pH 8.0 with Pd(OAc)2 or Pd(NO3)2
as a catalyst. With the usage of Pd(NO3)2, these cross couplings have even shown
limited toxicity to cells.92
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Figure1-10: Wittig labeling of a protein with an alkene containing phosphonium ylide (Top) and PictetSpengler type rearrangement with a fluorophore (blue star) containing tryptamine derivative (Bottom).

With the ever-growing need to label biomolecules, it is no surprise to see
the imaginative and ingenuitive array of chemical reactions that have been
optimized for chemoselectivity in the aqueous and chemically rich environment of
proteins, cells, and even entire animal hosts. These tools are constantly improving
and with their development, protein scientists will continue to expand the
knowledge landscape of biophysics, biochemistry, and medicine at a rapidly
increasing pace.
Backbone Modifications to Amino Acids
Side chain alteration is not the only tool available for changing a peptide or
protein’s amino acid composition in order to engineer new conformations, study
folding properties, or monitor biomolecule interactions. Modifications to the protein
backbone in the form of amide isosteres or amino acids containing additional
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methylene units have been studied in detail for their propensities to fold into
ordered secondary and tertiary structures found in proteins (e.g. arranged sheets
and helices). Any set of polymers, including those which contain amino acid
backbone modifications, which have the propensity to fold into a specific compact
conformation were dubbed “foldamers” by Gelman in 1998.93
Early exploration into the design of foldamers centered around β-amino
acids, which have similar architecture to α-amino acids but contain one extra
methylene unit in the backbone. Seebach and Gelman simultaneously published
reports of β-amino acid peptides adopting helical structures in 1996.94, 95 Following
this report, substitution patterns of β-amino acids (β3, β2, and β2,3) have been
explored to gain a more comprehensive understanding of how β-amino acids affect
the folding of helical structures.96,

97

Even though they are less synthetically

accessible than their α and β counterparts, γ-amino acids have even been used in
combination with α- and β-amino acids to yield folded, stable helices.98 New
classes of cyclic β-amino acids have also been developed and can lead to distinct
changes in folding propensities depending on the site of incorporation.94, 97, 99 The
applications of foldamers are numerous, but have recently been emphasized as
possible therapeutics, due to enhanced resistance to proteolysis.100 This is clear
in the design of hormone therapeutics that have an increased half-life in vivo. A
prime example is the peptide hormone GLP-1, which can be used to treat type-II
diabetes.101, 102 In this case, αααβ substitution patterns with cyclic β-amino acids
enabled the foldamer to adopt the appropriate conformation for activity and
increased the hormone’s resistance to proteolysis.
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Figure 1-11: Selected backbone modifications as found in Reinert et al. and Gopalakrishnan et al.
Backbone modifications can be used to probe the structure and function of proteins as well as mimic protein
structure in polymer/foldamer formation.

Although β- and γ-amino acids are useful backbone alterations, additional
work has been performed by modifying α-amino acids or using amide bond
isosteres. In the former, aminoisobutyric acid (Aib), D-amino acids, N-methyl
modified, or α-peptoids have all been used to confer different folding properties to
polypeptide foldamers (see Figure 1-11). Amide isosteres such as oxoesters and
thioamides have also been used in biophysical studies as α-amino acid
replacements. More exotic isosteres including alkene, thioether, α-aza, and
triazole linkages have also found usage in foldamers as backbone amide
replacements.98 Each of these linkages have different conformational preferences,
size, chemical stabilities, and physical properties.
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Having a wide array of chemical functionalities as backbone replacements
allows the user to tailor the substitution to the desired conformation and properties
of the envisioned foldamer for applications to an array of biochemical processes.
However, there is much still to be uncovered in translating predicted and
theoretical folding properties into practical usage. αβ-mixed folds (among others,
see review from Reinert and Horne)98 have been reported by mixing canonical
amino acids with a variety of α- and β-amino acid backbone modifications. Yet,
there is still a vast amount of work to be performed before partially, or even
completely ‘synthetic’, functional proteins can be designed and engineered. For
the time being however, these backbone replacements can still be powerful tools
in studying the hydrogen bonding networks and functional importance of individual
amino acids within protein structures.
Section 1.3 – Cellular Incorporation of Unnatural Amino Acids
In order to reap the benefits of the chemoselective reactions (discussed in
Section 1.3) and apply them to protein labeling, techniques have been developed
to use endogenous cellular machinery to cotranslationally insert Uaas into growing
peptide chains. This requires that the Uaa can be recognized and faithfully
incorporated by the translational machinery. If it cannot, then extensive
engineering may be required to enable cellular incorporation in a site-specific
manner. Currently, two distinct strategies exist to accomplish cellular incorporation
of Uaas: 1) incorporation through selective pressure and 2) genetic code
expansion.
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Selective Pressure Incorporation
Selective pressure was first demonstrated in the 1950s, where total
replacement of methionine with selenomethionine was accomplished in E. coli.104
In selective pressure incorporation, the substitute amino acid (generally a Uaa)
globally replaces a natural amino acid through genetic incorporation. Additionally,
the Uaa must be a substrate of the aminoacyl-tRNA-synthetase (aaRS) that is
used for the natural amino acid’s incorporation. During expression of the protein,
the Uaa must be present within the cell at high levels to achieve quantitative
incorporation.105 Auxotrophic bacteria, which lack the components necessary for
the target amino acid synthesis, are grown in the presence of Uaa enriched media
to achieve incorporation. Auxotrophic strains of E. coli have been used in the
reassignment of Ile, Leu, Met, Phe, Pro, and Trp.24 As previously discussed, azides
and alkynes are functional groups that are desirable for ‘click’ chemistry reactions.
Selective pressure incorporation has been used to incorporate these functionalities
in place of Met, as well as Leu and Phe. Uaas with ‘click’ chemistry handles used
for incorporation at Met can be azidohomoalanine (Aha), homopropargylglycine
(Hpg), and homoallylglycine (Hag).106-108 However, there are several amino acids
that are not tolerated for replacement by cellular machinery; mutations to the aaRS
must be made to increase the scope of Uaas that can be incorporated by selective
pressure. An excellent example of this was in the mutational screening of the Phe
aaRS (PheRS) from E. coli. Here a single mutation can be made (A294G) to make
the PheRS more permissive. Overexpression of a plasmid encoding this mutant
PheRS can allow for faithful incorporation of a number of Phe cognates, such as
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p-ethynylphenylalanine and p-azidophenylalanine, each of which can be used in
the labeling of proteins via ‘click’ chemistry.109 Although used to great effect for the
substitution of canonical amino acids, site-specific changes that don’t involve
global replacement are nearly impossible to achieve with this technology. Thus,
recent efforts have been focused on the expansion of the genetic code for single
and, in some cases, multiple site-specific substitutions, while retaining all other
canonical amino acids.
Genetic Code Expansion
To expand the genetic code, one must envision the reassignment or
insertion of codons that can be translated using reconstituted translational
machinery in vitro or even in concert with canonical translation in cellulo or in vivo.
According to Lang and Chin, the three requisites of expanding the genetic code
are the generation of an aaRS/tRNA pair that can operate orthogonally to cellular
aaRS/tRNA pairs, a “blank” codon that encodes for insertion of the Uaa into the
growing peptide chain, and specificity of the aaRS/tRNA to ensure that no
canonical amino acid cognates are aberrantly incorporated.24 To achieve these
lofty goals in living cells, Peter Schultz and coworkers developed an initial method
for Uaa incorporation into proteins translated by E. coli through stop-codon
suppression in 2001.110 Here, a TyrRS/tRNATyr pair from Methanocaldococcus
jannaschii was modified to allow for the incorporation of O-methyl-tyrosine into the
β-lactamase enzyme at the site of an amber stop codon (UAG) that was inserted
in place of a codon coding for a non-essential Ala residue. The ribosome can ‘read
through’ the stop codon on the basis that the aminoacylated tRNA containing the
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Uaa has high affinity for the UAG codon even though it must compete with
termination machinery such as release factors (see Chapter 2). A number of
aaRS/tRNA pairs have now been described for this process, with the most popular
systems being the aforementioned M. jannaschii TyrRS/tRNACUA pair, the E. coli
TyrRS/tRNACUA and LeuRS/tRNACUA pairs, as well as the pyrolysylRS/tRNACUA
pair from Methanosarcinae.111

Figure 1-12: Amber stop codon suppression. An orthogonal aminoacyl synthetase-tRNA pair directs
insertion of an Acd unnatural amino acid within the protein of interest at the site of the amber termination
codon. Figure courtesy of Itthipol Sungwienwong.

Several systems now exist to allow for the evolution of these aaRS/tRNA
pairs to ensure specificity for the desired Uaa. This has enabled the incorporation
of Uaas bearing ‘click’ chemistry handles, PTMs, fluorescent side chains,
photocrosslinker side chains, and other moieties of interest for the system to be
studied. However, not every aaRS/tRNA pair can be ubiquitously used across cell
types. In point of fact, pyrolysylRS/tRNACUA is the only aaRS/tRNA pair that is
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orthogonal to cellular processes in bacterial and eukaryotic cells.112 However, in
eukaryotic and mammalian cells, transcriptional machinery is often much more
complicated than in bacterial cells and can lead to inefficient usage of stop codon
suppression. To improve and optimize the genetic code expansion methodology,
it is important that additional read through codons are developed. To this end, there
have been preliminary reports demonstrating the feasibility of using opal and ochre
codons (UGA and UAA, respectively) to direct insertion of Uaas into proteins in
cellulo.113 In an even more ambitious venture, Guo and Schultz have even shown
that four base (quadruplet) frameshift codons can be used in place of stop
codons.114
Other equally ambitious ventures using orthogonal ribosomes in E. coli have
yielded remarkable results in advancing genetic code expansion technology.115
These ribosomes can function independently to translate an orthogonal set of
genetic sequences as they are not involved in the translation of the cellular
proteome. The important application of this technology is not only the ability of this
ribosome to read through amber stop codons, but also the ability to read
quadruplet codons using an extended anti-codon system that cannot be read
efficiently by the native ribosome.
The blossoming of genetic code expansion in the last fifteen years has
enabled selective incorporation of over 100 Uaas into virtually any protein system
in a myriad of organisms for applied biochemical and biophysical studies.41
Although revolutionary in the quest for efficient Uaa incorporation methodologies,
genetic code expansion can still be difficult to use. In stop codon read through, the
29

endogenous host machinery is constantly competing for termination of protein
synthesis at the stop codon site.116,

117

Truncated protein byproducts and the

aberrant insertion of Uaas at other stop codon sites within the cell may compromise
cell-health or lead to diminished protein yield. Indeed, these challenges have still
been a major roadblock for scalable Uaa incorporation by E. coli in bioreactors for
industrial applications (e.g. Uaa containing therapeutics).118 This is especially true
for proteins where it may be advantageous to include multiple Uaas through
multiple stop codon read through events. For mammalian cells, additional
accommodations must be made when considering the delivery of genetic material
to these cells and expression levels of the aaRS/tRNA pair.119 Genetic code
expansion is becoming a more ubiquitous technology in chemical biology,
necessitating quick progress towards solutions to these problems. Additionally, as
progress in other fields of Uaa incorporation is made (e.g. protein synthesis and in
vitro enzymatic Uaa insertion), combinatorial Uaa incorporation may be possible
for systems that suffer from the few, yet important, issues that have yet to be
completely solved in genetic code expansion.

Section 1.4 – Chemical Ligation for the Synthesis of Proteins
Chemical reactions used for the formation of amide bonds or amide bond
surrogates between long protein or peptide fragments have enabled a surge in the
total chemical synthesis or semisynthesis of proteins containing synthetic
modifications that may be unachievable by other Uaa incorporation methods.
Although solid phase peptide synthesis (SPPS) has been used in many classical
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examples to synthesize a variety of proteins in their entirety120-122, it commonly
suffers from low isolated yields in targets greater than 50 amino acids in length
due to low coupling efficiencies from on-resin aggregation and sequence specific
steric interference. The development of chemoselective condensation reactions for
the ligation of peptide fragments can overcome these issues by keeping the length
of peptides generated in SPPS shorter, thereby increasing the yields of the total
synthetic process. In the following section, the scope, limitations, and
improvements of chemical ligation strategies for the synthesis of proteins will be
discussed in detail to establish a basis by which Uaas can be incorporated into
proteins through synthetic means. A thorough review of strategies for the synthesis
of proteins that do not use thiol-thioester based capture reactions (keto-acid,
Staudinger, alkyne-azide, thioether, oxime ligations, and Ser/Thr ligations, among
others) can be found in detail elsewhere.123, 124

Native Chemical Ligation (NCL)
Native chemical ligation (NCL) specifically refers to a ligation reaction in
which two protein fragments are linked together by an amide bond (i.e. a “native”
peptide bond). The ideal reaction would be performed under mild conditions, such
as low temperature, aqueous buffer, and few chemical additives. These conditions
would potentially avoid degradation of the target protein product. Because this
technique often employs protein fragments made by SPPS, any number of Uaas
may be incorporated, thereby avoiding the potential pitfalls of Uaa mutagenesis
(see Section 1.3). This methodology was first realized in a study by Kent and
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coworkers in 1994, wherein they synthesized the 72 amino acid protein target
interleukin-8 (IL-8).125 The pioneers of this technique utilized a C-terminal peptide
containing a N-terminal Cys residue as a nucleophile and a N-terminal peptide
fragment containing a C-terminal thioester as an electrophilic site. As shown in
Figure 1-13, the Cys thiol group attacks the thioester in a transthioesterification
step, liberating a free thiol. This is followed by an intramolecular SàN acyl shift to
reveal the native amide bond between the Cys residue (C-terminal fragment) and
the C-terminal residue of the N-terminal fragment. These reactions are typically
performed in high concentrations of denaturant to prevent aggregation of the
peptide fragments. A particular advantage of this method is that it can be
performed on unprotected peptides, with neither the nucleophile nor electrophile
requiring any orthogonal protecting chemistry. Additionally, thiol additives can be
used as catalysts to increase the reactivity of the thioester by exchange of the thiol
and therefore increase the yield of the reaction. Aryl thiols such as thiophenol and
4-mercaptophenylacetic acid (MPAA), are most commonly used in this capacity
however,

alkyl

thiols

such

as

benzyl

mercaptan,

sodium

2-

mercaptoehtanesulfonate (MESNa), and even 2,2,2-trifluoroethanethiol have also
been used.126-128
Since its advent, this powerful technique has been used in a myriad of
syntheses of site-specifically modified proteins for use in biophysical and
biochemical studies. Notable examples include the synthesis of phosphorylated
proteins (TGF-β)129, lipoproteins (Rab GTPase)129, acetylated and ubiquitinated
proteins (histones)130, and sulfated proteins (Madanin-1 and chimadanin)131 used
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for biochemical studies and fluorescently labeled proteins for biophysical studies
(α-synuclein).132 In even more advanced efforts, an ester bond was substituted for
an amide backbone in the bacterial KcsA potassium channel to study its effects on
ion selectivity.133 Surprisingly, this membrane protein can easily refold once
introduced to reconstituted lipid vesicles, showcasing the ability of chemically
synthesized proteins to refold under optimized induction conditions. Furthermore,
NCL has enabled the synthesis of several modified protein therapeutics, such as
a human glycosyl-interferon-β134, which may offer better homogeneity and purity
when compared to their recombinant or extracted counterparts.135, 136 NCL has
even been used in the production of functional enzymes, such as barnase first
synthesized by Dawson et al.126 However, these syntheses would not have been
possible without advances in the scope and chemical reactivity of NCL peptide
fragments, which helped to overcome the initial limitations of the NCL
methodology. For example, many proteins do not contain a Cys residue to enable
NCL. Additionally, if the protein target is large (>100 amino acids), more than one
ligation may be necessary. This requires the development of mild, orthogonal
protecting reagents for either the thiol or thioester bearing peptides. Additionally,
creation of methods that enable the production of large (>70 amino acid) protein
fragments may be necessary. Each of these limitations, and the methods that have
been developed to overcome them, are discussed in detail in the following
sections.
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Figure 1-13: Scheme for native chemical ligation. The C-terminal fragment (magenta) captures the Nterminal fragment (blue) in a transthioesterification step, followed by an irreversible SàN acyl
rearrangement to give the native peptide bond (bottom).

Expressed Protein Ligation
Expressed Protein Ligation (EPL) is the synthesis of a protein by NCL where
at least one of the fragments is produced by recombinant expression. By taking
advantage of cellular expression systems, one can reduce the number and length
of peptides synthesized by SPPS. Often, the yield of long polypeptides (>30 amino
acids) can be a limiting factor in the scale of NCL reactions, especially if milligram
quantities are needed for high resolution biophysical studies or in vivo use. The
use of EPL requires the generation of either protein thioesters or protein fragments
containing an N-terminal Cys residue. To generate protein thioesters, an elegant
strategy involving engineered intein proteins was put forth by Muir and coworkers
in 1998.137, 138 Inteins (abbreviated from intervening proteins) are auto-processing,
self-splicing proteins that were first found in the ATPase gene of Saccharomyces
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cerevisiae and later discovered in bacteria, archaea, and other single celled
eukaryotes.139-141 Inteins are often expressed with two flanking exteins (N-terminal
and C-terminal) that are fragments of the desired protein splicing product. To
cleave the intein and join the extein sequences, a series of acyl transfer reactions
takes place (outlined in Figure 1-14).142 In short, the N-terminal residue (Cys or
Ser) of the intein undergoes a NàS acyl shift with the amide backbone carbonyl.
This is followed by a transesterification rearrangement by nucleophilic attack from
the C-terminal extein (Cys, Ser, or Thr residue). Finally, the intein is removed
through formation of a succinimide by nucleophilic attack of the C-terminal intein
Asn to the backbone amide carbonyl. The resulting spliced extein ester undergoes
a O/SàN acyl shift to form the final ligated protein product.
The N-terminal thioester formation in the first step of intein cleavage
attracted attention for use as an intermediate in C-terminal protein thioester
formation through the nucleophilic attack of exogenous thiols.137 Most commonly,
alkyl thiols such as MESNa are used at high concentrations to produce
hydrolytically stable protein thioesters (Figure 1-15, left).143, 144 Indeed, there have
been several engineered contiguous inteins derived from Nostoc punctiforme (Npu
DnaE)145 and Myobacterium xenopi (Mxe GyrA intein)146 that are now used as
“gold standards” for the generation of protein thioesters in EPL. More recently,
these inteins have been expressed with purification tags (His6, chitin binding
domain, etc.) for affinity chromatography, allowing for the removal of the spliced
intein after thiol cleavage. By genetically encoding an intein at the C-terminus of
an expressed protein fragment, one can create virtually any protein thioester for
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use in NCL synthesis, regardless of length and amino acid sequence. With the
emergence of intein usage in EPL, engineered contiguous and split inteins have
been utilized in a variety of other biotechnology functions, such as the generation
of segmentally isotopically labeled proteins147, protein and peptide cyclization148,
in vivo protein splicing149, and purification tags150, among others. For more details
on these uses, please refer to Section 2.1, or the exceptional reviews by Muir and
Camarero.141, 151, 152
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residue for each nucleophilic capture step. This figure is adapted from Muir and coworkers.

Protein thioesters are not the only protein fragment desired for EPL. The
generation of recombinantly expressed protein fragments bearing N-terminal Cys
residues have also been reported. Due to the necessity of a N-terminal Met residue
for translation to occur, a Cys residue cannot be directly placed at the N-terminus.
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However, masking the N-terminus through two methods can lead to the desired Nterminal Cys protein fragment.151 In one such method, the N-terminal Cys residue
of the protein fragment is preceded by an amino acid sequence recognized by a
protease, followed by a purification tag and the necessary N-terminal Met residue.
After affinity purification, this short leader sequence can be removed by treatment
with a protease specific to the recognition sequence. Often this recognition
element is an Ile-Glu-Gly-Arg-Xxx sequence, which the protease factor Xa
identifies and subsequently hydrolyzes the amide bond C-terminal to the Arg
residue.153 Another method for N-terminal Cys expression is to encode Cys as the
second residue following the initial Met (fMet-Cys-protein fragment, where f is
formyl) and express the protein in Escherichia coli as a host organism. After
translation of the protein fragment, an endogenous methionine aminopeptidase will
remove the Met residue and cyclize the Cys into a thiazolidine (Thz) ring using
cellular sources of formaldehyde.154 This thiazolidine can be converted back to Cys
by treatment with methoxylamine in aqueous buffer at pH 4.155,

156

This Thz

“protecting group” can be useful in controlling the Cys ligation site reactivity in more
complicated, multi-component, one-pot NCL reactions, such as the example
synthesis of the 148 amino acid protein α-synuclein (a protein implicated in
Parkinson’s disease) discussed in more detail in the following section on peptide
thioesters.157
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The preceding techniques enable the generation of large C- or N-terminal
protein fragments to be used in NCL. This combinatorial, semisynthesis strategy
can reduce the labor intensive SPPS steps necessary for multiple, iterative NCL
reactions in the synthesis of large protein targets. However, these large fragment
ligation reactions are not without drawbacks. Large fragments may lead to low
ligation efficiency due to steric occlusion of the reactive sites or accelerated
thioester hydrolysis in certain C-terminal sequences of the protein thioester
(generally sequences rich in Asp, Asn, Glu, or Gln).150 The optimal usage of this
technology lies at the generation of protein fragments that minimize these pitfalls,
while keeping synthetic fragments at an appropriate length to maximize yield, and
therefore incorporation of synthetically installed Uaas.
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Generation of Peptide Thioesters
For N-terminal fragments generated by SPPS, a variety of methods have
been developed to form C-terminal thioesters during cleavage from solid phase
supports. Moreover, solution phase thioesterification of the free peptide carboxy
terminus is possible after the removal of the peptide from solid support. The use
of chemical auxiliaries has even enabled the chemoselective deprotection of the
C-terminus in unprotected peptides to reveal thioesters for temporally controlled
NCL reactions involving more than two peptide fragments.123 At the confluence of
these chemical advances is the ability to synthesize increasing complex protein
targets containing “post-translational” or unnatural amino acid modifications at any
site throughout the protein sequence.
Traditionally, peptide thioesters were generated through a thioester linkage
to the resin in tert-butyloxycarbonyl (Boc)-based SPPS. However, this requires
cleavage from resin using HF, a dangerous, highly acidic reagent that requires
special equipment to handle and distill.125 Therefore, other methods using
fluorenylmethyloxycarbonyl (Fmoc)-based SPPS were developed to circumvent
the use of HF, yet, thioesters are unstable to the basic conditions needed for Fmoc
protecting group removal during elongation (e.g. piperidine). One solution is to use
resins which permit cleavage of the peptide from solid support while the N-terminus
and side-chains remain protected. The free carboxy-terminus is then treated with
a peptide coupling reagent and a free thiol in the presence of a mild base. In a
comprehensive study, reaction optimization showed that benzotriazol-1-yloxytripyrrolidinophosphonium (PyBOP), diisopropylethylamine (DIPEA) and
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methyl 3-mercaptopropionate gave high thioester yields, limited C-terminal
epimerization, and an alkyl thioester stable to hydrolysis during removal of the
side-chain and N-terminal protecting groups with trifluoroacetic acid (TFA).158
However, protected peptides may be insoluble due to a combination of polar amide
backbone and hydrophobic protecting groups and, depending on the C-terminal
amino acid identity, epimerization at this site may persist, thereby limiting the yield
of peptide thioester.
Alternative strategies are to use chemical auxiliaries connected to solid
support, which allow for peptide thioesters to be introduced after the peptide chain
is fully elongated. In some cases, a thiol nucleophile can be used to cleave the
peptide from resin, directly yielding the desired thioester, as is the case with
Kenner’s sulfonamide safety-catch linker (Figure 1-16).159 Perhaps even more
useful are C-terminal auxiliaries that can be removed from solid support in an
inactive form with normal TFA conditions. The removal of these auxiliaries can
then be chemically induced post-cleavage to “unmask” a thioester. Several studies
using this strategy have been published including: N-acyl-benzimidazolinones160,
NàS and OàS acyl-transfer auxiliaries161-163, o-aminoanilides164, and acyl
hydrazides165, as well as others.166
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Figure 1-16: SPPS chemical auxiliaries for use in generating peptide thioesters.

Recently, acyl hydrazides have been widely adopted as peptide thioester
surrogates due to their ease of installation. Hydrazide based solid supports for the
generation of C-terminal hydrazides can be generated by treating commercially
available 2-chlorotrityl chloride resin with an aqueous solution of 5% hydrazine for
short periods at room temperature.165 Furthermore, peptide hydrazides are
compatible with Fmoc-based SPPS and can be cleaved from solid support with a
TFA cocktail, purified by reverse phase HPLC and kept stably as dried solids for
long term storage. Perhaps most importantly, peptide hydrazides can be activated
selectively in unprotected peptides in situ by treatment with NaNO2 at acidic pH.
The resulting electrophilic acyl azide can be attacked by virtually any nucleophilic
thiol (most commonly 4-mercaptophenylacetic acid, MPAA) to generate a peptide
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thioester, which can be directly treated with a Cys containing peptide fragment to
initiate NCL. Peptide hydrazides have now been used in the synthesis of several
protein products such as α-synuclein and histone H2B, each of which contained
one or several site-specific post-translational modifications.167, 168 A key advantage
of these multi-component syntheses is that Cys residues do not need to be
protected, as synthesis proceeds from the N- to C-terminus. Zheng et al. have
used four synthetic fragments, each no longer than 36 amino acids in length, to
assemble the 148 amino acid protein α-synuclein in 54 % yield in three total NCL
reactions.165 The previously published C- to N-terminal synthesis from Fauvet et
al., which utilized a Thz based Cys protection and N-acyl-benzimidazolinone
mediated thioester formation, had a lower isolated yield (21%).157
With a large repertoire of reactions for forming peptide thioesters, one may
be able to screen many C-terminal ligation sites and thioester reactions to optimize
a particular NCL synthesis. It is also important to note that inteins can be cleaved
from expressed protein fragments using hydrazine to create protein hydrazide
fragments.169 The increased size of these fragments may also enable synthesis of
larger proteins in an N- to C-terminal direction, as Liu notes that syntheses using
only SPPS generated peptides may be limited to proteins that are, at maximum,
200 amino acids in length.165 Nonetheless, the scope of peptide thioester forming
reactions is sufficiently large that a user should be able to generate the necessary
component peptide for NCL with relative ease.
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Acyl Hydrazide Based Synthesis
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Figure 1-17: Convergent syntheses of the same protein product using two consecutive NCL reactions. Left:
Peptide hydrazides used for a N- to C-terminal synthesis with unprotected cysteine residues. MPAA is 4mercaptophenylacetic acid. Right: NCL using peptide thioesters and a protected cysteine as a thiazolidine
(Thz) on peptide 2. The Thz group is removed after NCL with peptide 3 by treatment with methoxylamine
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Ligation Masking
As previously discussed, not all proteins naturally contain the Cys residue
necessary for NCL (Cys is the least abundant amino acid in the human proteome
at 2.4 %).64 If NCL is to be used effectively, the protein to be synthesized should
be free of any “scar” sequences, such as a non-native Cys, after the ligation is
complete. Three main strategies have been employed in this regard: 1) alkylation
of the free thiol to mimic the native residue at the chosen ligation site, 2) use of a
thiol containing auxiliary that can be removed after ligation, and 3) removal of the
thiol to yield a free alkyl chain (e.g. a CysàAla transformation) using a radical
initiated desulfurization reaction.
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Owing to the nucleophilicity and pKa (~8) of the Cys thiol, this residue can
be selectively alkylated at neutral or slightly basic pH in the presence of all other
amino acid side chains. Transformation of Cys to Glu, Gln, and Lys mimics have
been

accomplished

by

using

iodoacetic

acid,

iodoacetamide,

and

2-

bromoethylamine, respectively (Figure 1-18).170-172 A more “traceless” ligation
reaction can be achieved by using a homocysteine (Hcs) residue as the thiol donor
in the NCL reaction and alkylating it with methyl iodide to yield a native Met
residue.173, 174 However, homocysteine ligations have decreased rates due to the
six-membered ring intermediate that occurs during the SàN acyl shift.
Nonetheless, these alkylating procedures are generally simple and result in a
quantitative conversion of free thiol to thioether. Yet, in the three former cases, a
non-native residue remains and the subtle differences in amino acid identity may
perturb the protein’s secondary and tertiary structure. Therefore, alternative
methodologies are needed to enable truly traceless NCL reactions.
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Cys Masking by Alkylation

Hcs Masking by Alkylation
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Figure 1-18: Alkylation strategies for the masking of thiol residues after NCL. Left: Cys can be alkylated by
K
Q
E
2-bromoethylamine, iodoacetamide, or iodoacetic acid to give Lys (Cys ), Gln (Cys ), or Glu (Cys ) mimics,
respectively. Right: Homocysteine (Hcs) is alkylated with methyl iodide to give a native Met residue.

Thiol auxiliaries or surrogates may be used as a ligation site and removed
through mild conditions. One such chemical auxiliary is a photocleavable
nitrobenzyl Cys surrogate that is attached through N-alkylation of a chemically
installed bromoacetamide functionality linked to a Lys side chain.175,

176

After

undergoing NCL, the photocleavage of this auxiliary is initiated with UV light to
reveal a Gly residue at the ligation site. Although the conditions for auxiliary
removal are mild and “traceless,” the installation of these auxiliaries may provide
difficult synthetic targets for SPPS. Consequently, other methods which use
selenocysteine (Sec) as a ligation site provide a nucleophilic selenol for the initial
capture step and facile post-ligation deselenization to Ala through the use tris(2carboxyethyl) phosphine (TCEP), a water soluble reducing reagent and radical
initiator.177, 178 The conditions of this reaction have even been optimized to avoid
unselective Cys desulfurization in peptides and proteins containing native Cys
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residues at non-ligation sites. Even more intriguing is the transformation of Sec to
Ser that can be leveraged in aerobic “deselenization” reactions.179 In a recent
study, Sec has even been used in an expressed protein fragment as a ligation site
using an optimized cysteinyl-tRNA misloading procedure.180 However, the
expressed fragment cannot contain any structurally critical Cys residues and the
maximum SecàCys substitution rate is 90%. Furthermore, incorporation into
peptide fragments by SPPS may require special protecting groups and selenol
containing amino acid synthesis may require the use of dangerous selenium
reagents. Therefore, thiol containing residues that can be selectively desulfurized
may provide a more practical approach for traceless ligations.
The desulfurization of Cys in a NCL synthesis, resulting in an Ala residue at
the site of ligation, was first described by Dawson and coworkers in 2001.181 The
authors used Raney Nickel hydrogenation of the C-S bond to achieve this
transformation. Alanine is significantly more abundant in proteins than Cys, making
it a favorable ligation site residue.64 In 2007, Chen et al. used the water soluble
radical initiator 2,2’-azobis[2-(2-imidazolin-2-yl)propane]dihydrochloride (VA-044),
in conjunction with TCEP, to achieve desulfurization without the use of harsh
hydrogenating reagents such as Raney Ni or palladium, which may not be
compatible with Uaa or post-translationally modified residues in peptide
fragments.182,

183

Since this initial study, VA-044 mediated desulfurization has

become the standard in the field for removal of thiol groups after ligation. This has
generated interest in a number of other thiol residues that contain a thiol at the βor γ-carbon of a canonical amino acid (see Figure 1-19). β-thiophenylalanine
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and β-thiovaline (penicillamine) were among the first β-thiol amino acids to be
synthesized, integrated into peptides, used in NCL, and desulfurized to reveal a
native residue (Phe and Val, respectively).184,

185

To date many other thiol

containing amino acids have been synthesized for this use, such as: γ-thiol valine,
γ- and δ-thiol lysine, γ-thiol threonine, and β-thiol leucine, as well as others (see
review from Payne and Malins).186
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Figure 1-19: Radical deselnization and desulfurization reactions for selenol and thiol containing residues.
Left: Sec can be deselenized to Ala or Ser using a phosphine reagent (TCEP). Middle and Right: Thiol
containing residues can be selectively desulfurized using VA-044 as a radical based initiator.

Ligation masking has become perhaps the most important consideration in
the semisynthesis of proteins, especially when carrying out biophysical studies or
in vivo experiments using the NCL product. Using the most “native-like” structure
ensures that the only relevant differences between the synthetic product and wild
type protein are the sites of modification installed by the user. Although there have
been an abundance of studies performed to improve its usage, NCL still has
limitations. For example, the synthesis β- and γ-thiol amino acids often requires
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several steps and total isolated yields are often low.186 Additionally, very few of
these amino acids are commercially available. Another consideration is the
applicability of β- and γ-thiol amino acids to EPL, as only C-terminal expressed
protein fragments bearing Cys, Hcs, and Sec, have been used in EPL.151, 177, 180,
187

Increasing the repertoire of thiol-bearing amino acids that can be integrated into

the N-terminal residue of proteins through Uaa mutagenesis or other methods
remains an important consideration in increasing the scope of EPL for use in the
semisynthesis of protein targets.
Section 1.5 – Chemoenzymatic Labeling of Proteins
Enzymatic labeling provides a post-translational means of site specifically
tagging a POI with a chemical functionality that can be a stand-alone probe or
chemoselectively modified in a secondary reaction. Generally, this method uses
an engineered enzyme that recognizes a sequence within a protein for transfer of
a functional group or whole amino acid. These recognition elements can be
genetically encoded as short peptides at the termini of proteins.188 An advantage
of this technique is the high specificity of enzymes for their recognition sequences
and the mild conditions under which labeling can be achieved. Typically, labeling
reactions are performed on isolated target proteins in vitro or on live cell surfaces,
but they have also been used in unique applications for biotin labeling in transgenic
mice.189, 190 A notable example of an enzymatic labeling technology is Biotin ligase
(BirA), which transfers biotin to a Lys embedded in a 15 amino acid peptide tag.
This biotin group can be recognized with high specificity by fluorescent streptavidin
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reporters for protein trafficking studies.191 Other enzymes, such as lipoic acid
ligase, tubulin tyrosine ligase, phosphopantetheinyl transferase, formylglycine
generating enzyme, and sortase A (SrtA) have been used to transfer a variety of
functional groups or stand-alone probes to proteins for imaging or pull-down
assays. More detailed information for these enzymes can be found in a review by
Seitz and Beck-Sickinger.189 However, of the aforementioned enzymes, it is
important to note that the recognition element of SrtA is the shortest, with a
sequence identity of LPxTG (where x can be any amino acid).192 Shorter
recognition elements are desirable, as they are likely to have less effect on the
function or structure of the POI. However, shorter recognition sequences may also
lead to a greater possibility of off-target labeling in certain enzyme systems. If a
single amino acid could be recognized at the N- or C-terminus of a protein, then
modification could proceed with high specificity, and with little change to the POI
sequence

and

structure/function.

To

this

end,

leucyl/phenalanyl

aminoacyltransferase (AaT) from E. coli has been developed as an additional
enzymatic labeling strategy.
Endogenously, AaT functions in the N-end rule protein degradation pathway
by adding Phe or Leu to the positively charged N-terminal Lys or Arg residues of
a protein via a phenylalanyl- or leucyl-tRNA substrate that is generated by an
aaRS.193 AaT has strict fidelity to the N-terminal residues of a protein as it has not
been observed to modify internal amino acids. Recent work has demonstrated that
a chemoenzymatic protocol with a simple aminoacyl adenosine analogue of tRNA
can be efficiently used as a minimalist substrate for AaT (see Figure 1-20).194
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Using either enzymatic (aaRS/tRNA) or chemoenzymatic transfer, AaT can
conveniently modify the N-termini of peptides and proteins with residues useful for
chemoselective labeling or as reactive chemical handles in NCL reactions. For
example, homocysteine (Hcs) was transferred to the N-terminal Lys of a fragment
of the protein α-synuclein, used in a NCL reaction to generate labeled α-synuclein,
and methylated, leaving Met at the ligation site.195 This “traceless” ligation allows
for the inclusion of a synthetic probe without the need to introduce a Cys into the
protein sequence, thereby enabling studies of the protein in a near-native state.
Additionally, click chemistry substrates such as Hpg, Aha, and Azf have all been
transferred by the WT enzyme, showcasing its versatility in substrate scope.194, 196
However, polyaromatic and β-branched amino acids, which could be used as
fluorescent probes and NCL handles (β-thiols), respectively, lie outside the current
substrate scope of the enzyme.197
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Figure 1-21: Substrate scope of the WT AaT enzyme. Canonical substrates are leucine, phenylalanine, and
methionine. Non-canonical substrates are amino acids bearing ‘click’ chemistry handles (Azf, Aha, and Hpg),
masked thiols for NCL (Hcm) and polyaromatic groups for the exploration of fluorescent amino acid transfer
(Nap).

Although some mutagenesis has been attempted with AaT, very little work
has been done to expand the scope of the N-terminal amino acids that AaT can
recognize as substrates.198 Enabling AaT to accept N-terminal residues other than
Arg or Lys could create a versatile chemoenzymatic technology for the installation
of NCL-capable residues onto expressed proteins. In addition to expanding the
scope of EPL sites, AaT could be used to selectively label the N-termini of proteins
with fluorescent amino acids. However, large fluorophores like β-(7-methoxycoumarin-4-yl)-alanine or acridon-2-ylalanine are unable to be transferred in high
yields via WT AaT and the enzyme will likely require extensive mutagenesis to
transfer these substrates.
Enzymatic methods such as AaT and SrtA can provide methods to posttranslationally modify a POI at a single site, without the need for bioorthoganality
that is generally necessary for genetic code expansion. The mild conditions used
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during these reactions enable labeling of folded substrate proteins, generally
without the need for denaturants and refolding as with many chemical ligation
methods. By expanding the recognition elements of AaT and using short
recognition sequences in other enzymatic transfer methods, these enzymes can
provide alternative methods for installing Uaas for biophysical and biochemical
studies both in vitro and in vivo.

The following section contains reprinted (adapted) passages with permission from
(Christopher R. Walters, John J. Ferrie, and E. James Petersson) John Wiley and
Sons Publication Company (Chemical Ligation: Tools for Biomolecule Synthesis
and Modification). Copyright (2017) John Wiley and Sons.199
Section 1.6 – Introduction to Thioamides
Modification of the peptide backbone has long held the interest of biological
chemists. Several modifications including esters, thioesters, thioamides,
selenoamides, telluroamides, alkenes, and fluoroalkenes, among others, have
been documented as potential backbone replacements for biophysical studies.200
The chalcogen amide functionalities are of particular interest as they are nearly
isosteric replacements of the amide oxygen with sulfur, selenium, or tellurium, and
preserve the hydrogen donor and acceptor capabilities of the native amide bond.
However, owing to the instability of selenoamides and telluroamides, the
incorporation of thioamides may hold the most promise as isosteric replacements
of the peptide backbone linkage.
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The thioamide carbon-sulfur bond length is 1.54 – 1.68 Å, which is

slightly longer than the 1.24 Å carbon-oxygen bond length in an amide.210 The carbonnitrogen bond is slightly longer in formamide (1.35 Å) than in thioformamide (1.32 Å).211
The covalent radius of oxygen (0.73 Å) is slightly smaller than that of sulfur (1.02 Å).128

Thioamide
The van der Waals radius of sulfur (1.85 Å) is slightly larger than that of oxygen (1.40
Å).212 Oxygen is more electronegative (3.50) than sulfur (2.44).212 Thioamides tend to
have larger dipole moments (~ 5 D) than corresponding oxoamides (~ 3.8 D), but these

Figure 1.23. Chemical Structures of an Amide and Thioamide. Space-filling models rendered in
values can be affected by neighboring groups.213 The amide carbon-oxygen bond (~170
PyMOL (Schrödinger; Portland, OR).
kcal•mol-1) is stronger than the thioamide carbon-sulfur bond (~130 kcal•mol-1).128 The

amide functional group can be described by three resonance structures, but the thioamide
functional group is more well-represented by only two, as shown in Figure 1.24.
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Figure 1.23. Chemical Structures of an Amide and Thioamide. Space-filling models rendered in
PyMOL (Schrödinger; Portland, OR).

Figure 1.1: Chromophore Size. Space-filling renderings of several chromophores, 52based on either crystal
structures or ab initio calculations. The green fluorescent protein (GFP) was rendered from PDB ID 1GFL9.
The benzylated SNAP tag protein was rendered from PDB ID 3L00 (S. Schmitt, B. Mollwitz, F. Pojer, M.

Figure 1-22: Top: The structure of an oxoamide and thioamide along with van der Waal’s surface
representation. Bottom: Relative size of other common biophysical probes compared to the thioamide
4
including: green fluorescent protein (GFP), FlAsH tetracysteine
coordinated fluorescein arsenical hairpin, 7hydroxycoumarin (Hco), tryptophan (Trp), and acridon-2-ylalanine (Acd).

Thioamides have different properties compared to oxoamides such as: a

Figure 1.1: Chromophore Size. Space-filling renderings of several chromophores, based on either crystal

structures or ab initio calculations. The green fluorescent protein (GFP) was rendered from PDB ID 1GFL9.

larger van der Waals radius, a red shifted π-π* absorption, lower oxidation

The benzylated SNAP tag protein was rendered from PDB ID 3L00 (S. Schmitt, B. Mollwitz, F. Pojer, M.

potential, lower infrared stretching frequency, and lower N-H pKa (see review from
4

Wang et al. and Table 1-1).201 The differing physical properties with respect to
oxoamides make the thioamide an attractive minimalist probe for a host of
biophysical techniques to study protein structure and dynamics. In this section,
thioamide incorporation will be discussed in the context of natural products,
peptides, and proteins. Each of these settings will showcase the versatility of this
functional group in nature and in laboratory based experiments. Specifically, a
review of thioamide installation in peptides and proteins, and the biophysical
studies that synthetic gains have enabled, will establish the basis by which
thioamides can be used as versatile probes in new protein systems. This will set
the stage for what additional information is still needed to inspire a broader usage
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of the probe in the biochemical community (See Chapters 3, 4, and 5).
Table 1-1: Physical properties of oxoamides and thioamides and their applications to biological systems.
Property

Oxo

Thio

Application

vdW radius (Å)
C=X bond length (Å)
Electronegativity

1.40
1.23
3.44

1.85
1.71
2.58

----Metal-substrate, n-π* interactions

C=X•••H-N BDE (kcal mol -1)
N-H pKa
π-π* absorption (nm)

6.10
17
200

4.80
13
270

Peptide folding
Hydrogen bonding probe
Photoswitch, FRET-based quencher

EOx (V vs. S.H.E.)

3.29

1.21

PeT-based quencher

vdW = van der Waals, BDE = bond dissociation energy, FRET = Förster resonance energy transfer; PeT = photoinduced
electron transfer, S.H.E. = standard hydrogen electrode

Thioamide Synthesis
In the literature, the thioamide functional group has historically been
referred to as a thionoamide, thioxoamide, endothiopeptide, mercaptoamide,
thiopeptide unit, thiodepsipeptide, and thiocarboxamide. For clarity, and in
agreement with most current Organic Chemistry literature, here it will be referred
to by the single name, the thioamide (as denoted by superscript S throughout).
Additionally, in the context of biologically relevant peptides, thiopeptide has been
used to describe thiazole- and thiazolene-containing natural products, but will be
used in the single context of thioamide containing peptides for the remainder of
this work.
The first reported synthesis of a thioamide was performed in 1815 by GayLussac and was synthesized through the combination of cyanogen and hydrogen
sulfide to form cyanothioformate and dithiooxoamide.202 This reaction yielded
thioamide products with little utility. However, this ignited a sustained interest in
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the discovery of additional chemical syntheses of the thioamide functionality.
Several thioamide forming reactions, from a multitude of functional groups
(ketones, aldehydes, isothiocyanates, and amides to name a few), have been
reported in the literature. Most notably the Wilgerodt-Kindler reaction, 2,4-Bis(4methoxyphenyl)-1,3,2,4-dithiadiphosphetane-2,4-dithione (Lawesson’s reagent),
and tetraphosphorus decasulfide (P4S10), have become standard reactions for the
installation of thioamides.203-205 As this functional group has transitioned to broader
usage in medicinal chemistry scaffolds, metal coordination frameworks, and
biological systems, a concomitant expansion of the processes to achieve these
chemical transformations has occurred. Increased scope of both the starting
material (now thioamides can be formed from acids, thiols, alkynyl bromides,
oximes, and azides) and the reaction conditions (e.g. safer temperatures, safer
chemicals, and easier product separation) have made thioamides accessible in
virtually any synthetic system. Yet, biological systems (peptides and proteins),
which often contain multiple functional groups primed for thioamidation, present
more extreme technical challenges when attempting to broaden the usage of this
probe. For individual applications in biophysics (vide infra) and medicinal
chemistry, the methodology used to incorporate thioamides must be adapted to
the context of the molecule.
Thioamide Incorporation into Natural Products, Peptides, and Proteins.
Thioamides are a motif engineered into many medicinally relevant
compounds such as ethionamide and prothionamide (Figure 1-23).206 Although
these products are designer small molecules, the thioamide motif has been
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observed in many small molecule natural products, such as ammosamide A, a
potent anti-cancer molecule against colon carcinomas.207 Here, the thioamide is
locked within a polycyclic iminoquinone scaffold, whereas other classes of natural
products contain more peptidic-like linkages. These polypepties are ribosomally
translated and post-translationally modified to site-specifically install the thioamide.
The mechanisms of these installations are currently being elucidated through the
study of thiazole producing enzymes from gene clusters found in a variety of
aerobic and anaerobic microbes.208
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Figure 1-23: Selected thioamide containing natural products isolated from bacteria and archaea.
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Some notable peptide products include methanobactin (a copper binding
metabolite)209,

closthioamide

(an

anti-biotic

against

methicillin-resistant

Staphylococcus aureus)210, and thioviridamide (an apoptosis inducing peptide for
anti-cancer applications).211 It is likely that, as natural product discovery continues,
the thioamide will be found in additional peptides showing therapeutic properties.
This makes site selective incorporations of thioamides in laboratory based
syntheses an important factor in the mass production of thioamide containing
natural products, as many of the microbes in these studies produce minimal
quantities of these products.
In addition to their prevalence in the medicinal chemistry globe, thioamides
have also recently been used as spectroscopic probes in peptides and proteins.
This adds to the need for synthetic strategies to thionate amino acids and peptides
at selective positions. The first amino acid derivative containing a thioamide was
phenyl thioglycine, synthesized by Gatewood and Johnson in 1926.212 A more
complicated synthesis of the thioamide containing cyclic peptide hormone
analogue thio-oxytocin was synthesized by Du Vigneaud and coworkers.213 Direct
thionation of a N-benzoyl-Gly-NH2 with P4S10, followed by a series of solution
phase couplings and a final coupling to the core of oxytocin, provided a novel
synthetic

approach.

Direct

thionation

of

short

peptides

containing

α-

aminoisobutyric acid (Aib) or β-amino acids has also been demonstrated as an
alternative approach. In each of these examples, Lawesson’s reagent was used to
yield efficient conversion of backbone amides to thioamides; however, a mixture
of different thionated positions was observed. Extensive purification and
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separation of these various thioamide analogues is time consuming and often
difficult, leading to a major drawback of this approach.
A variety of thioamide surrogate residues have been also been used in an
‘azirine/thiazolone’ method, yet this approach can lead to significant epimerization
of the α-carbon stereocenter at the site of thioamide incorporation.214 With the
popularization of solid phase peptide synthesis (SPPS), the development of
thioamino acid monomer building blocks would enable more diverse sets of
thiopeptides to be produced. At the forefront of this chemistry were Belleau and
coworkes,

who

established

thiobenzimidazolones

as

chemoselective

aminothioacylating reagents (see Figure 1-24).215 Following this report, a myriad
of other thioacylating reagents were prepared such as fluorobenzimidazolone,
thioacyl-N-pthalimide, and nitrobenzotriazolide derivatives aimed at improving
small molecule yields, thioacylating efficiency, and enantiopurity of the thiopeptide
product.216 The nitrobenzotriazolide thioacylating derivatives from Rappaport are
by far the most widely used as the synthetic route is often high yielding (the original
report lists yields of 80-85%), amino acid monomers can be stored without
appreciable

degradation,

and

couplings

proceed

with

no

observable

epimerization.217
Several Fmoc-protected benzotriazolide amino acid monomers have been
prepared using N-boc-1,2-phenylenediamine and para-deactivated 4-nitro-1,2phenylenediamine (Ala, Asp, Arg, Glu, Cys, Gly, Ile, Leu, Lys, Phe, Pro, Trp, Tyr,
and Ser) as amidating reagents.218 These monomers have been used in the
synthesis of several peptides, such as the Villin Head Piece variant HP35, the
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yeast transcription factor GCN4, and various β-hairpins.219-221 However, the
successful incorporation of a thioamide via thioacylating monomer can be largely
sequence dependent. Nucleophilic residues proximal to the thioamide may lead to
cyclic intermediates that can cleave the peptide or cause oxygen-sulfur exchange
during TFA cleavage of the peptide from resin. Moreover extended treatment with
TFA may lead to fragmentation of the peptide at the n+1 position through an
Edman degradation-like mechanism.153
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Figure 1-24: Synthesis of thioacylating monomers from commercially available Fmoc-protected amino
acids. a) IBCF, NMM, THF, 0 °C, 15 min; N-Boc-OPD or 4-nitro-OPD b) Lawesson’s Reagent or P4S10, CH2Cl2
or THF, 2-18 hours; c) R2=F, R3=H; phosgene or triphosgene, CH2Cl2 d) R2=NO2, R3=H; NaNO2, 95:5 AcOH/H2O,
30 min e) R2=H, R3=Boc; 50:50 TFA/CH2Cl2, 0 °C, 2 h; Then NaNO2, 95:5 AcOH/H2O, 30 min. IBCF = isobutyl
chloroformate.
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Recently, several improvements to the usage of these thioacylating
monomers have been published. One notable example is the use of anhydrous
dichloromethane (DCM) and short reaction times during the coupling reaction with
the free amino terminus of the resin-bound peptide.153, 222 This has increased the
coupling efficiency of the reaction when compared to N,N-dimethylformamide
(DMF) and solvents that may have water as an impurity, which can act as a
competing nucleophile with the free amine. Epimerization of the α-carbon of the
thioamino acid during Fmoc removal can also hinder the enantiopurity of the
peptide. Most commonly, piperidine is used to achieve this deprotection, yet these
basic conditions can lead to epimerization. Preliminary studies indicated that this
epimerizartion may be suppressed by using a lower concentration of piperidine (1
% vs 20 % in DMF) for shorter reaction times.223 Evidence supporting the benefits
of these conditions applied to thiopeptides is not fully delineated, but other
deprotection reagents may provide cleaner, high-yielding thiopeptide syntheses in
the future (see Chapter 5).
Although thioacylating amino acid derivatives provide a powerful tool for the
incorporation of backbone thioamides in synthetic peptides, their use is limited by
the inherent length constraints of SPPS. Thus, other procedures that circumvent
the size limitations of SPPS must be developed. To incorporate the thioamide into
proteins beyond the size constraints of SPPS, NCL can be used. However,
because of the thioamide’s enhanced carbonyl electrophilicity and sulfur
nucleophilicity, routine thioester formation and NCL reaction conditions needed to
be established. Our laboratory has recently undertaken the synthesis of a series
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of short peptides with the thioamide proximal to an N-terminal Cys or C-terminal
thioester.153 Each of these peptides contained a LeuS amino acid at varying
positions and were tested for compatibility with the necessary reagents used in
common NCL schemes such as: guanidinium•HCl, TCEP, thiophenol, MPAA,
MESNa, and MeONH2 (for Thz deprotection). One noticeable competing reaction
was the cyclization of the thioamide sulfur with the β-carbon of a thiophosphonium
intermediate during the reduction of disulfide species via TCEP. However, these
byproducts can be avoided if disulfide formation is prevented through sparging
reaction buffers with argon. Cyclization is also possible via nucleophilic attack of
the thioamide sulfur at the C-terminal thioester. This can again be avoided if one
can design a NCL scheme that places the thioamide at positions other than the n2 position, where cyclization was observed to be most prevalent. These sequencespecific effects notwithstanding, thioamides were found to be generally welltolerated in either thioester or N-terminal Cys peptides during NCL, with
conversions raging from 55-77 % and crude purities of 54-71%, as confirmed by
HPLC analysis. In subsequent studies, thioamides were also found to be
compatible with a variety of thioester forming auxiliaries (see Section 1.4) such as
Kawakami and MacMillan’s intrapeptide cyclization Csb-Pro-Gla linker (Csb is a tbutyl disulfide protected Cys and Gla is glycolic acid).153 Additional studies also
provided evidence for the compatibility of thioamides with Dawson’s N-acylbenzimidazolone method for thioester formation.224 However, any auxiliary method
requiring the removal of an allyloxycarbonate (Alloc) protecting group via catalytic
Pd0 should be avoided, as desulfurization of the thioamide has been observed.
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In a series of final tests, thioamide containing variants of α-synuclein have
been synthesized to establish, for the first time, a thioamide in a full-length protein
formed by EPL. This reaction was performed with yields greater than 50% and
99% retention of the thioamide. In the pilot study, ValS was incorporated as a proof
of concept, however the long-term interest of thioamides as fluorescence
quenchers to monitor protein conformations demands dual labeling strategies of a
protein. Therefore, the Uaa p-cyanophenylalanine (Cnf) was integrated into αS9140

through Uaa mutagenesis in E. Coli. This expressed fragment was purified and

treated with a protease to reveal a N-terminal Cys residue for NCL (see Section
1.4). NCL was then then performed with a peptide fragment αS1-8 containing a
PheS thioamide and a C-terminal thioester.132 Double labeled protein is purified
with yields ranging from 60 to 70 %. Yet, the remaining Cys residue may be
perturbing to protein structure as WT αS does not contain a Cys residue at the
ligation site. To mask the Cys residue, both alkylation and desulfurization of the
ligation site Cys or Hcy residue were tested for compatibility with the thioamide.
Alkylation of an Hcy residue with methyl iodide in a thioamide containing αS variant
yielded a native Met residue at a new ligation site.225 This alkylation is selective for
the Hcy residue, without alkylation of the thioamide sulfur, provided that the
reaction time is short (5 min) and the protein is treated with excess alkylating
reagent (5,000 equivalents). Additionally, one may wish to desulfurize the ligation
site Cys to Ala in the presence of thioamide. A recent study has applied and
adjusted Danishefsky’s VA-044 radical desulfurization method to enable this
strategy. An obvious byproduct during the use of radical desulfurization methods
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is the removal of the thioamide sulfur. However, this can be avoided when
thioacetamide is used as a ‘suicide scavenger’ in the reaction.218 These conditions
allow for selective desulfurization of the Cys residue while the thioamide remains
intact. This strategy has even been implemented in the total synthesis of a
thioamide containing variant (LeuS6) of the protein G, B1 domain (GB1) from
Streptococcus.
Thioamide Protein Semisynthesis by EPL
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Figure 1-25: Synthesis of doubly labeled thioproteins. Top: Expressed protein fragment containing Cnf from
Uaa mutagenesis and an N-terminal Cys. Ligation with a thiopeptide yields double labeled protein
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labeled protein with a native methionine at the ligation site. Figure adapted from Walters et al.
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It is important to note that thioamides have even been detected in full-length
proteins in nature. The nickel dependent methyl-coenzyme M reductase (MCR),
which catalyzes methane formation in all methanogenic archaea, contains a
thioglycine residue.226 Although this residue’s incorporation and function within the
enzyme remain undetermined, it has prompted an investigation into alternative
methods for thioamide installation in proteins.
New technology developed by Mitchell and coworkers in 2013, utilizes a
thiazole/oxazole-modified

microcin

(TOMM)

cyclodehydratase

enzyme

to

generate backbone azoline heterocycles at positions flanking the nucleophilic
residues Thr, Ser, and Cys.227 Following azoline formation, the peptide or protein
is treated with potassium hydrosulfide (KHS), resulting in ring-opening of the
azoline to reveal a thioamide at the n+1 position of the Thr/Ser/Cys residue.
Although this is not the first enzymatic method for installing thioamides, it has the
most potential for use on large proteins. However, despite the promise that this
method displays, there are some restrictions that must be noted. Firstly, any
additional Ser, Thr, or Cys residues in the protein of interest must be deleted in
order to avoid off-target azoline formation. Furthermore, the largest peptide
substrate used in the initial report is approximately 60 amino acids in length.
Thionation by the incorporation of benzotriazolide monomers in SPPS could also
conceivably be used to generate peptides of this length, although yields may vary
depending on sequence identity. Even in the case of this enzymatic method,
sequence specificity can be limiting and a leader sequence is often used for
recognition of the substrate by the cyclodehydratase. Suga and coworkers have
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shown that such leader sequences can be manipulated to some degree, but such
methods do not currently allow one to install thioamides into large proteins.228
Engineering of TOMM synthetases may serve as a solution to this shortcoming.
Additionally, as more is learned about the cellular pathways and enzymes that
generate

azoline

rings

and

other

masked

thioamides

(thioviridamide,

closthioamide, and thiobactin pathways, among others), other enzyme clusters
may be discovered, leading to new enzymatic, ‘post-translational’ methods for
thioamide installation into a peptide or protein backbone (see review by Dunbar
and Mitchell).208
Another strategy for thioamide incorporation into longer polypeptides, and
even proteins, is to genetically incorporate the thioamide through translational
machinery. In 2015, a mutant 23 rRNA, reconstituted ribosome from E. coli was
used to direct the translational insertion of dipeptides into the enzyme dihydrofolate
reductase (DHFR).229 This included a PheS-Gly dipeptide, showing for the first time
a backbone thioamide ribosomally incorporated into a protein. However, this
system has not yet been used for in cellulo translation. Furthermore, a particular
sequence is likely required to allow for the dipeptide to bind in the ribosome as
these mutants are based off of a puromycin permissive ribosome. As genetic
expansion technologies advance, thioamide mutations in proteins may become
more accessible. Yet, it appears that, contemporary thioamide incorporation for
biophysical applications is likely still limited to NCL, as it is the most robustly tested
and widely applied methodology.
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Thioamide Applications to Biophysical Studies
Thioamides have a wide array of applications when studying biomolecule
interactions and properties (as mentioned above). To establish their usage in
proteins, several groups have investigated if the thioamide can be incorporated
into secondary structural elements in short peptide fragments. The steric bulk of
(1.85 Å vs. 1.40 Å) the thioamide and the longer C=S bond (1.71 Å vs 1.23 Å),
when compared to oxoamides, makes the thioamide a weaker hydrogen bond
acceptor. Yet, the lower pKa of the N-H proton (13 vs. 17) makes the thioamide a
stronger hydrogen bond donor.201 These small, but important changes, are likely
to make the thioamide’s incorporation into helical and β-sheet structural elements
dependent upon the surrounding amino acid sequence and position of
incorporation.
Pilot computational studies monitoring the potential energy surfaces of
torsional backbone bond angles of thioamide containing dipeptides suggested that
they could be accommodated in the C-termini of α-helices and β-sheets.230
However, if incorporated in highly structured hydrogen bonding networks, the
conformational restrictions of the thioamide would likely interfere with these
networks, thus hindering the folding process of these motifs. Putting this
information into practice, Reiner et al. used circular dichroism (CD) and nuclear
magnetic resonance (NMR) spectroscopy to study a 16 residue polyalanine based
helix.231 Indeed, they found that the placement of the thioamide in the N-terminal
or central region of the helix was destabilizing (~1.7 kcal mol-1), likely due to the
disruption of the hydrogen bonding network. However, in a competing study, Miwa
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et al. described more nuanced effects of thioamide substitutions in a 35 amino acid
segment of a yeast derived GCN4 sequence.221 With thioamide substitutions at
central and C-terminal positions, they did not observe a significant change in the
helicity of the peptide. In fact, the placement of a central LeuS substitution
increased the thermal stability of the helical structure by ~10 °C. The discrepancies
laid out by these pilot studies has sparked a host of additional structural studies of
the thioamide in α-helical folding, β-sheet TrpZip peptides, type II’ β-hairpins, and
polyproline type II helices (discussed in more details in Section 4.1).220,

232, 233

However, each of these studies was performed on short, isolated structural motifs
without the comprehensive substitutional studies of a thioamide at each position.
This shortcoming elicits the need for studies of the impact of thioamide backbone
substitutions on the secondary and tertiary structure of folded, full-length proteins.
The details of initial studies of thioamides in folded protein structures is the basis
of Chapter 4 discussed herein.
There is also interest in applying the redshifted πàπ* absorption property
of the thioamide (270 nm vs 200 nm for oxoamide) to the study of biological
systems. This property allows the thioamide to undergo photoisomerization from
trans to cis and has been used to study the secondary structure of the RNase S
peptide-complex during the cleavage of a cyclic monophosphate nucleotide.234
Additionally, the absorbance in this region has enabled the tracking of the chiral,
and therefore structural, environment of the thioamide by CD spectroscopy. More
importantly, the red shifted absorbance properties of the thioamide could be used
in the fluorescence quenching of fluorophores via a FRET process in the study of
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biomolecule interactions. In this regard, the Petersson laboratory has clearly
demonstrated that the quenching of p-cyanophenylalanine (Cnf) is achieved
through the FRET mechanism.235 Although, fluorescence quenching of tryptophan
by a thioamide was first observed by Wiczk et al.236, the first assignable FRET
interaction of a thioamide with a fluorophore was with Cnf as described above.
Since FRET requires the spectral overlap between donor emission and acceptor
absorption, Cnf provides an excellent working range for this process with an
excitation range (230-240 nm) that avoids direct thioamide excitation and emission
range (centered at 295 nm) that provides sufficient spectral overlap for FRET. A
sigmoidal distance dependence of Cnf-thioamide quenching interaction was
observed in polyproline peptides, indicating that the interaction can effectively be
modeled by FRET with a working distance range of 8-30 Å.235 This initial study
highlights the use of thioamides in monitoring conformational changes of proteins
via distance dependent thioamide-fluorophore interactions.
Within the same study, the quenching of Cnf was used in tandem with CD
spectroscopy to monitor the thermal denaturation of a short helix-loop-helix
segment (35 amino acids) villin headpiece (Villin HP35). Additionally, Tyr can
provide a canonical fluorescent amino acid that is quenched by the thioamide.
Although the mechanism of this quenching interaction is not yet fully understood,
a proof of principle experiment involving the quenching of intrinsic protein Tyr
fluorescence by a thiopeptide binding partner has also been performed.237 This
study allowed for quantification of the protein-peptide interaction via intermolecular
quenching (vs intramolecular quenching in the prior Cnf example). In a separate,
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Unlike FRET quenching, PeT requires van der Waals contact for quenching,
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thereby necessitating the thioamide to come into close proximity with the
fluorescent probe. Thioamide PeT quenching has now been used in a variety of
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contexts, most notably for real time monitoring of proteolysis and again in the study
of αS compaction by TMAO.239

Figure 1-27: FRET/PET quenching during α-synuclein compaction. In the presence of increasing
concentration of TMAO, α-synuclein undergoes successive compaction. During this process, changes in the
distance between two regions of the protein have been monitored by FRET (Top), where quenching of Cnf
fluorescence by the thioamide occurs in a distance dependent fashion and PET (Bottom), where van der
Waals contact between fluorescein and thioamide is required for quenching. Figure adapted from Walters
199
et al.

The thioamide’s size and ability to quench a wide array of fluorophores
makes it an attractive probe to study intramolecular and intermolecular protein
dynamics. This is especially true when larger probes, such as Texas Red,
fluorescein, and rhodamine, have been demonstrated to disrupt the fold and
function of proteins when applied to fluorescence studies.240 Although some
studies have suggested that the thioamide may be accommodated in secondary
structure elements, further work must be done in full-length proteins to ensure that
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the thioamide is indeed minimally perturbing in comparison to larger probes. As
this technology evolves, it will also be important to demonstrate that the thioamide
can still effectively quench fluorescence when embedded within a minimally
perturbing position in a structured element (e.g. α-helix or β-sheet).
Section 1.7 - Conspectus
In total, there are many technologies that can be employed to effectively
label proteins for the tracking of structural changes and dynamic movements.
However, improving the accessibility of these technologies to the biochemical
community is of the upmost importance to enable a broader usage of chemical
probes, specifically in the context of site-specific amino acid modifications. In this
thesis, I describe several improvements to current methodologies for site-specific
backbone and side chain amino acid modifications. In one study, genetic code
expansion is improved by eliminating truncation byproducts through the use of selfsplicing intein purification tags. In other efforts, I examine the effects of thioamide
backbone substitutions in the secondary and tertiary structure of full-length
proteins synthesized by native chemical ligation. Understanding the effects of
these substitutions permits the user to more effectively use thioamides as
fluorescence quenching probes or as structural modulators in protein engineering
applications. Additionally, I have established more effective methods for thioamide
incorporation into peptides in solid phase synthesis. I have leveraged these gains
to install multiple thioamides into the protein calmodulin to assess their additive
thermodynamic effects on protein stability and for use in intermolecular
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fluorescence quenching experiments. Finally, I explored the substrate scope of the
enzyme AaT for application in modifying the N-termini of proteins with Uaas for
‘click’ chemistry and NCL reactions. By studying the effects of specific protein
modifications on protein structure and function, as well as improving the general
methodologies for Uaa incorporation, I have provided opportunities for the
biochemical community to enhance their usage of Uaas for the study of proteins in
a range of contexts.
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CHAPTER 2:
INTEINS AS TRACELESS PURIFICATION TAGS FOR UNNATURAL AMINO
ACID PROTEINS
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Reprinted (adapted) with permission from (Solongo Batjargal, Christopher R.
Walters, and E. James Petersson) the Journal of the American Chemical Society
(J. Am. Chem. Soc., 2015, 137 (5), 1734–1737). Copyright (2015) American
Chemical Society.

Section 2.1 - Introduction
Genetic incorporation of unnatural amino acids (Uaas) into proteins has
provided the ability to probe and control protein structure and function with
extraordinary precision.241,

242

To accomplish site-specific incorporation, an

orthogonal tRNA is selectively charged with a Uaa by its aminoacyl-tRNA
synthetase (RS) and directs the insertion of the Uaa into the nascent polypeptide
chain in response to nonsense (i.e., premature stop) or quadruplet codons during
translation.110, 243 The “suppressor” tRNA has an anticodon that recognizes the
nonsense codon; for example, tRNACUA pairs with the UAG stop codon. One of the
major limitations of this method is the competition of tRNACUA with release factor 1
(RF1) at the UAG codon, leading to protein truncation. Purification of the full-length
protein can be difficult, if not impossible, when the UAG codon is located near the
C-terminus. The use of C-terminal tags such as His6 can alter the native properties
of some proteins, and cleavage of the tags by proteases may not always be
specific. Other efforts to solve the “truncation problem” have centered on nontrivial
manipulations of the E. coli translation system, including genetic deletion of RF1
or reassignment of all the UAG stop codons in the bacterium.116,
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These

manipulations may lead to compromised cell health and lower levels of protein
production.
Here, we report a simple and efficient method for isolating full-length
proteins containing a Uaa in a traceless manner by exploiting the self-excising
property of inteins. Engineered inteins have been leveraged for the preparation of
protein thioesters, polypeptide cyclization, and the regulation of protein
functions.151 In our own laboratory, we have used inteins to prepare Uaacontaining protein fragments for ligation to synthetic peptides to label proteins with
both side chain and backbone modifications.132 This line of investigation led us to
develop a traceless intein tagging method for full-length Uaa proteins (Figure 2-1).
Section 2.2 - Results and Discussion
The C-terminal His-tagged Mxe GyrA intein provides an affinity purification
tool that, by virtue of its placement, can exist only in full-length Uaa protein 2-2 and
not in truncated protein 2-1 (Figure 2-1). Subsequent removal of the intein tag (23) in a β-mercaptoethanol (βME) triggered process yields the Uaa-labeled protein
with a C-terminal carboxylate (2-7) via intermediates 2-4 and 2-5. We demonstrate
the generality of this approach with three test proteins: an intrinsically disordered
protein, α-synuclein (αS), a small Ca2+ binding protein, calmodulin (CaM), and a
larger globular protein, maltose binding protein (MBP). In addition, we examine a
broad spectrum of Uaas including the spectroscopic probes p-cyanophenylalanine
(Cnf or F*)244,

245

and acridon-2-ylalanine (Acd or δ),246 the “click” chemistry

handles propargyltyrosine (Ppy or π) and p-azidophenylalanine (Azf or Z),247 and
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the photocrosslinker p-benzoyl-phenylalanine (Bzf or B).248 This technique should
be of general use to the Uaa mutagenesis community as it provides a
straightforward solution to the truncation problem.
We began our investigation with the expression of αS (140 amino acids)
containing Cnf at position 136, fused to Mxe GyrA intein followed by a C-terminal
His6 tag (αS-F*136-MxeH6, 2-2a). To incorporate Cnf, we transformed BL21(DE3)
cells with a pTXB1-αS-TAG136-MxeH6 plasmid and a plasmid encoding a
Methanocaldococcus jannaschii (Mj) mutant TyrRS/tRNACUA pair previously
selected for Cnf incorporation (pDULE2-pXF).249 After lysing the cells, both
truncation product αS1−135 (2-1a) and mature fusion protein (2-2a) were observed.
Only the mature protein with the Uaa was obtained from Ni-nitrilotriacetic acid (NiNTA) purification by elution with imidazole, leaving the truncation product in the
flow- through (Figure 2-1). Matrix-assisted laser desorption/ionization (MALDI)
mass spectrometry (MS) and polyacrylamide gel electrophoresis (PAGE) analyses
of the Ni-NTA purified αS-F*136-MxeH6 2-2a showed no evidence of the truncation
product.
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2-1

2-2

2-2

2-3

2-4

2-5

2-6

2-7

Figure 2-1: Purification of Unnatural Amino Acid Proteins Using a C-terminal Intein Tag. Unnatural amino
acid (Uaa; e.g., p-cyanophenylalanine, Cnf) proteins are expressed using a plasmid encoding the protein of
interest with a TAG stop codon (e.g., α-synuclein mutant at position 136, αS-TAG136) and a plasmid encoding
an evolved tRNA synthetase (UaaRS). The full length intein fusion protein containing the Uaa (2-2) is purified
away from the protein truncated at the stop codon (2-1) using Ni-NTA resin. Hydrolysis resulting from βmercaptoethanol (βME) treatment generates purified Uaa protein 2-7 via intermediates 2-4 and 2-5. Intein
cleavage with βME can be carried out on or off of the Ni-NTA column. Inset: A sample expression and
purification of αS-Cnf136 with either off- or on-column hydrolysis. Off: Crude cell lysate, flow through from
Ni-NTA column (FT), elution of Ni-NTA column with 300 mM imidazole, cleavage of eluted intein fusion with
200 mM βME for 24 h, and removal of intein and uncleaved fusion protein by incubation with Ni-NTA beads.
On: Crude cell lysate, FT, elution of Ni-NTA column with 200 mM βME after incubation for 24 h, and elution
of cleaved intein from Ni-NTA column with 300 mM imidazole: 2-1a, truncated αS1−135; 2-2a, Uaa protein
fusion αS-F*136-MxeH6; 2-3a, cleaved MxeH6 intein; 2-7a, pure full length Uaa protein αS-F*136, molecular
weight (MW) markers 17, 25, 30, 46, 58, 80, and 175 kDa.

Next, we carried out an in-depth analysis of hydrolysis of the fusion protein
by βME. A study carried out by New England Biolabs reported that dithiothreitol
(DTT) induced faster intein cleavage than βME.250 However, Kent and co-workers
showed that the conversion rate from peptide-thioesters (−COSR) to peptidecarboxylates (−CO2H) with DTT was significantly slower in comparison to βME in
6 M guanidinium.251 To test βME as a traceless cleaving reagent, we treated αSF*136-MxeH6 2-2a with 200 mM βME in HEPES buffer at pH 7.5 at room
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temperature (RT, 22 °C) and monitored the cleavage periodically using SDS PAGE
and MALDI MS. The fusion protein was >90% cleaved to give the protein−CO2H
after 8 h incubation. The intermediate product(s), presumably a mixture of αS-F*136
βME-thioester (2-4a) and βME-oxoester (2-5a), were observed at the 2 h time point
by MALDI MS. This mixture disappeared over time to form C-terminal carboxylate
2-7a, expelling ethylene sulfide (2-6). Similar analyses with DTT, performed by
colleague Dr. Solongo Batjargal, resulted in slightly faster splicing than βME, but
the formation of the desired C-terminal carboxylate was significantly slower with
DTT. MALDI MS analyses of full-length and trypsin-digested protein were used to
ensure the completion of carboxylate formation and the fidelity of Cnf insertion.
To optimize intein hydrolysis with βME, I incubated αS- F*136-MxeH6 2-2a
while varying conditions including temperature, βME concentration, and pH. As
expected, I observed a faster splicing rate as I increased the temperature or βME
concentration (Ea = 10.6 kcal·mol−1, k = 5.79 × 10−4 M−1 s−1). In contrast, the
splicing reactivity was not significantly influenced by pH, probably due to a balance
of acid- and base-catalyzed steps in transthioesterification, S−O rearrangement,
and hydrolysis. Based on these analyses, I carried out the rest of the hydrolysis
reactions with 200 mM βME at pH 7.5, 22 °C; conditions under which hydrolysis of
2-2a was >90% complete in 8 h, giving 2-7a in yields of 6 mg per L of cell culture.
However, hydrolysis conditions, including βME concentration, may need to be
optimized for a protein of interest depending on factors such as stability and the
identity of the C-terminal residue forming the intein thioester.
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Instead of eluting the protein from the Ni-affinity column (off-column),
hydrolysis can be carried out when the protein is still bound to the column (oncolumn). After removing cellular proteins by washing, resin-bound αS-F*136-MxeH6
2-2a was either retained on the beads or eluted from the column with imidazole.
The on- and off-column approaches were both hydrolyzed in >95% yield (Figure
2-1). For on-column hydrolysis, βME treatment inherently led to elution of pure
product. For off-column hydrolysis, incubation with Ni-NTA resin allowed for easy
removal of cleaved intein 2-3a and unhydrolyzed fusion protein 2-2a. It should be
noted that some reduction of the Ni2+ resin can occur with on-column hydrolysis,
and the resin should be regenerated with fresh NiSO4 if discoloration is observed.
It is important that the use of the intein fusion does not disrupt the native
fold of the protein of interest. Since αS is a disordered protein, we chose to
evaluate the impact of the intein on folding using CaM (work by Solongo Batjargal).
Previous attempts to express CaMF-F*139 (2-7b) using standard stop codon
suppression methods resulted in ∼70% truncation. In contrast, when we expressed
CaMF-F*139-MxeH6 (2-2b) and carried out off-column hydrolysis, we obtained 2-7b
in 8 mg/L yield. Through the use of circular dichroism spectroscopy and peptide
binding assays, Dr. Solongo Batjargal confirmed that the CaMF-F*139 structure was
not perturbed by fusion to the intein. However, it must be noted that the use of high
concentrations of βME may compromise the folding or activity of some proteins
that rely on key, labile disulfide bond; a separate activity assay should always be
used.
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To test the viability of the intein tag strategy for larger Uaas that are
incorporated less efficiently, I incorporated Acd in CaM and Bzf in αS and triggered
hydrolysis with βME to efficiently isolate CaM-δ139-CO2H (2-7c, Figure 2-2) or αSB136-CO2H (2-7d, Figure 2-2) in 3−10 mg/L yields, in spite of substantial truncation
(≥50%). Although the crude on-column hydrolysis products (“+ βME” lanes in
Figure 2-2) were relatively clean, additional fast protein liquid chromatography
(FPLC) purification should be used to purify proteins for biophysical assays, as is
typical of most Ni-NTA purifications. I also tested the compatibility of our method
with azide amino acids that may be subject to reduction by βME. Azf was
incorporated into αS as a “click” chemistry handle for reactions with strained
cyclooctynes. After on-column hydrolysis of αS-Z136-MxeH6 (2-2e), the incubation
of αS-Z136-CO2H (2-7e) with tetramethylrhodamine dibenzocyclooctyne (Rco)
resulted in labeling of αS to give αS-ZRco136-CO2H (2-8e, Figure 2-3). Again, at
least one round of additional purification is typically necessary to remove
unreacted dye.
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We also wished to ensure that our methods were applicable to larger
proteins, alternate immobilization tags, and other inteins. Therefore, I tested an
MBP (367 amino acids) fusion with a C-terminal Mxe GyrA intein and chitin binding
domain (CBD). I introduced a UAG codon at position 363, four residues from the
normal MBP C-terminus, and expressed the construct with Ppy. Isolation of the
full-length protein MBP-π363-MxeCBD (2-2f) by incubation with chitin beads and
subsequent treatment with βME resulted in the liberation of MBP-π363-CO2H (2-7f)
in an 8 mg/L yield. After additional purification
via FPLC, 2-7f was treated with a
S25
fluorescent azide compound (Rhodamine 110 azide, Faz) under Cu-catalyzed
“click” conditions to give MBP-πFaz363-CO2H (2-8f). In additional experiments
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take place.116, 117, 243 We expect that our method will expand the applications of
suppression-based Uaa methodology for labeling near the C-terminus, including
protein therapeutics or studies of protein structure and function.
Section 2.3 - Materials and Methods
2.3.1 – Materials
L-4-Azidophenylalanine (Azf, Z), L-4-benzoylphenylalanine (Bzf, B), Boc-Lthionophenylalanine-1-(6-nitro)benzotriazolide, and L-4-cyanophenylalanine (Cnf,
F*) were purchased from Bachem (Torrance, CA, USA). Acridon-2-ylalanine (Acd,
δ) was synthesized following the procedure described previously.246 Propargyl
tyrosine (Ppy, π) was synthesized following a procedure reported by Zhang et al.253
Rhodamine 110 azide (Faz) was purchased from Click Chemistry Tools
(Scottsdale, AZ, USA). Tetramethylrhodamine dibenzocyclooctyne (Rco) was
synthesized from 5(6) -carboxytetramethylrhodamine (EMD Millipore; Darmstadt,
Germany) and dibenzocyclooctyne-amine (Click Chemistry Tools) as described
previously.254 A QuickChange® site-directed mutagenesis kit, E. coli BL21(DE3)
cells, and all restriction enzymes were purchased from Stratagene (currently
Agilent Technologies; Santa Clara, CA, USA). Ni-NTA resin and a QIAquick gel
extraction kit were purchased from Qiagen (Valencia, CA, USA). Protease inhibitor
cocktail was purchased from Sigma-Aldrich. DNA oligomers were purchased from
Integrated DNA Technologies, Inc. (Coralville, IA, USA). All other chemical
reagents were purchased from Fisher Scientific (Pittsburgh, PA, USA). DNA
sequencing was performed at the University of Pennsylvania DNA sequencing
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facility. Milli-Q filtered (18 MΩ) water was used for all solutions (currently EMD
Millipore; Billerica, MA, USA). Matrix-assisted laser desorption ionization (MALDI)
mass spectra were collected with a Bruker Ultraflex III MALDI-TOF-TOF mass
spectrometer (Billerica, MA, USA). Protein purification was conducted on an ÄKTA
fast protein liquid chromatography (FPLC) system (GE Healthcare Life Sciences;
Piscataway Township, NJ, USA). Gels were imaged using a Typhoon FLA 7000
(GE Healthcare Life Sciences).

2.3.2 - General Protocol for Expression of Intein-Containing Proteins
E. coli BL21-Gold (DE3) cells were transformed with a plasmid containing a
protein of interest with a TAG mutation at the desired site and a plasmid containing
the UaaRS and tRNACUA pair (see below for specific UaaRS/tRNA pair used). In
all cases, the plasmid encoding the UaaRS/tRNA pair was streptomycin (Strep)
resistant, whereas the plasmid encoding the protein of interest was ampicillin
(Amp) resistant. Thus, cells were selected on the basis of Amp (100 μg/mL) and
Strep (100 μg/mL) resistance. A starter culture of 4 mL LB media was inoculated
with a single colony and was grown at 37 °C in the presence of Amp (100 mg/L)
and Strep (100 mg/L) for approximately 4 h. A secondary culture of 1 L M9 media
was inoculated with 4 mL of the starter culture and grown at 37 °C with the same
concentrations of Amp and Strep. M9 minimal media was prepared by adding the
following autoclaved solutions to 1 L of autoclaved water containing 6 g Na2HPO4,
3 g KH2PO4, 0.5 g NaCl and 1 g NH4Cl: 1 mL of 2 M MgSO4, 1 mL of 15 mg/mL
FeCl2 (in 1.0 M HCl), 1 mL of 15 mg/mL ZnCl2 (in acidified H2O), 2 mL of 10%
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Bacto™ Yeast Extract, 20 mL of 10% glycerol (v/v) and 1 μL of 1 M CaCl2. The
culture was induced by the addition of the Uaa (0.5 – 1 mM) followed by 0.5 mM
of IPTG when it reached an OD600 of 0.7 – 1.0 and allowed to grow at 18 °C
overnight, with shaking at 250 rpm.

Expression of αS-F*136-intein and αS-Z136-intein Fusions
These protein expressions followed the general protocol for inteincontaining fusions. Each plasmid containing an αS-TAG136-intein (pαS-TAG136MxeH6, pαS-TAG136-AvaH6, pαS-TAG136-MchH6, or pαS-TAG136-NpuH6) was
transformed into pDULE2-pXF (formerly known as pDULE2-pCNF) containing E.
coli BL21(DE3) cells. Once the secondary culture reached OD600 of 0.8, Cnf or Azf
(0.6 mM) was added to the culture just before induction with IPTG.

Expression of CaMF-F*139-intein Fusions
These protein expressions followed the general protocol for inteincontaining fusions. Each plasmid containing CaM-TAG139-intein (pCaMF-TAG139MxeH6 or pCaMF-TAG139-MchH6) was transformed into E. coli BL21(DE3) cells
carrying the pDULE2-pXF plasmid. After the secondary culture reached OD600 of
0.8, the culture was induced by the addition of 0.6 mM Cnf, followed by the addition
of IPTG.
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Expression of CaMF-δ139-MxeH6 Fusion
This protein expression followed the general protocol for intein-containing
fusions. The pCaMF-TAG139-MxeH6 plasmid was used to transform E. coli
BL21(DE3) cells carrying the pDULE2-Acd plasmid.246 When the OD600 reached
0.8, 70 mg of Acd (for 250 mL expression) was solubilized in 4 mL sterile water
(with 6 drops 5 M NaOH) and added into the culture, followed by induction with
IPTG.

Expression of αS-B136-MxeH6 Fusion
This protein expression followed the general protocol for intein-containing
fusions. A plasmid encoding pαS-TAG136-MxeH6 was co-transformed with the
pDULE2-Bzf plasmid255 into E. coli BL21(DE3) cells. Bzf was solubilized in 4 mL
of sterile water with (4 drops of 10 M NaOH) and added to the culture such that the
final concentration of Bzf was 0.5 mM. After the addition of Bzf at OD600 of 0.8,
protein expression was induced with IPTG. Bzf is a light sensitive compound, thus
the protein expression and the following purification were carried out in a dark
room.

Expression of MBP-π363-MxeCBD Fusion
This protein expression followed the general protocol for intein-containing
fusions. A plasmid encoding pTXB10-MBP-TAG363-MxeCBD was co-transformed
with the pDULE2-pXF plasmid into E. coli BL21(DE3) cells. When OD600 of the
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protein expression culture reached 0.8, Ppy (1 mM) was added, followed by IPTG
induction.

Expression of pET15b-CaM Mutant
A pET15b plasmid encoding CaMF-TAG139 was transformed into E. coli BL
21(DE3) cells carrying the pDULE2-pXF plasmid. This protein expression followed
the protocol for intein-containing fusions except that the culture was induced with
1.0 mM IPTG when it reached an OD600 of 0.8 and allowed to grow at 37 °C
overnight, shaking at 250 rpm.

2.3.3 - General Procedure for Purification of Proteins with His6 Tags
Cells (1 L expression) were harvested at 5,000 RPM using a GS3 rotor and
Sorvall RC-5 centrifuge for 15 min at 4 °C. After discarding the supernatant, the
pellet was resuspended in 30 mL of resuspension buffer: 40 mM Tris, 5 mM EDTA,
pH 8.3, protease inhibitor cocktail and 1 mM phenylmethanesulfonyl fluoride
(PMSF). The cells were lysed by sonication on ice, and the lysate was centrifuged
at 13,900 RPM for 20 min at 4 °C. The supernatant was then incubated with NiNTA resin (CV = 3 mL) for 1 - 2 h on ice. This slurry was loaded into a fritted
column, and the liquid allowed to flow through. The resin was washed extensively,
first with 15 mL of Buffer A (50 mM HEPES, pH 7.5), then twice with 10 mL of
Buffer B (50 mM HEPES, 5 mM imidazole, pH 7.5). At this point, the protein can
be eluted with 300 mM imidazole for off-column hydrolysis or can be incubated
with βME for on-column hydrolysis.
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Purification of MBP-π363-MxeCBD
Cells (1 L expression) were harvested at 5,000 RPM using a GS3 rotor and
Sorvall RC-5 centrifuge for 15 min at 4 °C. The supernatant was discarded, and
the pellet was resuspended in 30 mL of resuspension buffer: 20 mM Tris, 500 mM
NaCl, pH 7.5, protease inhibitor cocktail and 1 mM PMSF. After lysing the cells by
sonication on ice, the lysate was centrifuged at 13,900 RPM for 20 min at 4 °C.
The supernatant was incubated with chitin beads (CV = 3 - 4 mL) for 1 - 2 h on ice.
This slurry was loaded into a fritted column, and the liquid allowed to flow through.
The resin was washed extensively with 10 mL of 20 mM Tris, 500 mM NaCl, pH
7.5 three times. Then, the bound protein was subjected to on-column hydrolysis.

2.3.4 - General Procedure for On-Column Hydrolysis
To the resin (either Ni-NTA or chitin beads) bound with the protein of
interest, Buffer A (50 mM HEPES, pH 7.5) was added into the column such that
the final volume (resin CV + buffer volume) was 10 mL. Then, 141 μL of βME stock
(stock concentration = 14.2 M) was added such that the final concentration of βME
was 200 mM, and the column was incubated for 16 – 24 h at the desired
temperature, without shaking or on a tube rotisserie (gentle mixing). After overnight
incubation, the flow-through was collected, dialyzed against 20 mM Tris, pH 8.0,
and purified over HiTrap Q column using a 100 min NaCl gradient (0 to 0.5 M NaCl
in 20 mM Tris, pH 8.0). The product fractions were pooled and dialyzed against
the appropriate storage buffer and stored at - 80 °C until further use. Storage buffer
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for αS and MBP: 20 mM Tris, 100 mM NaCl, pH 7.5. Storage buffer for holo CaM:
6 mM CaCl2, 15 mM HEPES, 140 mM KCl, pH 6.7.

2.3.5 - General Procedure for Off-column Hydrolysis.
The mature fusion protein was eluted from the Ni-NTA resin with 6 x 2 mL
portions of elution buffer (50 mM HEPES, 300 mM imidazole, pH 7.5). The eluted
fractions were combined, and βME stock was added such that the final
concentration of βME was 200 mM. The protein solution was incubated for 16 – 24
h at desired temperature without shaking or on a tube rotisserie (gentle mixing).
The hydrolyzed protein was dialyzed against 20 mM Tris, pH 8.0 and incubated
with Ni-NTA resin for 1 h on ice. The flow-through was collected and purified by
HiTrap Q column as described above.

2.3.6 - Comparison of On- and Off-Column Hydrolysis.
After Ni-NTA purification, but before eluting the fusion protein with
imidazole, 50% of the Ni-beads were transferred into another fritted column and
then eluted with 50 mM HEPES, 300 mM imidazole, pH 8.0. Based on SDS PAGE
analysis, clean fractions were pooled and treated with 200 mM βME without
removal of imidazole. The other resin was brought up in 50 mM HEPES pH 8.0 in
the column, to the same volume as the off-column fraction volume, and treated
with 200 mM βME (Figure 2-1). Both batches were incubated at 4 °C or RT for 24
h without shaking, producing the hydrolyzed product, αS-F*136-CO2H, in a similar
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yield. However, one must be cautioned that the high concentration of βME may
reduce the Ni2+ in the Ni-NTA, which can be observed by brown discoloration.

Table 2-1: Calculated and Observed Protein Masses.
Peptide

Calculated m/z [M+H]

+

Observed m/z [M+H]

αS-F*136-MxeH6 (2-2a)

37328

37328

αS-F*136-CO2H (2-7a)

14469

14469

F

39560

39562

F

16701

16703

F

39652

39653

F

CaM -d139-CO2H (2-7c)

16793

16793

αS-B136-MxeH6 (2-2d)

37406

37406

αS-B136-CO2H (2-7d)

14548

14548

αS-Z136-MxeH6 (2-2e)

37345

37346

αS-Z136-CO2H (2-7e)

14486

14488

(2-8e)

15175

15176

MBP-p363-MxeH6 (2-2f)

67438

67445

MBP-p363-CO2H (2-7f)

39597

39597

40171

40171

CaM -F*139-MxeH6 (2-2b)
CaM -F*139-CO2H (2-7b)
CaM -d139-MxeH6 (2-2c)

αS-Z

Rco

MBP- p

136-CO2H

Faz

363-CO2H

(2-8f)

+

The masses for full length MBP-π363-MxeH6 (68242 Da) and MBP-π363-CO2H
(40401 Da) were not observed. Observed masses in the table above correspond
to proteolyzed MBP8-367-π363-MxeH6 and MBP8-367-π363-CO2H consistent with the
N-terminal cleavage of a ‘MKTEEGK’ fragment to reveal a N-terminal leucine. The
mass of the Cu click reaction with Faz is consistent with this proteolysis event.
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2.3.7 - Variation of Cleavage Conditions
To analyze the effect of temperature on the protein splicing rate, the fusion
protein, αS-F*136-MxeH6 (2-2a, 1 mg/mL, 100 μL) was incubated in the buffer (50
mM HEPES, pH 7.5) supplemented with 200 mM of βME (3.5 μL of 14.2 M stock
solution) at various temperatures (4 °C, 15 °C, RT, or 37 °C), without shaking. For
βME concentration dependent analysis, βME was added to each protein solution
(100 μL) such that the final concentration of βME was 25, 100, 200, 500, or 1000
mM. The mixture was incubated at room temperature for 24 h without shaking.
Lastly, to test the pH dependent hydrolysis rate, the fusion protein (250 μL in 50
mM HEPES at pH 7.5) buffer was exchanged to 50 mM MES at pH 6.0, 50 mM
HEPES at pH 7.0, 50 mM HEPES at pH 8.0, or 50 mM CHES at pH 9.0 using an
Amicon (EMD Millipore) Ultra 0.5 mL 3 kDa spin column. The concentration of the
buffer-exchanged protein was re-measured using a BCA assay and adjusted to ~
1 mg/mL. Each protein solution (100 μL) at various pHs was incubated with 200
mM of βME at room temperature. As a control reaction, the protein solution (25
μL) at various pHs was incubated without βME addition. The reactions were
sampled at various times for PAGE analysis as described above.
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2.3.8 - Analysis of Splicing Kinetics
The intensities of the Coomassie-stained gel bands were quantified using
ImageQuant TL software (GE Healthcare). The intensity of the fusion protein 2-2a
at t = 0 was normalized to unity. The fractional intensity values were plotted as a
function of time and fit to a pseudo first order kinetic model with KaleidaGraph
(Synergy software; Reading, PA, USA) using the equation 2.1:
y = y0 + A • exp (-kobst)

(2.1)

Here, y is the fractional intensity of the fusion protein, t is the time in hours, A is a
scaling factor for the fusion protein depletion (adjustable parameter), and y0
indicates the fraction of the fusion protein remaining at the reaction endpoint
(adjustable parameter). The rate data for cleavage reactions with varying βME
concentrations (Figure 2-5), pHs (Figure 2-6), and temperatures (Figure 2-7) were
all fit to equation (2.1). The observed rate constants at different concentrations of
βME were then fit to equation 2.2 to obtain a second order rate constant (k) of 5.79
x 10-4 M-1• s-1 (Figure 2-8).
kobs = [βME] • k

(2.2)

Rate constants obtained at different temperatures were fit to the Arhenius
expression to determine the activation barrier (Ea) using equation (2.3), where R
is the gas constant, T is temperature, and A is the pre-exponential factor (Figure
2-8):
ln(kobs) = -Ea/RT + ln(A)

(2.3)

A value of 10.6 kcal•mol-1 was obtained for Ea.
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Supporting Information

Figure 2-8: Dependence of Splicing Rate of Fusion Protein 2a on Reaction Conditions. Plots of reaction
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2.3.9 – Analysis of Uaa Proteins
Analysis of CaMF-δ139.
After the Ni-NTA purification, 25% (v/v) of the beads were transferred to
another fritted column and eluted with 300 mM imidazole for further analyses. The
remaining 75% of the beads were incubated with 200 mM βME at 22 °C for 24 h.
The flow-through was collected and purified by the procedure described above.
The fluorescent gel was imaged using a UVP Model UVLS-28 long wave UV lamp
and a Samsung Galaxy S4 13 megapixel camera.

Analysis of αS-B136.
After the Ni-NTA purification, 25% (v/v) of the beads were transferred to
another fritted column and eluted with 300 mM imidazole for further analyses. The
remaining 75% of the beads were incubated with 200 mM βME at 22 °C for 24 h.
The flow-through was collected and purified by the procedure described above.
Bzf is a light sensitive compound, thus direct exposure to light should be avoided.
Total protein content was visualized using Coomassie brilliant blue.

Labeling and Analysis of αS-Z136.
After Ni-NTA purification, 25% (v/v) of the 2-2e beads were aliquotted to a
fritted column and eluted with 300 mM imidazole for further analyses. The
remaining 75% of the 2-2e beads were incubated with 200 mM βME at 22 °C for
20 h. The flow- through was collected and purified by FPLC. 100 μL of Q-column
purified αS-Z136 (2-7e, 1 mg/mL) was reacted with 10 eq. of tetramethylrhodamine
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dibenzocyclooctyne (Rco) at 37 °C for 20 h. Excess dye was removed by buffer
exchange using Amicon Ultra 3 kilodalton centrifugal filters and an Eppendorf
5415R benchtop centrifuge. The gel fluorescence images and MALDI MS of the
purified αS-ZRco136 (2-8e) confirmed the presence of the Azf and Rco labeled
protein.

Labeling and Analysis of MBP-π363.
The Q-column purified MBP-π363-CO2H (12.5 μL; in 20 mM Tris, 250 mM
NaCl, pH 8.0) was labeled with 0.5 μL fluorescent Rhodamine 110 azide (Faz, 10
mM) using 2.5 μL of premixed catalyst solution, composed of THPTA (20.2 mM),
CuSO4 (5.11 mM), and sodium ascorbate (53.77 mM), at 37 °C for 4 hours. The
reactions were then boiled with a gel loading dye (5 μL) for 10 min at 95 °C and
analyzed by SDS PAGE. Fluorescence images were obtained with a Typhoon FLA
7000. Fluorescein was imaged using 473 nm excitation and a Y520 filter. Total
protein content was visualized using Coomassie brilliant blue.
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CHAPTER 3:
SYNTHESIS AND CHARACTERIZATION OF THIOAMIDE CONTAINING PROTEINS
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Reprinted (adapted) with permission from (Christopher R. Walters, D. Miklos
Szantai-Kis, Yitao Zhang, Zachary Reinert, W. Seth Horne, David M. Chenoweth,
and E. James Petersson) the Royal Society of Chemistry (Chem. Sci., 2017,8,
2868-2877). Copyright (2017) Royal Society of Chemistry.256
Section 3.1 – Introduction
The incorporation of functional molecules for monitoring and manipulating
protein folding has greatly facilitated studies of biochemical phenomena.257 The
optimal choice of modification to a protein of interest depends on the type of
process to be tracked, disrupted, strengthened, or isolated. Recently, there has
been an emerging interest in making subtle alterations to the protein backbone to
provide additional means to probe and mimic dynamic protein movements and
interactions.98, 103, 258-260 In particular, substituting a thioamide peptide linkage at
single or multiple positions provides a small but powerful means to influence and/or
monitor protein dynamics or function.
Thioamides (a.k.a. thionoamides, thioxoamides) have distinct properties
from oxoamides, including a larger van der Waals radius, red shifted πàπ* and
nàπ* transitions, lower oxidation potential, lower infrared (IR) stretching frequency
and lower N–H pKa.261-265 These properties have allowed thioamides to be
leveraged as photoswitches, Förster resonance energy transfer (FRET) acceptors,
and photoinduced electron transfer quenchers, as well as IR and circular dichroism
(CD) spectroscopic probes in biochemical systems.220,

221, 232, 234, 235, 237, 266-269

Although thioamides have already proven to be valuable multifaceted probes, few
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studies have sought to elucidate the energetic impacts they have on peptide or
protein folding. This consideration is of the utmost importance in assessing the
thioamide's potential as a “minimalist” spectroscopic label.
Previous structural studies of thioamide substitutions largely relied upon
short, isolated protein motifs in the absence of a tertiary structure context. In fact,
when we began this work, there were no published studies of thioamides in
proteins of defined tertiary structure. Fischer, Kiefhaber, and coworkers provided
the most complete study of the effects of thioamides in α-helices, using model
helical polyalanine peptides bearing thioalanine (AlaS, thioamide substitutions are
denoted by superscript “S” throughout) substitutions.231 Their analysis revealed
that the thioamide disrupts the helix if substituted at a central position, but is less
destabilizing at the N-terminus. Their results suggest that the thioamide is similar
to a glycine substitution at the same position in terms of helix disruption.
Thioamides have also been incorporated into the 15-mer S peptide, which forms
an α-helix upon binding to ribonuclease S.270 Substitutions were made throughout
the helix and were destabilizing at every position, with varying ΔΔG values in
comparison to the WT complex (0.6–4.7 kcal mol-1). However, in a different study,
Miwa and coworkers observed that a LeuS substitution in the central region of an
α-helical coiled-coil dimer gave a similarly helical structure to the oxoamide
counterpart (as observed by CD) and increased the melting temperature by 10
°C.221 This discrepancy, which likely arises from subtle geometric differences
between an isolated a-helix and that in a coiled coil271, implies that tertiary structure
may serve to lessen or even reverse destabilization by a thioamide.
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In an alternate secondary structure context, the thioamide was found to be
tolerated between residues i + 2 and i + 3 in a type II β-turn.220 Here, the
thiocarbonyl is solvent-exposed, and the interior of the turn does not require any
reorganization to accommodate the larger sulfur atom. Thioamide substitutions
have been made in a tryptophan-rich β-hairpin to interrogate the role of hydrogen
bond formation in the folding transition state.232 However, the results of this study
may not be general to all b-sheets due to the highly engineered sequence of the
tryptophan zipper peptide. Most recently, Raines and coworkers made thioamide
substitutions in collagen model peptides (CMPs) to assess their impact in the ProPro-Gly (PPG) repeats of an all PPG polyproline type II (PPII) helix.233 It was found
that incorporation of GlyS (i.e., PPGS) was significantly destabilizing, whereas
substitution with ProS (i.e., PPSG) was slightly stabilizing to the triple helix.
Taken together, the above studies present a limited understanding about
where thioamides can be utilized most efficiently in biological systems. Thioamides
are likely to have much more nuanced effects in proteins with complex tertiary folds
and dynamic regions. Thus far, only three full-length thioamide proteins have been
described in the literature: the semi-synthetic constructs a-synuclein and
dihydrofolate reductase, and the natural protein methyl-coenzyme M reductase.153,
226, 229

Consequently, there have been no systematic studies of thioamides in

folded proteins, which will be essential to guiding their future use as spectroscopic
probes or as modulators of protein structure and function.
Herein, we describe an in-depth study of the effects of thioamide backbone
substitution in two benchmark protein systems: (1) the C-terminal loop and helix of
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calmodulin (CaM), an α-helical protein and (2) the β-sheet of the B1 domain of
protein G (GB1), a compact α/β tertiary structure. For each protein, we performed
CD spectroscopy studies to elucidate the structural and thermodynamic stability
changes resulting from thioamide insertion. The two systems represent new hosts
for examination of the effects of thioamides on protein secondary structure in a
tertiary fold context. Overall, the findings reported here lay the groundwork for the
rational implementation of thioamides as biophysical probes in diverse protein
systems.

Figure 3-1: Top: NCL synthesis of CaM thioproteins. Cys135 is masked as glutamine by alkylation with
iodoacetamide. Bottom: Synthesis of GB1 thioproteins by hydrazide ligation. Cys24 undergoes
desulfurization to the native residue Ala24.

104

Section 3.2 – Results and Discussion
3.2.1 – Design and Semisynthesis of CaM Thioproteins
CaM is a 148 amino acid, α-helical calcium signaling protein that is
ubiquitous in eukaryotes. It is comprised of two structurally similar domains (N- and
C-terminal), each containing two calcium binding sites.272 Upon binding calcium,
CaM undergoes a conformational change to expose a trans-domain helix, which
acts as a binding platform for many of its regulatory target proteins.273,

274

Previously, a semisynthesis of CaM was performed to modify the C-terminal EFhand.275 Since these authors observed some destabilization of CaM, we decided
to limit thioamide substitutions in our investigations to the C-terminal loop and
helix, near the highest affinity calcium binding site. Thus, I performed native
chemical ligation (NCL) reactions between the expressed fragment CaM1–134 and
the synthetic fragment CaM135–148.
An existing CaM intein fusion was modified to produce CaM1–134-GyrA-His6,
which was expressed, purified, and cleaved with 2-mercaptoethanesulfonate
(MES) to yield the C-terminal thioester CaM1–134-MES (Figure 3-1, Top).252 Each
thiopeptide was made by solid phase peptide synthesis (SPPS) with the thioamide
installed as previously described.222 NCL reactions were performed between the
CaM135–148 fragment and CaM1–134-MES using published conditions optimized for
thiopeptides.153 The native residue at position 135 in CaM is a Gln. Therefore, Cys
at this position was masked after NCL to mimic Gln (denoted as CysQ) by
iodoacetamide treatment. This process routinely yielded 1–2 mg quantities of
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purified CaM (8–25% isolated yield with CaM1–134-MES protein as a limiting
reagent).
Positions for thioamide substitutions were selected with three criteria in
mind: importance to local secondary structure, functional importance for Ca2+
binding, and ease of synthesis of peptides and thioamide precursors. Of particular
interest were residues in the C-terminal helix of Ca2+-bound CaM (Tyr138, Glu139,
Glu140, Phe141, and Val142). Glu140 is functionally important as it undergoes
significant conformational change from the apo protein in order to directly chelate
a Ca2+ ion in the holo protein.273 Tyr138, Glu139, Phe141, and Val142 reside in the Nterminal and central portions of the helix. I hypothesized that thioamide substitution
at these sites would be destabilizing due to the weaker hydrogen bond acceptor
capacity of the thiocarbonyl. Two additional sites were chosen to assess the impact
of substitutions in loops and solvent exposed areas proximal to this helix (Val136
and Ala147, the penultimate residue in CaM).
Proteins bearing each of these thioamide substitutions were synthesized
using the MES thioester method described above and verified by MALDI-MS
(Table 3-5). Wild-type (WT) CaM and a Cys135 mutant were expressed in E. coli as
controls for proper refolding of the thioproteins. The Cys135 mutant was subjected
to denaturing NCL conditions similar to the thioproteins and subsequently
underwent the same purification and capping reaction.

106

3.2.2 – CaM Thioprotein Folding Thermodynamics
Each CaM variant was characterized by CD spectroscopy under two
different buffer conditions: one for the calcium-bound holo protein (10 mM Tris pH
7.5, 2 mM CaCl2) and another for the calcium-free apo form (10 mM Tris pH 7.5,
0.5 mM ethylenediaminetetraacetic acid, EDTA). CaM CD spectra show a
prototypical α-helical signature with minima at 208 and 222 nm (Figure 3-2).
Spectra for the thioprotein variants include a small minimum between 260 and 280
nm resulting from the thioamide πàπ* transition. This peak is weaker than the
comparable transition observed in GB1 and collagen (vide infra), or in previous
reported small thiopeptides.220, 221, 234 The attenuation of the thiocarbonyl CD signal
is likely an environmental and concentration based effect, as the thioamide in CaM
is a small fraction of the overall amide content and the region containing the
thioamide is destabilized in several variants. The thioamide nàπ* transition at 340
nm is not visible in any of the CaM CD spectra.
Among the holo proteins, the spectrum of CysQ135 is similar in shape and
magnitude to that of WT CaM, indicating the side chain modification necessary to
enable NCL has no significant effect on the fold (Figure 3-2, Top). Most of the
thioamide substitutions appear well tolerated in the holo protein; however, the
TyrS138 and PheS141 modifications considerably alter the folded state, with a nearly
three-fold decrease in molar residue ellipticity (MRE, θ) at 222 and 208 nm. These
mutants show a similar helical signature to the N-terminal truncation mutant CaM1–
71,

suggesting that the C-terminal domain may be completely disordered as a result

of thioamide incorporation (Figure 3-3). To understand more about the nature of
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each thioamide substitution, I subjected the CaM variants to thermal denaturation.
Like WT CaM, each of the thioamide variants and the CysQ135 oxo control have
melting temperatures greater than 80 °C in the presence of Ca2+ (Figure 3-4).
Upon the removal of calcium by EDTA, CaM reverts to the apo structure,
which lacks the stable transdomain helix and open EF hands observed in the holo
form.276, 277 I hypothesized that the substantial structural differences between the
apo and holo folds may lead a thioamide at a given site to have distinct effects in
those two contexts. Thus, I carried out an analogous series of CD experiments to
characterize folding in the apo CaM variants. Surprisingly, the CysQ135 modification
appears to be significantly perturbing to the apo form, reducing helicity by half
relative to apo WT CaM (Figure 3-2, Bottom). While the origins of the effect of side
chain modification at residue 135 are not clear, we used the data observed for the
CysQ135 oxo control as a benchmark to probe the impact of thioamide incorporation
on the apo fold.
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Figure 3-2: Holo (top) and apo (bottom) θMRE spectra for the WT, Cys
S
S
Glu 140, and Phe 141 show the largest disruptions in helicity.
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Figure 3-3: Molar ellipticity (θn) of holo CaM truncations (top) and apo CaM truncations (top). Tyr 138 and
S
Phe 141 modifications are more disruptive than losing the C-terminal helix (CaM1-134), but not as disruptive
as removal of the C-terminal domain (CaM1-71) in the apo structure.
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Figure 3-4: Thermal melting profiles of holo CaM variants plotted as θMRE transformed data.

Each of the apo proteins show complete unfolding transitions over the
temperature range of 5 to 95 °C. Initial apo thermal melts were performed on WT
CaM and the CysQ135 control. The melting temperature for the WT CaM sample is
lower than values previously reported in literature,278-281 likely due to different
buffer conditions. Although I attempted to fit our data to a two-state model (Table
3-9, Figures 3-18 through 3-21), I ultimately chose to analyze our results using a
three-state model. The three-state model has been rigorously tested for CaM and
has shown residuals that are more random and have smaller variance than those
from two-state model, indicating that CaM unfolding proceeds through a semistable intermediate.281 Additionally, the enthalpy and melting temperature values
obtained in two-state fitting had higher error values, suggesting that the three-state
fitting procedure was superior for our analysis. Therefore, I report thermodynamic
data for each transition (TM1, ΔH1, TM2, and ΔH2) and an overall ΔGU that is the
sum of the individual unfolding free energies for each transition calculated at 25 °C
(Table 3-1).
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For comparison of three-state CaM unfolding to the two-state unfolding of
GB1, I generated pseudo fraction folded (Ff*) plots based on this three-state model,
where the intermediate state makes a weighted contribution to the total fraction of
folded protein (Figure 3-5). I denote the half-point of these weighted unfolding
curves as TM*. Using this fitting model, I determined that CysQ135 CaM is slightly
less stable than WT CaM in TM* and ΔGU; however, this minor change in stability
should not prevent it from serving as an appropriate control to study the effects of
the thioamide substitutions.
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Figure 3-5: Thermal Stability of CaM Thioamide Variants. CD thermal melts of stabilizing and
destabilizing apo CaM variants plotted as fraction folded (Ff*) fits showing a weighted contribution
of the intermediate to the folded state as discussed above. Melting curves were obtained by
measuring the θ222 at 1 °C increments in 10 mM Tris, 0.5 mM EDTA pH 7.5. Transformation of raw
CD signal to MRE values and three-state fitting procedures were performed as described in Section
3.3.
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Table 3-1: Apo CaM thermodynamic values.
CaM
Variant

TM1
(°C)

ΔH1
-1
(kcal mol )

TM2
(°C)

ΔH2
-1
(kcal mol )

TM *
(°C)

ΔTm*
(°C)

ΔGU
-1
(kcal mol )

ΔΔGU
-1
(kcal mol )

WT

43.5 ± 0.6

33.1 ± 0.8

48.6 ± 0.6

60.5 ± 0.7

46.8 ± 0.3

---

6.4 ± 0.2

---

38.9 ± 0.8

30.2 ± 0.9

48.8 ± 0.7

61.7 ± 0.8

45.5 ± 0.4

---

5.9 ± 0.1

---

Cys

Q

135

Val

S

Oxo

136

39.6 ± 0.5

36.7 ± 0.6

55.3 ± 0.8

52.0 ± 0.5

48.6 ± 0.7

3.2

6.5 ± 0.1

0.6

S

Tyr 138

34.7 ± 0.8

39.7 ± 0.7

43.0 ± 0.9

51.1 ± 1.0

39.3 ± 0.8

-6.2

4.1 ± 0.2

-1.8

S

40.7 ± 0.7

40.1 ± 0.4

51.9 ± 0.6

53.9 ± 0.9

47.0 ± 0.1

1.6

6.4 ± 0.1

0.5

S

Glu 140

33.9 ± 1.1

34.5 ± 0.6

45.5 ± 0.8

45.9 ± 1.0

40.4 ± 0.8

-5.1

3.9 ± 0.2

-2.0

S

Val 142

36.4 ± 0.6

35.5 ± 0.8

48.4 ± 0.8

62.9 ± 0.9

44.0 ± 0.7

-1.5

5.8 ± 0.2

-0.1

S

37.2 ± 0.9

32.1 ± 0.2

47.0 ± 0.6

63.2 ± 1.3

43.7 ± 0.7

-1.8

5.5 ± 0.2

-0.3

Glu 139

Ala 147

Using the CysQ135 protein as a basis for comparison, AlaS147 slightly
destabilizes the apo fold, lowering ΔGU by 0.4 kcal mol-1. In agreement with the
CD spectra, TyrS138 and GluS140 appear to be the most destabilizing mutations,
decreasing ΔGU by 1.8 and 2.0 kcal mol-1, respectively. ValS142 is well tolerated,
giving rise to a ΔGU within error of the oxoamide. Unexpectedly, both ValS136 and
GluS139 show elevated melting temperatures and an increase of ΔGU by 0.5 kcal
mol-1. The unstable PheS141 construct was prone to aggregation during thermal
denaturation, precluding rigorous thermodynamic analysis. Nevertheless, the
thioamide substitutions that I could study span a range of thermodynamic effects,
which we can interpret in terms of known structures.
The analysis of the thioamide substitutions in apo CaM is limited by the
small number of high-resolution structures available. Here, the analysis will focus
on structures of the apo protein from Rattus norvegicus (crystal, PDB entry 1QX5)
and Xenopus laevis (NMR, PDB entry 1CFD).276, 277 While the differences in these
two structures are valuable in considering the dynamics of apo CaM, it should be
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noted that crystal packing in the 1QX5 structure gives rise to non-native
intermolecular interactions. However, these are analogous to intramolecular
interactions observed in the NMR structure (Figure 3-6 and described in detail in
Figures 3-27 through 3-30). As detailed below, both structures provide valuable
insight into the effects of the thioamide substitutions.
Based on comparison to the CysQ135 control, AlaS147 is mildly destabilizing.
This is somewhat surprising as the thioamide in question is located at the Cterminal end of the helix and therefore should serve as an N–H hydrogen bond
donor with the thiocarbonyl sulfur oriented into solvent (Figures 3-27 and 3-28).
ValS142 shows only a minimal reduction in TM (Figure 3-5). In both the NMR and Xray structure, the C--O/N distance for the hydrogen bond that the ValS142
thiocarbonyl would make with Thr146 is somewhat long (3.1 Å and 3.3 Å,
respectively), so the thiocarbonyl could reasonably be accommodated there
(Figure 3-29). Placing a thioamide near the start of the C-terminal helix (TyrS138 or
GluS140) is highly destabilizing, presumably due to disruption of backbone hydrogen
bonding. Both these residues have relatively short C--O/N hydrogen bond
distances and also interact with neighboring loops or helices (Figure 3-6 Right,
Figure 3-30 and Table 3-10).
Two thioamide variants were significantly stabilized relative to the
oxoamide: ValS136 and GluS139. In both cases, the stabilization appears to arise
from a combination of a location sterically tolerant to the thioamide carbonyl and a
strengthening of hydrogen bonds involving the thioamide N–H. In the 1CFD
structure, the C--O/N distance for the hydrogen bond that the ValS136 thiocarbonyl
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would make with Ile100 is 3.4 Å and the C--O/N angle is 137°. In the 1QX5 structure,
this carbonyl makes an intermolecular hydrogen bond with another CaM molecule
in the crystal lattice (Figure 3-6 Left, Figure 3-29, and Table 3-10). Thus, the longer
thiocarbonyl could certainly be accommodated in this flexible region of apo CaM
and might even make for a more favorable interaction. In the 1QX5 structure, the
GluS139 carbonyl C--O/N distance from the Val142/Gln143 amide N–H is 3.0 Å and
the C--O/N angle is 144°, making it seemingly unfavorable for thioamide
substitution. However, in the 1CFD NMR structure, this distance and angle are 3.4
Å and 145°, respectively, indicating sufficient flexibility in this region to
accommodate the thiocarbonyl (Figure 3-6 and Table 3-10).
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Figure 3-6: Structural Analysis of CaM Thioamide Variants. Top Left: Potential hydrogen bonding
S
S
S
S
interactions for stabilization observed in Val 136 and Glu 139 substitutions. Right: Neutral (Val 142 and Ala 147)
S
S
S
S
S
and destabilizing (Tyr 138, Glu 140, and Phe 141) substitutions. Destabilization of CaM by Phe 141 and Tyr 138
S
and may be due to disruption in the packing of the helix. Glu 140 disrupts hydrogen bond acceptance without
making a compensatory hydrogen bond donor interaction. Increased C=O---N distance (3.1 Å) in the turn of
S
S
the helix at Val 142 may allow for better accommodation of the thioamide sulfur. Ala 147 is the penultimate
C-terminal residue and only serves as a hydrogen bond donor. Structures rendered from PDB entry 1QX5
277, 282
chains D (yellow) and R (green) and from PDB entry 1CFD (orange, only N-terminal region shown).

For both ValS136 and GluS139, there is also a potential to acquire a new
favorable thioamide N–H interaction. In the 1QX5 structure, the Glu140 N–H (part
of a thioamide in GluS139) is positioned ideally in the plane of the backbone carbonyl
of Asn137 with a 3.3 Å N/O--C hydrogen bond length (Figure 3-6, Left). Alternatively,
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in the 1CFD structure, the GluS139 thioamide N–H makes a hydrogen bond with the
sidechain carbonyl of Asn137 (Figure 3-29). Although this region of CaM is dynamic,
both structures offer plausible explanations for the increased stability of the GluS139
variant. On the other hand, for ValS136, the explanation is less clear-cut. In the
1QX5 structure, the distance from the side chain carbonyl of Glu140 to the
backbone nitrogen of Asn137 is 4.2 Å and the carbonyl is out of plane from the N–
H bond (Figure 3-29). No interaction of this N–H with Glu140 is apparent in the
1CFD structure. Nonetheless, the side chain of Glu140 appears to be highly mobile
(average B-factor of 86.5 Å2 in 1QX5) and reorientation of the side chain to favor
this hydrogen bond may be possible. Although previously unappreciated, these
interactions may be responsible for the positioning of the C-terminal helix for
correct folding of the helix-loop-helix motif in the EF-hand. However, it is
impossible to know the exact details of how each thioamide is changing the local
and distal dynamics of the protein without high-resolution structural studies.
3.2.3 – 1H – 15N Heteronuclear Correlated Single Quantum Coherence
Nuclear Magnetic Resonance Studies of CaM
15

N isotopically labeled proteins have been traditionally used to enable two-

dimensional NMR studies of proteins to inform upon changes in the environment
of single amino acid residues in distinct conformers. In particular, acquisition of
heteronuclear single quantum coherence (HSQC) spectra have been used to great
effect in the study of CaM conformational changes and protein-protein
interactions.283-286 Because of the wealth of previous CaM NMR experiments in the
literature, NMR was an attractive target as a high-resolution technique by which to
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study the thioamide’s effects on the C-terminal domain of CaM. To begin
preliminary investigations into the site-specific effects of thioamide incorporation, I
modified the CaM semisynthesis to allow for isotopic labeling of residues 1-134.
Although this will not provide complete coverage of the entire CaMS thioprotein
structure, this partially isotopically labeled system can be used as a model for
future NMR studies of the protein. Additionally, this system will provide insight into
how distal sites that are not proximal to the thioamide are perturbed by its inclusion.

15 NH

4Cl

HS
S
+
O

1) Thiophenol

H 2N
2)

RS

S

O
I

NH 2

15

Figure 3-7: Scheme for generating CaM proteins that contain N isotopically labeled residues 1-134 for
HSQC NMR structural studies.

To initiate NMR studies of the protein, I slightly modified the growth
conditions of the CaM1-134-GyrA fusion protein so that the

15

N isotope can be

incorporated into the protein. Minimal M9 media was prepared that was devoid of
any nitrogen sources other than 15NH4Cl (see Section 3.3.3). E. coli containing the
appropriate plasmid for CaM1-134-GyrA were grown in this media and protein
production

was

induced

through

the

addition

of

isopropyl

β-D-1-

thiogalactopyranoside (IPTG). From a 1 L expression, I estimate a yield of ~30 mg
CaM1-134-GyrA is produced from which approximately 25-28 mg of CaM1-134-MES
can be isolated after MESNa cleavage (dry weight calculation).
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I initially began these studies by synthesizing a CysQ135 oxo control as well
as ValS136 and TyrS138 single thioamide constructs. These constructs were prepared
with yields similar to those of the proteins used for CD studies, but expressions
were performed a much larger scale to produce quantities sufficient for NMR
studies (5-8 mg). After NCL, purification, and capping each Cys135 residue with
iodoacetamide, the proteins were frozen in liquid nitrogen and lyophilized to a
powder. Dried protein stocks were then dissolved in 475 μL of holo NMR buffer
(100 mM KCl, 6 mM CaCl2, 0.02 % NaN3, 10 mM d4-imidazole, pH 6.5). However,
it was found that dried CaM proteins did not completely dissolve in NMR buffer as
they did previously with CD sample buffers. This lead to insufficient quantities of
15

N-labeled CaM in solution for HSQC spectra acquisition. Therefore, the CysQ oxo

control and the ValS136 constructs were synthesized again and after a final FPLC
purification, buffer exchanged into minimal Tris buffer instead of lyophilizing them
to a solid. Each protein’s buffer was then exchanged into holo NMR buffer and the
volume reduced to ~500 μL using Amicon 3K MWCO spin filters. By keeping the
protein in solution during NMR sample preparation, I found that the insolubility
issues encountered through the previously attempted preparation could be
avoided. However, the protein samples (~0.2 mM) were still lower than the target
concentration for HSQC acquisition (0.5 mM). Nonetheless, each sample had D2O
added to a final concentration of 5% v/v to enable shimming of the magnet, and
HSQC acquisition was attempted. Although the samples may be insufficiently
concentrated to acquire all desired chemical shifts, the data set obtained provided
an initial hint of the residue specific structural changes that arise from inserting a
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thioamide at the ValS136 position, and provided a basis by which future NMR HSQC
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Figure 3-8: NMR HSQC ( H- N) spectra. Each protein displays characteristic folded CaM features such as
1
the H downfield chemical shift of the EF Hand glycine residues 25, 61, 98, and 134. Leu116 and Thr117 both
Q
show small changes in the chemical shift compared to the Cys oxo protein.

HSQC spectra were acquired by Dr. Kathy Valentine (Professor Josh
Wand’s laboratory) using previously described methods for CaM NMR
acquisition.285, 286 Although definitive assignments cannot be made on the basis of
the collection performed here, a spectra of the 100 % homologous Xenopus laevis
(frog) CaM from Kainosho et al.284 can be used as reference data set to make
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tentative resonance peak assignments and comparisons between the oxo control
and ValS136.
As shown in Figure 3-8, the CysQ135 and ValS136 proteins have overlapping
resonances for the majority of peaks that can be detected for the ~0.2 mM
samples. Additionally, these spectra have several characteristics that indicate that
the proteins are well folded compared to the reference spectrum from X. laevis
CaM. One such characteristic is a distinct grouping of glycine amide resonances
(observed in both samples), one from each of the EF hands responsible for binding
Ca2+ ions (residues 25, 61, 98, and 134). Gly134 is proximal to the ValS136 thioamide
substitution and shows an identical chemical shift to oxo control, indicating that the
domain architecture of this EF hand may be intact. This is also corroborated by the
similarity to the chemical shift observed in Kainosho et al.’s HSQC data.284
However, there are two notable differences in individually assigned residues based
on the X. laevis spectra. The first distinct change comes at the resonance centered
around the coordinates (1H: 9.2 ppm,

15

N: 115 ppm). For the CysQ135, this

resonance overlays exactly with the Thr117 in the reference spectrum. However,
the ValS136 spectrum shows an upfield chemical shift for each axis. The resonance
corresponding to the Leu116 residue (1H: 8.8 ppm,

15

N: 125 ppm) also shows a

similar difference from the CysQ spectrum. These two residues are present in the
loop of the second EF hand in the C-terminal domain (see Figure 3-9) and directly
precede the second helix of this helix-loop-helix motif. These residues are
approximately 17-20 Å away from the site of modification (measurement from
1UP5 and 1J7P), indicating that a thioamide modification, such as ValS136, can
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have long range effects on the chemical environment of residues in other calcium
binding domains.

S

Figure 3-9: Left: Crystal structure of CaM showing the positions of the thioamide substitution (Val 136)
relative to the two perturbed residues (Leu116 and Thr117). Right: NMR solution phase structure of the Cterminal domain of CaM showing an identical relationship between the two highlighted regions. The
approximate distance between Val136 and Leu116/Thr117 is 17 Å as measured in Pymol (PDB accession
283, 287
numbers 1UP5 and 1J7P)
.

Although the samples used in this preliminary study are underconcentrated, and not every resonance can be detected and assigned in the
spectra, these data suggest that the thioamide modification can have long-range
effects on the structural dynamics of proteins. This structural modulation could be
useful in engineering protein structure or in the disruption of protein-protein
interactions. However, the syntheses of these proteins must be optimized to
produce larger quantities of protein so that an increased signal-to-noise ratio can
be obtained during HSQC spectra acquisition. Therefore, it may be more
advantageous to screen crystallization conditions for CaMS in the pursuit of high
resolution X-ray crystal structures of thioamides embedded in secondary and
tertiary folds.
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3.2.4 – Design and Synthesis of GB1 Thioproteins
The immunoglobulin-binding B1 domain of protein G from Streptococcus
bacteria is 56 amino acids in length and has a tertiary structure comprised of three
of the most common secondary structural motifs in proteins.288 The compact GB1
fold consists of a protein-spanning α-helix packed against a four-stranded β-sheet
with both parallel and anti-parallel strands, making it an ideal model to study local
folding dynamics in a tertiary structure context. Indeed, NMR, X-ray
crystallography, and an array of computational studies have been used to great
effect in understanding the order in which individual secondary structure elements
fold to form the final tertiary structure of GB1.289,

290

More recently, various

unnatural backbone substitutions have been examined in GB1.291-293 While these
substitutions were thermodynamically destabilizing to the folded state, many of the
proteins showed a native-like fold by X-ray crystallography and CD. Given these
precedents, GB1 is an excellent platform to examine effects of thioamides on
folding in a β-sheet, a structural motif not yet studied in detail with thioamide
substitutions.
GB1 and three thioamide variants were synthesized using a combination of
automated and manual SPPS, followed by NCL (work by D. Miklos Szantai-Kis).
We originally intended to synthesize thioamide GB1 through SPPS only, but
encountered low yields due to suboptimal coupling reactions after thioamide
insertion and Edman degradation-type cleavage of the amide bond C-terminal to
the thioamide under acidic deprotection conditions. Thioprotein production by NCL
allowed us to work with shorter thiopeptide fragments where the number of
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couplings subsequent to thioamide insertion and the length of the deprotection
reactions can be limited. In the synthesis of GB1 and variants, D.Miklos SzantaiKis performed a ligation between a thioamide containing GB11–23 thioester and
GB124–56Cys24. After desulfurization of Cys24 using VA-044 and sacrificial
thioacetamide, thioamide GB1 constructs were obtained with no trace of the
ligation point and yields ranging between 10 and 20 % (Figure 3-1, Bottom).218
Using this NCL and desulfurization strategy, we synthesized three GB1
variants with single thioamide substitutions at Leu5, Ile6, or Leu7 (synthesis
performed by D. Miklos Szantai-Kis). The Leu5 residue acts as a hydrogen bond
acceptor in an anti-parallel β-sheet interaction and as a hydrogen bond donor in a
parallel β-sheet interaction. In contrast, Ile6 acts as a hydrogen bond acceptor in a
parallel β-sheet interaction and as a hydrogen bond donor in an anti-parallel βsheet interaction. The hydrogen bonding pattern of Leu7 is similar to that of Leu5
(anti-parallel acceptor, parallel donor), but the carbonyl points outward slightly,
increasing the hydrogen bond distance by 0.2 Å and placing it out of plane with
respect to its partner in the sheet. Thus, we anticipated that the increased size and
C==X bond length of the thiocarbonyl might be better accommodated at Leu7 than
at Leu5 or Ile6. These three substitutions, while not comprehensive, provide
examples of how thioamides may be accommodated into both types of b-sheet
folds within the context of a complex tertiary domain.
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3.2.5 – GB1 Thioprotein Folding Thermodynamics
GB1 CD spectra typically contain a broad minimum between 208 and 222
nm with few defined features in this range due to the combination of the α-helical
and β-sheet contributions to the signal. The LeuS5 and IleS6 substitutions have
nearly identical spectra and maintain similar curve features as the GB1 Oxo
control, but with significantly reduced MRE values (Figure 3-10). It is likely that the
internal hydrogen bonding networks are perturbed by these substitutions, leading
to a disruption in the packing of the tertiary structure. LeuS7 seems to be the most
tolerated thioamide substitution with a CD signature closest in magnitude to the
control at 208 nm. However, the MRE values are still significantly reduced across
the entire set of spectra.
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Figure 3-10: CD scans of GB1 Oxo and GB1 thioproteins. Each of the thioproteins displays the characteristic
minimum centered at 270 nm from the thioamide absorbance.

For GB1, the thermal denaturation curves (See Section 3.3, Figures 3-35
and 3-36) fit well to a two-state unfolding model. The TM of GB1 Oxo is 78.2 °C
and includes a sharp unfolding transition that is preceded by only a modest initial
unfolding event occurring gradually between 5 and 65 °C (Figure 3-11). The
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thermodynamic differences for each thioamide substitution track with the changes
in signal observed in the wavelength scans. IleS6 leads to a 9.5 °C destabilization
in melting temperature while LeuS5 leads to an even greater destabilization of 12.6
°C. LeuS7 is the least destabilizing thioamide substitution with a melting
temperature only 2.3 °C lower than WT GB1. The corresponding unfolding free
energies (ΔΔGU), show that LeuS7 is destabilized by only 0.5 kcal mol-1. Thus, I
have demonstrated that the precise context of thioamide substitution is also
important for β-sheet systems.
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Figure 3-11: Thermal Stability of GB1 Thioamide Variants. CD thermal melts of GB1 variants plotted as
fraction folded values generated from a two-state fitting model. Melting curves were obtained by
measuring the θ220 at 1 °C increments in 20 mM Na2HPO4 pH 7.0. Transformation of raw CD signal to MRE
values and two-state fitting procedures were performed as described in Section 3.3.

Table 3-2: GB1 Thermodynamic Values.
GB1 Variant
Oxo
S
Leu 5
S
Ile 6
S
Leu 7

Tm
(°C)
78.2 ± 0.0
65.6 ± 1.6
68.7 ± 0.5
75.9 ± 1.2
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ΔTM
(°C)
---12.6
-9.5
-2.3

ΔΔGU
-1
(kcal mol )
---2.5 ± 0.3
-1.9 ± 0.1
-0.5 ± 0.2

In GB1, the thermodynamic and structural changes from thioamide
incorporation can be readily rationalized based on existing structural data (PDB
entry 2QMT).290 LeuS5 thiocarbonyl substitution likely disrupts the hydrogen bond
with the N–H of Thr16, altering packing of only the outer strand of the β-sheet
(Figure 3-12). The LeuS5 thioamide N–H should maintain the hydrogen bond to the
Phe52 carbonyl in the core parallel β-sheet interface and might even strengthen
this interaction. Computational modeling indicates that Leu5 forms part of the
folding nucleus of GB1,289 so perhaps it is not surprising that the Leu5 substitution
has the most significant effect on the TM and reduced the cooperativity of the
folding transition. IleS6 reverses this hydrogen bonding pattern, maintaining the N–
H hydrogen bond to the carbonyl of Gly14 in the outer strand and disrupting
hydrogen bonding with the Val54 amide N–H in the core strand. Disturbance of the
core of the β-sheet region would explain why the IleS6 substitution induces such a
significant change in the TM. LeuS7 causes almost no disruption in folding as
determined by CD. It seems that the longer hydrogen bond distance (3.1 Å to the
Lys13/Gly14 amide N) and out-of-plane orientation of the Leu7 carbonyl are
permissive of the sulfur substitution, as I anticipated. If there is any minor
disturbance, it could be compensated for by the increased strength of the LeuS7
thioamide N–H hydrogen bond with the carbonyl of Val54. Taken together, these
analyses reinforce my observation that the effects of thioamide incorporation in βsheets can depend dramatically on the location of the substitution (Table 3-2).
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Figure 3-12: Structural Analysis of GB1 Thioamide Variants. Left: Overall structure of GB1 with modeled
thioamide substitutions. Each thioamide substitution is poised to make two hydrogen bonding interactions
S
with opposing strands. Right: Zoomed in region showing that the Leu 7 thiocarbonyl is skewed out of the
plane of the anti-parallel β-sheet (C=O---N angle = 134°), providing a potential explanation for why it is less
S
S
294
destabilizing than Leu 5 or Ile 6. Structures rendered from PDB entry 2QMT.

3.2.6 – Outlook and Conclusions
Collaborative work by Dr. Yitao Zhang and Professor David Chenoweth
gave us a third protein system (collagen) to examine thioamide backbone
substitutions and compare our results in CaM and GB1. To probe the effect of the
thioamide on collagen model peptide (CMP) self-assembly, they installed the
moiety

near

the

central

positions

of

the

21-mer

host

system

Ac-

(POG)3(XYG)(POG)3-NH2. Peptides were synthesized through SPPS, coupling
Fmoc-POG-OH trimers at all but the central POG subunit (the ‘O’ denotes 2S,4R4-hydroxyproline or Hyp). Here, individual residues were installed, including the
suitable building block for incorporation of the thioamide. Analysis of thioamide
substitutions in PPG and POG CMPs illustrates the three fundamental effects that
thioamides are expected to have on proteins. In PSPG, the combination of weaker
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hydrogen bonding and steric clashes due to the larger van der Waals radius of
sulfur and longer C=S bond length significantly destabilizes (ΔTM = -25.7 °C) the
protein (Figure 3-13). In contrast, both PPSG and POSG collagen peptides are
moderately stabilized compared to their oxoamide counterparts. At the Yaa
position, the thioamide N–H can form a stabilizing inter-strand hydrogen bond,
while the thiocarbonyl projects into solvent. Thus, thioamide substitution at the Yaa
position confers the energetic benefits of the stronger hydrogen bond donor
without the penalties of the weaker acceptor or steric clashes. The disruption
introduced by the PPGS thioamide is not as drastic as the PSPG replacement
because it does not pack against the core of the triple helix, but it may provide
general steric interference with neighboring strand contacts. The POSG and POGS
peptides recapitulate the positional effects of the thioamide while retaining the
stabilizing effects of Hyp. The additivity of the backbone and sidechain
substitutions supports the idea that the conformations of the thioamide collagen
variants are similar to the parent collagen model peptides (with the exception of
PSPG, for which few conclusions can be drawn). In this regard, our data shows
that a thioamide substitution can act synergistically with a proline ring substitution
for potential applications in thiopeptide based collagen materials.
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Like for CaM and GB1, thioamide substitutions in collagen have
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Thioamides have the potential to be one of the most multifunctional probes
in the large repertoire of unnatural amino acid substitutions available for protein
labeling. They can be used as functional handles in IR, CD, or fluorescence
spectroscopy, as photoswitches, or as perturbants in structure/ function studies.
With thioamide substitutions across three protein systems, CaM, GB1, and
collagen model peptides (work by Dr. Yitao Zhang and Professor David
Chenoweth), the data set amassed in our recent publication represents the most
comprehensive study to date bearing on the question of how thioamides affect
protein thermostability.256 While virtually all previous reports of thioamides in
secondary structure contexts have found the modification to be disruptive, I have
shown that, within CaM, the replacement is tolerated in some positions within the
C-terminal α-helix as well as the preceding loop. While all thioamide substitutions
in the β-sheet of GB1 were destabilizing, at one position the impact was minimal.
The CMP (Zhang and Chenoweth) results are consistent with findings by Newberry
et al,233 and although high resolution structures have not yet been obtained, the
additive stabilizing effects of thioamidation and proline hydroxylation suggests that
these CMPs adopt a fold consistent with structures like PDB entry 2CUO.
Overall, our analysis based on existing crystal and NMR structures allows
us to rationalize many of our findings in terms of the physical properties of the
thioamide bond, and to consider how both perturbing and non-perturbing thioamide
locations might be useful. Thioamide incorporation in the first turn of an a-helix is
a strong helix breaker, and it is disruptive in sheets where it replaces a short
hydrogen bond that is in the plane of the sheet. These findings can be explained
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by the longer C=S bond length and larger van der Waals radius of sulfur, and
highlight the potential of thioamides as tools to modulate protein folding.
Thioamides can be tolerated in helices where the substituted amide oxygen
participates in longer H-bonds and in sheets where the carbonyl bond is at a more
acute angle. I have also seen that thioamides are tolerated, or even stabilizing,
when the disruptive effect of the thiocarbonyl is compensated by the stronger
hydrogen bond donation of the thioamide N–H. Minimally perturbing substitutions
are ideal for fluorescence studies using the thioamide as a quenching moiety.
Increased thermal stability of ValS136 and GluS139 in CaM highlight the fact that
thioamides can serve as stabilizing backbone replacements for interrogating
hydrogen bonding networks.
The results reported here have set a foundation for rational thioprotein
design to realize the above benefits to biophysics and protein engineering. A
growing database of thioamide “mutants” could, in conjunction with appropriate
computational models, allow one to predict the effects of thioamide substitution to
achieve the desired destabilizing, neutral, or stabilizing effects on a protein of
interest. Efforts are underway to obtain high resolution structural and dynamic
information on the thioamide substitution. In addition to the generation of thioamide
proteins by NCL, Hecht's recent co-translational incorporation of thioamide
dipeptides using mutant ribosomes offers a potentially more facile semisynthetic
route to thioproteins.229 Deciphering the mechanism of incorporation of the natural
thioglycine residue in the archael methyl-coenzyme M reductase could also permit
the in vivo biosynthetic incorporation of backbone thioamides.226 As thioamide
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proteins become more synthetically accessible, the results reported here should
provide valuable insights into the design of appropriate thioproteins for diverse
applications.

Section 3.3 – Materials and Methods
3.3.1 – Materials
Fmoc protected amino acids and peptide coupling reagents as well 2chlorotrityl resins were purchased from EMD Millipore (Billerica, MA, USA).
Hydrazide hydrate solution was purchased from Oakwood Chemical (Estill, SC,
USA). Piperidine was purchased from American Bioanalytical (Natick, MA, USA).
VA-044 was purchased from Wako Pure Chemical Industries (Osaka, Japan).
Triisopropylsilane (TIPS) was purchased from Santa Cruz Biotechnology, Inc
(Dallas, TX, USA). GB124-56 A24C was purchased from Genscript (Piscataway, NJ,
USA). Restriction enzymes and chitin purification resin were purchased from New
England Biolabs (Ipswich, MA, USA) and Pfu Turbo DNA Polymerase was
purchased from Agilent Technologies (Santa Clara, CA, USA). DNA oligomers
were purchased from Integrated DNA Technologies, Inc (Coralville, IA, USA). The
pTXB1 plasmid containing CaM1-116 S17C, was a gift from the Linse Laboratory of
the Department of Biochemistry and Structural Biology at Lund University.
Isopropyl β-D-1-thiogalactopyranoside (IPTG) was purchased from LabScientific,
Inc (Highlands, NJ, USA). Protease inhibitor tablets were purchased from Roche
Boehringer Mannheim (Indianapolis, IN, USA). Amicon Ultra centrifugal filter units
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were purchased from EMD Millipore (Billerica, MA, USA). Sodium 2mercaptoethanelsulfonate (MES•Na) was purchased from TCI America (Portland,
OR, USA). β-mercaptoethanol (βME) was purchased from Bio-Rad Laboratories
(Hercules, CA, USA). FPLC purification of proteins was performed on an AKTA
system with HiTrap Q columns (GE Healthcare Bio-Sciences, Pittsburgh, PA,
USA), while peptide HPLC was performed on a Varian Prostar system (currently
Agilent Technologies, Santa Clara, CA, USA) for CaM and GB1 peptides.
Thiopropyl sepharose 6b resin was also purchased from GE Healthcare
(Princeton, NJ, USA). Cuvettes for CD spectroscopy were purchased from Hellma
Analytics USA (Plainview, NY, USA). All other reagents, solvents, and materials
were purchased from either Fisher Scientific (Pittsburgh, PA, USA) or SigmaAldrich (St. Louis, MO, USA) unless otherwise specified. CMPs were designed,
synthesized, and analyzed by Dr. Yitao Zhang in Professor David Chenoweth’s
laboratory. GB1 constructs were synthesized by D. Miklos Szantai-Kis. Matrix
assisted laser desorption/ionization mass spectrometry (MALDI) was performed
on a Bruker Ultraflex III mass spectrometer (Billerica, MA). High Resolution Mass
Spectrometry (HRMS) for small molecules were obtained on a Waters LCT
Premier XE LC/MS system (Milford, MA, USA). Nuclear magnetic resonance
spectra were obtained on a Bruker DRX 500 MHz instrument. HSQC spectra were
obtained by Dr. Kathleen Valentine in Professor Josh Wand’s laboratory. Common
abbreviations

for

all

other

chemicals

[Bis(dimethylamino)methylene]-1H-1,2,3hexafluorophosphate

(HATU),

are

as

triazolo[4,5-b]pyridinium
2-(1H-benzotriazol-1-yl)-
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follows:

1-

3-oxid
1,1,3,3-

tetramethyluronium hexafluorophosphate (HBTU), O-(1H-6-Chlorobenzotriazole1-yl)-

1,1,3,3-tetramethyluronium

methylmorpholine

(NMM),

hexafluorophosphate

isobutyl

chloroformate

(HCTU),
(ICBF),

NN,N-

diisopropylethylamine (DIPEA), trifluoroacetic acid (TFA), 1,2-ethanedithiol (EDT),
hydroxybenzotriazole (HOBt), 4-(2-hydroxyethyl)-1- piperazineethanesulfonic acid
(HEPES), tris(2-carboxyethyl)phosphine (TCEP), and guanidinium hydrochloride
(Gdn•HCl).
3.3.2 – Chemical Synthesis of Thioacylating Monomers
The below route was adapted from Shalaby et al.296 Abbreviations for
reagents can be found in the general information section. The syntheses of Ala,
Phe, Glu, Val, Pro, and Leu thioamide precursors have been reported
previously.132, 153, 218, 266, 297, 298
R
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H
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Figure 3-14: Scheme outlining the synthesis of thioacylating monomers.

Synthesis and Purification of Thiotyrosine (Fmoc-TyrS-NBt) Precursor
(9H-fluoren-9-yl)methyl

(S)-(1-((2-amino-5-nitrophenyl)amino)-3-(4-(tert-

butoxy)phenyl)-1- oxopropan-2-yl)carbamate (3-1). Fmoc-Tyr(t-Bu)-OH (1.49
g, 3.25 mmol) was dissolved in 25 mL of tetrahydrofuran (THF) under argon flow
with stirring. The solution was then cooled to -10 °C in a 1:3 NaCl/ice bath. To this
solution, 2 equiv of N-methylmorpholine (6.25 mmol, 0.71 mL) and 1.1 equivalents
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of isobutyl chloroformate (3.58 mmol, 0.464 mL) were added dropwise,
respectively. The reaction was then allowed to stir at -10 °C for 15 min. Next, 1.1
equivalents of 4-nitro-o-phenylenediamine (3.58 mmol, 0.55 g) was added to the
reaction. The reaction was then stirred for 2 h at -10 °C and then stirred at room
temperature (RT) overnight under Ar. The resulting solution turned orange
overnight. The reaction was then removed from argon flow and the solvent was
removed under reduced pressure. The resulting orange solid was dissolved in N,Ndimethylformamide (DMF, 20 mL) and added to a saturated aqueous potassium
chloride solution (200 mL) to precipitate the desired product. This precipitate was
removed from solution by vacuum filtration with a Büchner funnel and washed with
cold water. The solid was then allowed to air dry for 2 h before being dried under
vacuum. The resulting solid was still judged impure by thin layer silica
chromatography (TLC) and purified further by flash chromatography by dissolving
the solid in THF (5 mL) and loading it on silica (500 mL bed volume in 45:55 ethyl
acetate:hexane). Compound 3-1 eluted with an Rf of 0.5 and was dried by rotary
evaporation, washed with chloroform, and dried under high vacuum overnight.
Compound 3-1 was obtained in 71.4 % yield (1.38 g, 2.32 mmol). HRMS (ESI) m/z
calculated for C34H34N4O6Na [M+Na]+ is 617.2376, found 617.2379. 1H NMR (500
MHz, C2D6OS): δ 9.44 (1 H, s), 8.13 (1 H, s), 7.88 (4 H, d, J = 7.5), 7.71 (2 H, d, J
= 7.4), 7.41 (2 H, t, J = 7.4), 7.32 (2 H, q, J = 7.4), 7.25 (2 H, d, J = 8.6), 6.87 (2 H,
d, J = 8.5), 6.78 (1 H, d, J = 9.1), 6.39 (2 H, s), 4.45 (1 H, d, J = 7.5), 4.28 – 4.15
(3 H, m), 3.13 – 2.89 (2 H, m), 2.80, 1.22 (9 H, s). 13C NMR (126 MHz, C2D6OS):
δ 171.1, 162.3, 156.1, 153.56, 149.3, 143.7, 140.7, 135.5, 132.2, 129.8, 127.6,
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127.0, 125.3, 123.4, 123.4, 123.2, 121.8, 120.1, 113.6, 77.6, 65.8, 56.7, 46.6, 39.5,
36.7, 28.5.

(9H-fluoren-9-yl)methyl

(S)-(1-((2-amino-5-nitrophenyl)amino)-3-(4-(tert-

butoxy)phenyl)-1-thioxopropan-2-yl)carbamate

(3-2).

Sodium

carbonate

(0.246 g, 2.32 mmol) and phosphorus pentasulfide (1.03 g, 2.32 mmol) were added
to THF (20 mL) in an oven-dried round bottom flask and allowed to stir under Ar at
RT until the phosphorus pentasulfide was completely dissolved (30 min). Then the
solution was cooled to 0 °C in an ice bath and 3-1 was dissolved in minimal THF
and added to the reaction. The reaction was then monitored by TLC with a mobile
phase of 2:3 ethyl acetate/hexanes. The product has an Rf of 0.4. After 4 h, the
starting material was mostly consumed and a small amount of the benzimidazole
byproduct had been formed, therefore the reaction was judged to be at completion.
The reaction was condensed to dark yellow oil by rotary evaporation. This oil was
then dissolved in minimal ethyl acetate and was loaded onto silica plug (bed
volume approximately 400 mL in ethyl acetate) to remove the phosphorus
pentasulfide. The crude product was eluted in ethyl acetate as a dark yellow band.
This solution was dried by rotary evaporation and redissolved in 2:3 ethyl
acetate/hexanes (5 mL). This mixture was purified by flash chromatography on
silica with a running solvent of 2:3 ethyl acetate/hexanes. The product eluted as a
yellow solution and solvent was removed under reduced pressure. The resulting
yellow solid was washed with dichloromethane and chloroform, then dried under
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high vacuum overnight. Compound 3-2 was obtained in 71.1% yield (1.01 g, 1.65
mmol). HRMS (ESI) m/z calculated for C34H35N4O5S [M+H]+ is 611.2328, found
611.2339. 1H NMR (500 MHz, C2D6OS): δ 11.24 (1 H, s), 8.37 – 8.25 (1 H, m),
8.10 (1 H, d, J = 6.6), 7.94 (1 H, dd, J = 9.1, 2.7), 7.89 (2 H, d, J = 7.6), 7.73 (2 H,
dd, J = 13.1, 7.5), 7.65 (1 H, d, J = 2.7), 7.42 (1 H, t, J = 7.5), 7.36 – 7.30 (1 H, m),
7.29 (2 H, d, J = 8.5), 6.91 (2 H, d, J = 8.4), 6.77 (1 H, d, J = 9.0), 6.25 (2 H, s),
4.68 (1 H, q, J = 7.2), 4.35 – 4.25 (1 H, m), 4.21 (2 H, q, J = 7.5), 3.14 (1 H, dd, J
= 13.4, 7.2), 3.05 (1 H, dd, J = 13.4, 7.6), 1.26 (9 H, s).
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C NMR (126 MHz,

C2D6OS): δ 206.8, 156.2, 153.8, 150.5, 143.8, 143.6, 140.7, 135.3, 131.8, 130.0,
127.6, 127.0, 125.4, 125.3, 124.9, 124.4, 123.3, 122.2, 120.1, 113.8, 79.2, 77.7,
65.9, 62.6, 46.6, 39.5, 28.5.

(9H-fluoren-9-yl)methyl

(S)-(3-(4-(tert-butoxy)phenyl)-1-(6-nitro-1H-

benzo[d][1,2,3]triazol-1-yl)-1-thioxopropan-2-yl)carbamate (3-3, Fmoc-TyrSNBt). Compound 3-2 (1.01 g, 1.65 mmol) was dissolved in glacial acetic acid
diluted with 5% water (15 mL) and allowed to stir while cooling to 0 °C in an ice
bath. After 5 min, 1.25 equiv of NaNO2 (0.142 g, 2.06 mmol) was added slowly to
the reaction. The reaction was monitored by TLC using 2:3 ethyl acetate in
hexanes as the mobile phase; compound 3-3 has an Rf of 0.7. After 30 min, no
starting material remained by TLC and the reaction became thick with an orange
precipitate. Cold Milli-Q water (100 mL) was added to the reaction to precipitate
the remaining product. The resulting orange precipitate was filtered on a Büchner
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funnel, washed with additional cold Milli-Q water, allowed to air dry for 20 min, and
then dried under high vacuum overnight. The product was then lyophilized due to
residual water remaining after high vacuum. The crude yield of the reaction was
82% (0.836 g, 1.35 mmol) and was used directly in solid phase peptide synthesis
without further purification. HRMS (ESI) m/z calculated for C34H31N5O5S [M-H]- is
621.2046, found 621.2055. 1H NMR (500 MHz, CDCl3): δ 9.62 (1 H, s), 8.44 (1 H,
d, J = 8.6), 8.28 (1 H, d, J = 8.8), 7.77 (2 H, d, J = 6.9), 7.61 – 7.53 (3 H, m), 7.47
– 7.36 (4 H, m), 7.36 – 7.28 (3 H, m), 7.05 (2 H, d, J = 7.7), 6.82 (2 H, d, J = 7.8),
6.59 (1 H, d, J = 7.2), 5.74 (1 H, d, J = 8.9), 4.51 – 4.40 (2 H, m), 4.39 – 4.33 (1 H,
m), 4.20 (1 H, s), 3.33 (1 H, dd, J = 13.5, 5.7), 3.15 (1 H, dd, J = 13.6, 7.5), 1.25
(9 H, s).
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C NMR (126 MHz, CDCl3): δ 208.4, 155.6, 154.9, 149.7, 149.2, 143.8,

141.5, 131.8, 129.9, 127.9, 127.2, 125.1, 124.3, 122.35, 121.7, 120.2, 112.7,
100.1, 78.6, 77.4, 77.2, 76.9, 67.3, 62.4, 47.3, 42.6, 28.9.

Synthesis and Purification of Thioisoleucine (Fmoc-IleS-NBt) Precursor

(9H-fluoren-9-yl)methyl ((2S,3S)-1-((2-amino-5-nitrophenyl)amino)-3-methyl1-oxopentan-2-yl)carbamate (3-4). Fmoc-Ile-OH (3.53 g, 10.0 mmol) was
dissolved in anhydrous THF (90 mL). N-methylmorpholine (2.20 mL, 20.0 mmol)
was added and the reaction was cooled to -10 °C while the flask was purged with
argon. Isobutyl chloroformate (1.30 mL, 10.0 mmol) was added dropwise while
stirring. The reaction mixture was stirred for 15 min at -10 °C, then 4-nitro-ophenylenediamine (1.53 g, 10.0 mmol) was added. The reaction was stirred under
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argon for 2 hours at -10 °C, then at room temperature overnight. After removing
the solvent in vacuo, the residue was dissolved in DMF (50 mL). Upon addition of
saturated aqueous KCl (250 mL) solution and Milli-Q water (250 mL), a yellow solid
precipitated. The solid was filtered, washed with Milli-Q water and dried under
vacuum. Compound 3-4 was isolated in 78.5% yield (3.84 g, 7.85 mmol) and
79.4% purity, as determined by HPLC. HRMS (ESI) m/z calculated for C27H28N4O5
[M+H]+ is 489.2138, found 489.2130. 1H NMR (500 MHz, C2D6OS): δ 9.54 (s, 1H),
8.29 (d, J = 2.7 Hz, 1H), 7.91 – 7.83 (m, 3H), 7.80 – 7.72 (m, 3H), 7.41 (t, J = 7.2
Hz, 4H), 7.32 (t, J = 7.5 Hz, 2H), 6.79 (d, J = 9.1 Hz, 1H), 6.52 (s, 2H), 4.35 – 4.20
(m, 4H), 4.09 (t, J = 8.2 Hz, 1H), 1.90 (ddt, J = 12.4, 8.5, 4.2 Hz, 1H), 1.56 (ddd, J
= 13.7, 7.4, 3.3 Hz, 1H), 1.30 – 1.17 (m, 1H), 0.94 (d, J = 6.8 Hz, 3H), 0.88 (t, J =
7.4 Hz, 3H).
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C NMR (126 MHz, C2D6OS): δ 171.2, 156.4, 148.8, 143.7, 140.7,

135.5, 127.6, 127.0, 125.3, 122.9, 121.2, 121.1, 120.1, 113.7, 65.8, 59.8, 46.7,
35.8, 24.7, 15.4, 10.7.

(9H-fluoren-9-yl)methyl ((2S,3S)-1-((2-amino-5-nitrophenyl)amino)-3-methyl1-thioxopentan-2-yl)carbamate (3-5). Anhydrous Na2CO3 (0.239 g, 2.25 mmol)
and P4S10 (1.00 g, 2.25 mmol) were suspended in anhydrous THF (30 mL) in an
oven-dried round bottom flask and stirred under argon for 30 minutes until solution
became clear. Compound 3-4 (1.10 g, 3.00 mmol) was added and the reaction
stirred over night at room temperature under argon. The next day the solvent was
removed in vacuo. The resulting residue was resuspended in ethyl acetate and
filtered over a pad of Celite® (Sigma-Aldrich, St. Louis, MO) to remove insoluble
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P4S10 adducts. The filtrate was washed twice with 5% NaHCO3 and once with
brine. The aqueous layer was acidified with HCl and back extracted twice with ethyl
acetate. The combined organic layers were dried over MgSO4, filtered and the
solvent was removed in vacuo. The crude product was redissolved in
dichloromethane and purified over silica to afford pure product as a yellow foam in
50.8% yield (0.770 g, 1.52 mmol). Rf = 0.5 in ethyl acetate/hexanes (1:1). HRMS
(ESI) m/z calculated for C27H28N4O4S [M+H]+ is 505.1910, found 505.1909. 1H
NMR (500 MHz, CDCl3) δ 9.57 (s, 1H), 7.98 (s, 1H), 7.95 (d, J = 8.9 Hz, 1H), 7.77
– 7.70 (m, 2H), 7.49 (d, J = 7.5 Hz, 1H), 7.44 (d, J = 7.4 Hz, 1H), 7.42 – 7.33 (m,
2H), 7.27 (s, 2H), 7.30 – 7.20 (m, 2H), 6.58 (d, J = 9.0 Hz, 1H), 5.70 (s, 1H), 4.27
(d, J = 7.7 Hz, 3H), 4.14 (t, J = 7.1 Hz, 1H), 2.10 – 2.02 (m, 1H), 1.29 – 1.20 (m,
2H), 1.02 (d, J = 6.7 Hz, 3H), 0.97 (t, J = 7.3 Hz, 3H). 13C NMR (126 MHz, CDCl3)
δ 206.2, 157.4, 148.5, 143.3, 141.3, 138.4, 128.1, 128.0, 127.4, 127.3, 125.6,
125.0, 125.0, 124.9, 122.3, 120.3, 120.2, 115.3, 77.4, 67.6, 66.89, 47.0, 39.1,
29.83, 15.9, 11.1.

(9H-fluoren-9-yl)methyl

((2S,3S)-3-methyl-1-(6-nitro-1H-

benzo[d][1,2,3]triazol-1-yl)-1-thioxopentan-2-yl)carbamate (3-6, Fmoc-IleSNBt). Compound 3-5 (0.770 g, 1.52 mmol) was dissolved in 95% glacial acetic acid
diluted with 5 % water (20 mL). The solution was cooled to 0 °C and NaNO2 (156
mg, 2.26 mmol) was added slowly. Upon complete addition, the reaction mixture
was stirred for 30 min at 0 °C, after which cold Milli-Q water (125 mL) was added.
The precipitated orange solid was filtered, washed with cold Milli-Q water and dried
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in vacuo. The crude yield of the reaction was 57.7% (0.453 g, 0.88 mmol) and was
used directly in solid phase peptide synthesis without further purification. Rf = 0.45
in dichloromethane. HRMS (ESI) m/z calculated for C27H25N5O4S [M+Na]+ is
538.1525, found 538.1508. 1H NMR (500 MHz, CDCl3) δ 9.70 (s, 1H), 8.46 (d, J
= 8.7 Hz, 1H), 8.32 (d, J = 8.9 Hz, 1H), 7.76 (d, J = 7.6 Hz, 2H), 7.60 (d, J = 7.5
Hz, 2H), 7.40 (t, J = 7.5 Hz, 2H), 7.31 (q, J = 8.1 Hz, 2H), 6.22 (dd, J = 9.9, 6.2 Hz,
1H), 5.70 (d, J = 9.9 Hz, 1H), 4.49 (dd, J = 10.9, 6.9 Hz, 1H), 4.41 (dd, J = 10.9,
6.8 Hz, 1H), 4.22 (t, J = 6.9 Hz, 1H), 2.13 – 2.04 (m, 1H), 1.72 – 1.61 (m, 1H), 1.30
– 1.19 (m, 1H), 1.03 (d, J = 6.7 Hz, 3H), 0.91 (t, J = 7.4 Hz, 3H).
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C NMR (126

MHz, CDCl3) δ 209.5, 156.0, 149.5, 149.0, 143.6, 143.6, 141.3, 131.7, 127.7,
127.0, 127.0, 125.0, 124.9, 122.2, 121.5, 119.9, 112.8, 66.9, 65.7, 47.2, 41.1, 24.1,
16.2, 11.2.

Synthesis

and

Thiophenylalnine

Purification

of

(Fmoc-PheS-NBt),

Thioglutamate

(Fmoc-GluS-NBt),

Thioalanine

(Fmoc-AlaS-NBt),

Thioleucine (Fmoc-LeuS-NBt), Thioproline (Fmoc-ProS-NBt), Thioglycine
(Fmoc-GlyS-NBt), and Thiovaline (Fmoc-ValS-NBt) Precursors. Each of these
precursors were synthesized using modified synthesis from Shalaby et al. and
have been reported previously.132, 153, 222, 237, 296, 297
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3.3.3 – Calmodulin Synthesis and Analysis
Peptide Synthesis of CaM135-148 Cys135 PheS138
The first CaM thiopeptide construct made was CaM135-148Cys135PheS138.
Residue 138 is a tyrosine in the native sequence, but PheS was used for the initial
method development as it had been previously synthesized and used in our lab for
ligation. Solid phase peptide synthesis (SPPS) of CaM135-148 Cys135 PheS138 (H2NCVNFSEEFVQMMTAK-OH) was performed on 2-chlorotrityl resin (100-200 mesh)
on a 50 μmol scale. The peptide was elongated up to the thioamide position using
standard SPPS protocols by adding 5 equiv of amino acid, HBTU, and DIPEA in
DMF (2 mL) and stirring each coupling for 40 min at RT. Fmoc removal was
performed by stirring the resin in 20% piperidine in DMF (5 mL) for 20 min at RT.
It should be noted that each amino acid coupling was performed twice to improve
isolated peptide yields (data not shown). Prior to the thioamide coupling, the resin
was washed with dry dichloromethane (DCM, obtained by drying over molecular
sieves; washed 2 x 4 mL). Fmoc-PheS-NBt (1.5 eq.) was then added to the vessel
with DIPEA (1.5 equiv) in DCM (1.5 mL) and the reaction was stirred at RT for 30
min. The vessel was then drained and the resin washed with dry DCM (2 x 4 mL)
before repeating the thioamide coupling. At completion of the second coupling, the
resin was washed with DCM, then DMF (2 x 4 mL each) and standard SPPS was
used to add the remaining amino acids. After the Fmoc deprotection of Cys135, the
resin was washed with DMF and DCM, before being dried by vacuum for 10 min.
A

cleavage

cocktail

was

prepared

with

24:16:1:1:1

DCM:TFA:TIPS:EDT:Thioanisole (total volume of 4.3 mL). This was added to the
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dried resin and allowed to stir at RT for 1 h before being drained and collected.
DCM (4 mL) was added to the resin to wash out any remaining peptide and the
collected solution was dried to a yellow oil by rotary evaporation. This oil was
washed with DCM (3 x 5 mL) to remove any excess organic reagents. The crude
peptide product was then precipitated by adding cold diethyl ether (10 mL) and
vortexing vigorously. The resulting precipitate was centrifuged to a pellet and the
supernatant was discarded. Crude peptide was stored under argon at 4 °C until
purification by HPLC could proceed.

HPLC Purification of CaM135-148 Cys135 PheS138
The crude white solid was dissolved in 35% v/v acetonitrile in Milli-Q water
with 0.1 % TFA. The peptide was purified by reverse phase HPLC using a binary
solvent system (Buffer A: water with 0.1% TFA; Buffer B: acetonitrile with 0.1%
TFA). A Grace Vydac C18 Preparatory column was used with the gradient in Table
3-3 to purify CaM135-148-Cys135 PheS138.
Table 3-3: Solvent gradient used for HPLC purification.
Time (min)

Buffer A (%)

0:00

98

5:00

98

10:00

75

34:00

62

35:00

2

40:00
41:00

2
98

46:00

98
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Synthesis of Remaining CaM Thiopeptides
Synthesis of each CaM thiopeptide was performed as described above.
MALDI (Table 3-4) and MALDI tandem MS/MS (data not shown) analysis was used
to confirm the mass and intact thioamide presence in each peptide. We routinely
obtained 2-6 mg (2-7% yield) of thiopeptide with these syntheses.

Table 3-4: Calculated and observed m/z for isolated CaM thiopeptides.

CaM135-148 Sequence
S

H2N-CV NYEEFVQMMTAK-OH
H2N-CVNFSEEFVQMMTAK-OH
H2N-CVNYSEEFVQMMTAK-OH
H2N-CVNYESEFVQMMTAK-OH
H2N-CVNYEESFVQMMTAK-OH
H2N-CVNYEEFSVQMMTAK-OH
H2N-CVNYEEFVSQMMTAK-OH
H2N-CVNYEEFVQMMTASK-OH

Calculated m/z [M+H]+

Observed m/z

1708.72
1693.73
1708.72
1708.72
1708.72
1708.72
1708.72
1708.72

1709.94
1693.74
1710.25
1709.47
1709.21
1710.28
1709.37
1710.19

Expression and Purification of WT and Cys135 CaM
Expression (1 L in LB media) and purification of these CaM constructs were
done as previously reported.237 Yields for each protein totaled ~20 mg/L and each
protein was stored as a lyophilized powder prior to further processing and
preparation for CD measurements.

Cloning of CaM1-134-GyrA-H6
Full-length CaM was previously cloned into the pTXB1 vector containing the
MxeGyrA intein and a six residue histidine tag for Ni-NTA purification.252 The 14
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amino acid deletion was carried out in four rounds of QuikChangeÒ PCR using the
following four sets of primers. Deletions were confirmed by DNA sequencing with
T7 promoter and terminator primers.

i. Deletion of CaM146-148
Forward: 5’-GAAGAGTTTGTACAGATGATGTGCATCACGGGAGAT-3’
Reverse: 5’-ATCTCCCGTGATGCACATCATCTGTACAAACTCTTC-3’
ii. Deletion of CaM142-145
Forward: 5’-CAAGATAACTATGAAGAGTTTTGCATCACGGGAGAT-3’
Reverse: 3’-ATCTCCCGTGATGCAAAACTCTTCATAGTTTACTTG-3’
iii. Deletion of CaM138-141
Forward: 5’-GATGGTGATGGTCAAGTAAACTGCATCACGGGAGAT-3’
Reverse: 5’-ATCTCCCGTGATGCAGTTTACTTGACCATCACCATC-3’
iv. Deletion of CaM135-137
Forward: 5’-GACATTGATGGTGATGGTTGCATCACGGGAGAT-3’
Reverse: 5’-ATCTCCCGTGATGCAACCATCACCATCAATGTC-3’
Original Protein Sequence:
(M)ADQLTEEQIAEFKEAFSLFDKDGDGTITTKELGTVMRSLGQNPTEAELQDMI
NEVDADGNGTIDFPEFLTMMARKMKDTDSEEEIREAFRVFDKDGNGYISAAELR
HVMTNLGEKLTDEEVDEMIREADIDGDGQVNYEEFVQMMTAKCITGDALVALP
EGESVRIADIVPGARPNSDNAIDLKVLDRHGNPVLADRLFHSGEHPVYTVRTVE
GLRVTGTANHPLLCLVDVAGVPTLLWKLIDEIKPGDYAVIQRSAFSVDCAGFAR
GKPEFAPTTYTVGVPGLVRFLEAHHRDPDAQAIADELTDGRFYYAKVASVTDA
GVQPVYSLRVDTADHAFITNGFVSHATGLTGLKLHHHHHH
Resulting Protein Sequence:
(M)ADQLTEEQIAEFKEAFSLFDKDGDGTITTKELGTVMRSLGQNPTEAELQDMI
NEVDADGNGTIDFPEFLTMMARKMKDTDSEEEIREAFRVFDKDGNGYISAAELR
HVMTNLGEKLTDEEVDEMIREADIDGDGCITGDALVALPEGESVRIADIVPGARP
NSDNAIDLKVLDRHGNPVLADRLFHSGEHPVYTVRTVEGLRVTGTANHPLLCLV
DVAGVPTLLWKLIDEIKPGDYAVIQRSAFSVDCAGFARGKPEFAPTTYTVGVPG
LVRFLEAHHRDPDAQAIADELTDGRFYYAKVASVTDAGVQPVYSLRVDTADHA
FITNGFVSHATGLTGLKLHHHHHH
The sequence in black is the WT calmodulin sequence. The portion in blue is the
deleted sequence to be added by NCL with Cys in place of Gln at the ligation site.
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The sequence in green is the Mxe GyrA intein followed by the His6 tag in red. The
initial methionine (M) is removed during expression by an endogenous Escherichia
Coli methionine aminopeptidase.

CaM1-134-GyrA-H6 Expression
CaM1-134-GyrA was transformed into BL21-Gold (DE3) E. Coli cells and
grown against ampicillin (100 μg/mL) on an LB-agar plate. Single colonies were
picked and grown in liquid LB media (3 x 5 mL, 100 μg/mL ampicillin) with shaking
(250 RPM) at 37 °C until saturation. Each primary culture was then added to a
secondary culture of autoclaved LB media (1 L, 100 μg/mL ampicillin) and grown
at 37 °C, with shaking (250 RPM) until OD600= 0.8-1.0 (3-4 h). IPTG was then
added (final concentration = 1 mM) and the temperature and shaking speed were
reduced to 25 °C and 225 RPM respectively for 16 h of additional incubation.

Expression of 15N Isotopically Enriched CaM1-134-GyrA-H6
The plasmid encoding CaM1-134-GyrA was transformed into BL21-Gold
(DE3) E. Coli cells and grown against ampicillin (100 μg/mL) on an LB-agar plate.
A single colony was picked and grown in liquid LB media (5 mL, 100 μg/mL
ampicillin) with shaking (250 RPM) at 37 °C until saturation. The bacteria were
then pelleted by centrifugation and resuspended in a sterile 50 % solution of
glycerol in water (1 mL) and flash frozen in liquid nitrogen prior to being stored at
-80 °C. This glycerol stock will be used directly in culture growth and protein
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expression.

For bacterial culture growth, a minimal media was prepared as

follows. First, a 10 x stock of M9 salts was prepared by dissolving Na2HPO4 (90
g), KH2PO4 (45 g), and NaCl (7.5 g) in 1 L of Milli-Q water. A 50 mL and a 1 L 1x
M9 media were prepared by making a ten-fold dilution in Milli-Q water and were
autoclaved for sterilization. Next, a master mix of additives and nutrients were
prepared by dissolving
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NH4Cl (1 g), glucose (2 g), MgSO4 (0.24 g), CaCl2 (0.15

g), yeast extract (0.2 g), and ampicillin (0.1 g) in 20 mL of sterile (autoclaved) MilliQ water in a sterile 50 mL falcon tube. 1 mL of master mix was then added to the
50 mL aliquot of media and the remaining master mix was added to the 1 L media
portion. To each was added FeSO4 (15 mg/mL stock) and ZnCl2 (15 mg/mL) to a
final concentration 0.1 % v/v. The 50 mL M9 1x is used primary culture for protein
expression. To begin bacterial growth, 20 μL of CaM1- 134-GyrA BL21 glycerol stock
was added to the starter culture flask and the culture was grown at 37 °C (250
RPM) until saturation (~8 hours). Once at saturation, this 50 mL culture was added
to the 1 L 1x M9 secondary culture and was grown at 37 °C (250 RPM) until OD600
= 0.8 (~3-4 hours). Then protein expression was induced by adding IPTG to a final
concentration of 1 mM and the culture was grown an additional 20 hours at 25 °C
with shaking (225 RPM). Purification then proceeded as described below.

CaM1-134-GyrA-H6 Purification
Cells (3 x 1 L expression) were harvested by centrifugation at 5,000 RPM
in a GS3 rotor and Sorvall RC-5 centrifuge for 10 min at 4 °C. The supernatant
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was discarded and the cell pellet was suspended in 25 mL lysis buffer (50 mM
HEPES, pH 7.5) containing two broad spectrum protease inhibitor tablets.
Resuspended cells were then lysed on ice by sonication (30 amps power, 1 second
pulse, 1 second rest, 2 minute total sonication time) and then pelleted at 13,000
RPM in an SS-34 rotor (Sorvall RC-5 centrifuge) for 15 min at 4 °C. The
supernatant was collected and incubated with Ni2+-NTA resin (4 mL column
volume) for 1 h on ice with shaking. The slurry was then added to a fritted column
and the liquid was allowed to flow through. The resin was then washed with 3 x 10
mL of buffer (50 mM HEPES, pH 7.5) and 3 x 10 mL of wash buffer (50 mM
HEPES, 10 mM imidazole, pH 7.5). CaM1-134-GyrA was then eluted from the resin
in 5 fractions each containing 5 mL of elution buffer (50 mM HEPES, 300 mM
imidazole, pH 7.5). The pooled fractions were dialyzed against MES•Na cleavage
buffer (20 mM Tris, pH 7.3) overnight at 4 °C.

CaM1-134-GryA-H6 MES•Na Intein Cleavage and Purification of CaM1-134-MES
Thioester
MES•Na (200 mM final concentration) was added to 25 mL of the solution
containing CaM1-134-GyrA in MES•Na cleavage buffer and allowed to incubate with
stirring for 16 h at 4 °C. After 16 h, a 1:30 dilution in water of the cleavage solution
was analyzed by MALDI-MS and the reaction appeared to be at completion. The
cleavage reaction was dialyzed against 20 mM Tris, pH 8.0 at RT for 2 h to remove
the remaining MES•Na from solution. CaM1-134-MES was purified in three batches
over a HiTrap Q column using a 120 min NaCl gradient (0.1 M to 0.8 M NaCl in 20
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mM Tris, pH 8.0). The desired product partially coelutes with the impurity CaM1135-OH,

a hydrolytic byproduct of the intein cleavage reaction, which can be

resolved after ligation. This eluent was collected in 6 x 1.5 mL fractions (product
presence confirmed by MALDI-MS). The pooled fractions were dialyzed against
Milli-Q water at 4 °C overnight before being flash frozen with liquid nitrogen and
lyophilized to a solid. Total yield from a 3 x 1 L expression is approximately 30 mg
of 90% pure CaM1-134-MES.

Purification of CaM1-134-OH
CaM1-134-GyrA-H6 was expressed as above. After Ni2+-NTA purification, the
eluent was dialyzed against 20 mM Tris pH 7.3 (2 L) overnight at 4 °C. CaM1-134GyrA-H6 was then treated with βME (200 mM) to cleave the intein and reveal CaM1134-OH.

This cleavage process is discussed elsewhere.252 This protein was then

purified by anion exchange over a HiTrap Q column as described above for CaM1134-MES.

The protein was sufficiently pure after one round of FPLC purification and

was dialyzed against Milli-Q water overnight at 4 °C before being frozen in liquid
nitrogen and lyophilized to a white powder. The total isolated yield of CaM1-134-OH
was 8 mg per L of culture.

Expression and Purification of CaM1-71-OH
CaM1-71-GyrA-CBD was transformed into BL21-Gold (DE3) E. coli cells and
grown on an LB-agar plate with ampicillin (100 μg/mL). A single colony was picked
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and grown in liquid LB media (5 mL, 100 μg/mL ampicillin) with shaking (250 RPM)
at 37 °C until saturation. The primary culture was then added to a secondary
culture of sterile Terrific Broth media299 (1 L, 100 μg/mL ampicillin) and grown at
37 °C, shaking (250 RPM) until OD600= 0.8-1.0 (3-4 h). IPTG was then added (final
concentration = 1 mM) and the temperature and shaking speed were reduced to
25 °C and 225 RPM. The culture was allowed to grow for 16 h. Cells were
harvested by centrifugation at 5,000 RPM in GS3 rotor and Sorvall RC-5 centrifuge
for 10 min at 4 °C. The supernatant was discarded and the cell pellet was
resuspended in 10 mL lysis buffer (20 mM Tris, pH 8.0) containing one broad
spectrum protease inhibitor tablet. Resuspended cells were then lysed on ice by
sonication (30 amps power, 1 second pulse, 1 second rest, 2 minute total
sonication time) and spun down at 13,000 RPM in an SS-34 rotor in a Sorvall RC5 centrifuge for 15 min at 4 °C. The supernatant was collected and incubated with
chitin beads (5 mL column volume, CV) for 1 h on ice with shaking. The slurry was
then added to a fritted column and the liquid was allowed to flow through. The
beads were washed with 10 x CV of 20 mM Tris pH 8.0. Intein cleavage buffer (20
mM Tris, 200 mM βME, pH 7.5, 10 mL) was then added to the beads and incubated
on a rotisserie at RT for 16 h. The column was then drained and the flow through
collected. The eluent was dialyzed against 20 mM Tris, pH 8.0 to remove any
excess βME and purified by FPLC using anion exchange as described above. The
protein was pure after one round of FPLC purification and was dialyzed against
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Milli-Q water overnight at 4 °C before being frozen in liquid nitrogen and lyophilized
to white powder. The total isolated yield was 6 mg per L of culture.

Native Chemical Ligation (NCL) for Synthesis of Thioamide CaM Constructs
The following general protocol was used for the synthesis of all thioamide
containing constructs. Ligation buffer (2 mL) was prepared fresh prior to each
reaction by adding NaH2PO4 (0.2 M), Gdn•HCl (6 M), TCEP•HCl (20 mM) and
thiophenol (2% v/v) to 1.7 mL of water and adjusting the pH to 7.3 followed by the
volume to 2 mL. Approximately 10 mg (660 nmol) of CaM1-134-MES of was weighed
out using an analytical balance and added to an Eppendorf tube. To this tube,
ligation buffer (500 μL) was added and the tube was vortexed to ensure all dried
protein dissolved and then incubated at RT for 2 min to allow the more electrophilic
CaM1-134-SPh to form by transthioesterification of the MES thioester with
thiophenol (see Figure 3-15). Thiopeptide (2 equiv) was then weighed out into a
separate Eppendorf tube and ligation buffer (500 μL) was added. This tube was
then vortexed to ensure that all of the thiopeptide dissolved. The thiopeptide was
then added to the tube containing the CaM1-134-SPh protein and incubated at 37
°C with constant shaking (500 RPM) for 20 h. The reaction was monitored by
MALDI for product formation and it should be noted that additional CaM1-134-OH
byproduct was formed during the reaction. At reaction completion, the mixture was
diluted to 3 mL with Milli-Q water and dialyzed against 20 mM Tris pH 8.0 overnight
at 4 °C in preparation for FPLC purification.
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Figure 3-15: NCL methodology used to generate all CaM thiproteins. Transthioesterification of CaM1-134MES with thiophenol, followed by ligation to CaM135-148-Cys135 thiopeptide.

NCL Control for CaM Cys135
The expressed CaM Cys135 protein was subjected to NCL conditions by
incubating it with ligation buffer for 20 h with constant shaking (500 RPM) at 37 °C.
This protein was then subjected to the same purification and alkylating protocols
as the thioamide CaM mutants.

Purification of Thioamide CaM NCL Reactions
The dialysate from the crude reaction was filtered and treated with TCEP
Bond-Breaker™ (5 μL) prior to being manually loaded onto a 4 mL bed volume
HiTrap Q column. The purification proceeded using the same gradient as the
CaM1-134-MES thioester purification. The full-length CaM thioprotein elutes over 5
fractions with CaM1-134-OH but the two proteins cannot be completely separated
using any gradient on anion exchange. To remove the impurity, a cysteine capture
thiopropyl sepharose 6b resin is used. The NCL product containing a cysteine will
form a covalent disulfide bond with the thiopropyl group while the impurity CaM1134-OH

will flow through the resin. Prior to purification by this resin, the fractions

from anion exchange purification were dialyzed against 2 L thiopropyl binding
buffer (20 mM Tris, 1 mM EDTA pH 7.5) overnight at 4 °C. The resin (0.6 g, 1.5
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mL CV) is prepared by washing it with 50 x CV of Mili-Q water, followed by 10 x
CV of binding buffer. The dialysate is then added to the slurry and incubated on a
rotisserie for 1 h at RT. The flow through is collected and analyzed by MALDI to
ensure that the thioamide CaM bound to the resin. The resin was then washed
with 10 x CV of binding buffer, 25 x CV of wash buffer (20 mM Tris, 100 mM NaCl,
1 mM EDTA, pH 7.5), and again with 10 x CV binding buffer. Elution buffer is
prepared by adding βME to a final concentration of 30 mM in 6 mL binding buffer.
Elution buffer (4 mL) is then added to the resin and incubated on a rotisserie for
20 min at RT. The eluent is collected and the resin washed with the remaining 2
mL of elution buffer, followed by 3 mL of binding buffer to elute the remaining
protein. The presence of thioamide CaM is determined by MALDI by observing the
mass of the βME disulfide adduct (M+76 Da). This solution is then dialyzed against
2 L of capping buffer (20 mM Tris, pH 8.3) for 2 h at RT before proceeding to the
alkylation of Cys135.
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S

Figure 3-16: MALDI mass spectra analysis of purification of CaM-Cys135Phe 138 by thiopropyl sepharose resin.
S
(A) Mixture of CaM1-134 (*) and CaM1-148-Cys135Phe 138 (*) prior to resin incubation. (B) Flow through
+
containing only CaM1-134 (calculated m/z [M+H] = 15008 Da; observed 15008 Da) after resin incubation. (C)
S
+
Elution containing only the desired CaM1-148-Cys135Phe 138 NCL product (calculated m/z [M+H] = 16682 Da;
observed 16682 Da). Masses corresponding to (M+2)/2 (half-mass) and M+206 Da (adduct formed with
sinapic acid matrix for depositing samples) are commonly observed in each spectrum.

Alkylation of Cys135 with Iodoacetamide
The dialysate from the previous step was added to a 15 mL Falcon tube
and incubated with TCEP Bond-Breaker™ (10 mM) for 2 min. Next, iodoacetamide
(final concentration = 200 mM) was added and the solution was vortexed slowly
until all of the iodoacetamide was dissolved. The reaction was incubated at RT for
five min and the presence of singly alkylated thioamide CaM or CaM-Cys135 was
confirmed by MALDI-MS (Table 3-5). This solution was then dialyzed against 2 L
of water for 2 h, followed by a second round of dialysis overnight at 4 °C to remove
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the excess TCEP and iodoacetamide. The resulting solution was flash frozen in
liquid nitrogen and lyophilized to a fine white powder. For 15N isotopically enriched
samples, at completion of the capping reactions, the samples were dialyzed in two
rounds (2 L for 2 hours each at room temperature) against 20 mM Tris pH 8.0. The
samples were then subjected to FPLC purification if any impurities persisted using
the previously described procedure. Samples were again dialyzed against 20 mM
Tris pH 8.0 and were then concentrated and buffer exchanged using the protocol
outlined below (see NMR sample preparation).
+

Table 3-5: Calculated and observed protein m/z. All CaM thioproteins routinely fly as [M+Na] .
CaM Variant

Calculated m/z
+
[M+H]

Calculated m/z
+
[M+Na]

Observed m/z

WT

16708

16730

16705

CaM1-134-OH

15008

15030

15007

CaM1-134-MES

15130

15152

15130

CaM1-71

7832

7854

7832

16740

16762

16740

135Val 136
S
CaM-Cys 135Phe 138
Q
S
CaM-Cys 135Tyr 138
Q
S
CaM-Cys 135Glu 139
Q
S
CaM-Cys 135Glu 140
Q
S
CaM-Cys 135Phe 141
Q
S
CaM-Cys 135Val 142

16756

16778

16777

16740

16762

16762

16756

16778

16777

16756

16778

16778

16756

16778

16775

16756

16778

16778

16756

16778

16775

Q

16756

16778

16777

CaM-Cys
CaM-Cys

Q

Q

135
S

Q

CaM-Cys

S

135Ala 147
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Table 3-6: Calculated and observed protein m/z for N isotopically labeled proteins.
CaM Variant
15

CaM1-134-MES ( N1-134)
CaM-Cys
CaM-Cys

Q

CaM-Cys

Q

15

135 ( N1-134)
S
15
135Val 136 ( N1-134)

Q

S

135Tyr 138 (

15

N1-134)

Calculated
+
m/z [M+H]

Calculated m/z
+
[M+Na]

Observed m/z

15290

15312

15290

16899

16921

16920

16915

16937

16936

16915

16937

16935
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Trypsin Digest of CaM-CysQ135 AlaS147
To a 5 μL aliquot of sequencing grade trypsin (0.1 mg/mL), 50 μL of a 25
μM stock of CaM-CysQ135AlaS147 was added. This mixture was incubated at 37 °C
for 16 h. The resulting tryptic peptide mixture was analyzed by MALDI. The desired
[M+Na]+ (expected: 2561.8 Da, observed: 2561.2 Da) was detected for the peptide
H2N-EADIDGDGCQVNYEEFVQMMTASK-OH obtained from the cut site at Arg126.
The spectrum was absent of any peaks indicating multiple or missed alkylations
by iodoacetamide. To ensure that Cys135 was alkylated while leaving the thioamide
sulfur intact, MALDI-MS/MS of this peptide was performed. The resulting mass
spectrum could be assigned for fragmentation to the x-, y-, b- and a-series of this
peptide (Figure 3-17 and 3-18). Fragments could be unambiguously assigned to a
peptide containing the alkylated CysQ and unmodified AlaS147 without any
detectable missed or aberrant alkylations, respectively (Table 3-7).
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Figure 3-17: Top: Trypsin digest. The blue box indicates the desired peak selected for MS/MS
+
([M+Na] expected: 2561.8 Da, observed: 2561.2 Da). Bottom: MS/MS spectrum of fragmented tryptic
peptide. Ions from the a-,b-,x- and y-series are observed.
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Figure 3-18: Fragmentation patterns of the H2N-EADIDGDGC VNYEEFVQMMTA K-OH tryptic peptide.
Table 3-7: Expected (black) and observed (red) MS/MS fragment m/z (a-, b-, x- and y- series ions) for the
Q
S
tryptic peptide H2N-EADIDGDGC VNYEEFVQMMTA K-OH. Nearly complete coverage of the peptide is
observed.

Sequence

Observed Series

a (m/z)

E

b

102.113

A

a,b,x,y

173.192

D

a,b

288.280

Obs a (m/z)

b (m/z)

Obs b (m/z)

x (m/z)

130.123

129.031

---

Obs x (m/z)

y (m/z)

175.091

201.202

200.068

2436.690

288.113

316.290

316.115

2365.611

2339.617

401.163

429.450

429.166

2250.522

2224.528

544.538

547.022

2137.363

2111.369

Obs y (m/z)

2539.811
2437.508

2410.696

I

a,b

401.440

D

b

516.528

G

a

573.580

571.227

601.590

2022.274

1996.280

D

a

688.669

690.220

716.679

1965.222

1939.228

G

b

745.721

C

a,b

905.899

V

a

1005.032

N

---

Y

2412.637

773.731

773.218

1850.134

1824.140

930.107

933.909

934.077

1793.082

1767.088

1005.909

1033.042

1632.903

1606.909

1119.136

1147.146

1533.771

1507.776

b

1282.312

1310.322

1308.626

1419.667

E

b,x

1411.427

1439.437

1452.515

1256.491

E

---

1540.543

1568.553

1127.375

1101.381

F

---

1687.719

1715.729

998.260

972.266

V

a

1786.852

1814.862

851.083

Q

x

1914.983

1942.993

751.951

M

y

2046.175

2074.185

623.820

M

---

2177.368

2205.378

492.627

495.222

466.633

T

x,y

2278.473

2306.483

361.435

361.199

335.441

334.140

A

a,x,y

2365.612

2387.506

2393.622

260.330

261.142

234.335

235.096

K

a,x,y

2493.786

2495.692

2521.796

173.191

175.091

147.197

1785.055
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1393.672
1258.493

1230.496

825.089
773.218

725.956
597.826

598.194

Observed: 16705 Da

Observed: 16740 Da

Observed: 16777 Da

Observed: 16777 Da

Observed: 16778 Da

Observed: 16775 Da

Q

S

S

S

S

Figure 3-19: MALDI MS spectra showing CaM proteins (WT CaM, Cys 135, Val 136, Tyr 138, Glu 139, and Glu 140;
see Table 3-5 for observed and expected molecular weights) without any impurities. Masses corresponding
to (M+2)/2 (half-mass) and M+206 Da (adduct formed with sinapic acid matrix for depositing samples) are
commonly observed in each spectrum.
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Observed: 16778 Da

Observed: 16775 Da

Observed: 16777 Da

S

S

S

Figure 3-20: MALDI MS spectra showing CaM proteins (Phe 141, Val 142, and Ala 147; see Table 3-5 for
observed and expected molecular weights) without any impurities. Masses corresponding to (M+2)/2 (halfmass) and M+206 Da (adduct formed with sinapic acid matrix for depositing samples) are commonly
observed in each spectrum.
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15

Figure 3-21: MALDI MS spectra showing segmental (residues 1-134) N isotopically labeled CaM proteins
Q
S
S
(Cys oxo, Val 136, and Tyr 138). Isolated yields were not calculated for these proteins but final concentration
of each sample prior to NMR spectra acquisition was estimated based upon UV absorption at 276 nm.
Table 3-8: Synthesized CaM variants for CD and their yields based upon BCA quantification prior to CD
measurements.
CaM Variant
CaM-Cys

Q

Percent Yield
S

135Val 136
S
CaM-Cys 135Tyr 138
Q
S
CaM-Cys 135Glu 139
Q
S
CaM-Cys 135Glu 140
Q
S
CaM-Cys 135Phe 141
Q
S
CaM-Cys 135Val 142
Q
S
CaM-Cys 135Ala 147

7.0%

Q

13.9%
7.6%
13.0%
8.2%
24,8%
11.2%
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Preparation of Samples for Circular Dichroism (CD) Measurements
For each pure CaM variant, the lyophilized powder was dissolved in 2 mL
of holo CD buffer (10 mM Tris, 2 mM CaCl2, pH 7.5) and incubated for 10 min at
RT to anneal the protein. This solution was then aliquoted into 2 x 1 mL samples.
The holo aliquot for Ca2+ bound CaM measurements was dialyzed once more
against 2 L of holo buffer for 2 h at RT to ensure any remaining iodoacetamide or
TCEP salt from the capping reaction was removed. The apo aliquot for Ca2+ free
CaM measurements was dialyzed against 2 L of calcium stripping buffer (10 mM
Tris, 1 mM EDTA, pH 7.5) for 2 h at RT before an additional round of dialysis
against 2 L of apo CD buffer (10 mM Tris, 0.5 mM EDTA, pH 7.5) for 2 h at RT.
The dialysis buffers were saved to be used for further dilutions of the samples as
well as background measurements in CD spectra acquisition.

Preparation of Samples for HSQC NMR Acquisition
Samples were concentrated and buffer exchanged into NMR buffer (100
mM KCl, 6 mM CaCl2, 0.02 % NaN3, 10 mM d4-imidazole, pH 6.5) through Amicon
3 kDa MWCO spin filters (spun at 13,200 RPM for 5 minutes each round).
Approximately 10 rounds of centrifugation were needed to concentrate the
samples and another 10 rounds of buffer exchange was performed by adding 400
μL of NMR buffer to the spin-filter tube and spinning at 13, 200 RPM for 5 minutes
in an Eppendorf 5415r benchtop centrifuge (4 °C) for each round. Sample volume
was then adjusted to 475 μL and 25 μL of D2O was added to a final concentration
of 5 % v/v. These samples were then used directly in HSQC NMR data acquisition.
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HSQC NMR Acquisition and Data Analysis
NMR data was obtained by a collaborator (Dr. Kathy Valentine and
Professor Josh Wand; University of Pennsylvania) on a Bruker 500 MHz
instrument at 30 °C. The raw HSQC spectra was processed in Bruker TopSpin
(Billerica, MA). The raw data was individually phase adjusted using the commands
‘abs1’ and ‘abs2’ and then overlaid to compare chemical shifts. The phase
adjusted spectra were manually contour adjusted until negative resonances were
no longer visible. CaM reference HSQC data from X. laevis were downloaded from
the biological magnetic resonance data bank (BMRB; accession number 6541)
and analyzed using the DEVise plot plug-in.284

Modified BCA Assay for Concentration Determination of CaM CD Samples
A commercial Pierce™ Thermo Fisher Scientific BCA assay kit (Bellefonte,
PA) was used to determine the concentration of each sample of CaM. However,
the assay was modified slightly to give more consistent concentration readings
amongst replicates of samples. BCA reagent was prepared as described by the
commercial protocol. A set of standard bovine serum albumen (BSA) dilutions
(1.25, 1.0, 0.75, 0.5, 0.25, and 0.125 mg/mL) were used as a calibration curve. A
separate calibration curve was generated for holo and apo samples as each buffer
affects the absorbance measurement differently. BCA reagent (200 μL) was added
to each empty Eppendorf tube for standards and samples. A 0 mg/mL BSA control
tube was also used. Then each standard and sample (25 μL) were added to their
corresponding BCA reagent tubes. The 0 mg/mL sample received either holo or
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apo CD buffer. The samples were then vortexed to mix and incubated at 37 °C for
30 min. Each sample was then diluted with 1.2 mL of buffer and vortexed to mix.
Absorbance at 562 nm (A562) was obtained by a HP 8452 UV/Vis
spectrophotometer in a 1 cm path length cuvette. The A562 values were fit linearly
and the fit was used to determine the concentration of the CaM samples. This
method was compared to CaM quantification based upon the A276 and a previously
published extinction coefficient (ε276 = 3006 M-1 cm-1) and was in good agreement
for WT CaM samples.300 However, direct quantification by A276 for thioamide
containing constructs using this method is not viable as the extinction coefficient
in this absorbance region for each thioamide position in the context of the protein
is unknown.

CD Wavelength Measurements
Based upon the concentrations obtained from the BCA assay, each holo
and apo protein was divided into three aliquots and diluted to 10 μM in their
respective buffers with the exception of TyrS138, which was diluted to 30 μM to
obtain a sufficiently high signal-to-noise ratio for CD measurements. The
wavelength measurements were taken in triplicate to average out any small error
in the concentration measurements or dilutions. Each sample (300 μL) was added
to a 1 mm path length Helma Analytics 110-QS CD cuvette and loaded into a Jasco
J-1500 CD Spectrometer. CD wavelength scans were taken at 25 °C by scanning
at a 1 nm step between 350 nm and 190 nm with a bandwidth of 1 nm and an
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averaging time of 8 s per measurement. Background spectra were obtained by
measuring the CD signal of the relevant buffer in each cuvette with an averaging
time of 2 s. The raw signal (θd, mDeg) from each sample was background
subtracted against the blanks and converted to molar residue ellipticity (θMRE)
using
𝜃"#$ = 𝜃& /(𝑐𝑙𝑛# )

(3.1)

where c is the concentration (M), 𝑙 is the path length (1 mm), and 𝑛# is the number
of residues in the protein. The resulting averaged scans for each holo and apo
protein along with a table of θ222 and θ208 values are shown in Figure 3-2 and Table
3-9. Plots showing non-residue adjusted molar ellipticity (θn) for holo and apo
CaM1-135 and CaM1-71 truncations, as well as selected thioproteins, are shown in
Figure 3-3.
Table 3-9: Average values for θ222 (holo and apo) and θ208 (holo) MREs from three replicate spectra. The
ratio between θ222 and θ208 is only given for the holo proteins due to the shift in global minima from 208 to
205 nm between holo and apo CaM.

CaM
Variant

Holo θ222

Holo θ208

Holo θ222/θ208

Apo θ222

WT

-13.40

-13.74

0.98

-13.20

135

-11.73

-11.85

0.99

-7.39

136

-12.31

-13.07

0.94

-6.89

-4.77

-5.91

0.81

-4.92

-13.36

-14.63

0.91

-4.98

-10.80

-12.55

0.86

-3.99

Cys

Q

Val

S

Tyr

S

138
S
Glu 139
S
Glu 140
S
Phe 141
S
Val 142
S
Ala 147

-4.80

-5.22

0.92

-3.52

-13.56

-15.24

0.89

-6.33

-12.03

-13.39

0.90

-5.52
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Thermal Denaturation of CaM Measured by CD
Thermal denaturation was performed by monitoring θd at 222 nm over a
temperature range of 5 to 95 °C. The temperature increase was set to 0.5 °C per
min with an equilibration time of 10 s. Measurements were made with an averaging
time of 8 s per sample and a bandwidth of 1 nm. All holo samples did not
completely melt over this temperature range and have melting temperatures (TM)
greater than 85 °C (Figure 3-4). All apo proteins melted over this temperature
range with significant initial transitions prior to global unfolding. Fitting procedures
for raw apo melting data are described in the following sections.

Two State Fit of Apo CaM CD Data
The two state model assumes that there is a single transition between the
folded and unfolded states, with no intermediate state populated. For this model,
the folded and unfolded linear baselines were fit between 5 to 20 °C and 65 to 80
°C, respectively, by using the low temperature (𝜃- = 𝑚- 𝑇 + 𝑏- ) and high
temperature (𝜃3 = 𝑚3 𝑇 + 𝑏3 ) equations. The entire data set was then fit to
𝜃-45 = 𝜃- 𝑇 1 − 𝐹9:;9 + 𝜃3 𝑇 𝐹9:;9

𝐹9:;9 =

< =(>?@A>B)/CA
DE< =(>?@A>B)/CA

(3.2)

where ΔH and ΔS are adjustable parameters and R = 1.9872 cal•mol-1•K-1. The
fraction unfolded curve is generated by minimizing the root mean square difference
(RMSD) between 𝐹9:;9 and the experimental fraction unfolded (𝐹<FG , calculated
from the experimental θMRE using equation 3.3) against the parameters listed
above over the entire temperature range.
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𝐹<FG =

IJCK LIM

(3.3)

IN LIM

The 𝐹9:;9 fits of the θMRE data and fraction folded (1 − 𝐹9:;9 ; 𝐹- ) plots for all controls
and mutants can be seen in Figures 3-22 through 3-25. The TMs were calculated
by 𝑇" =

PQ
PR

, assuming the free energy ΔGU = 0 at the midpoint of the transition.

The free energy at 25 °C (ΔGU(25)) was determined by 𝛥𝐺 = 𝛥𝐻 − 𝑇𝛥𝑆 using the
𝛥𝐻 and 𝛥𝑆 calculated from the fits and T = 298.15 K. All data fitting was performed
using the solver function in Microsoft Excel (Redmond, WA) and the plots were
rendered in GraphPad Prism (LaJolla, CA). We note that although the ΔΔGU(25)
values obtained from these two state fits are unreasonably low, using the simple
analysis based on ΔTM values in equation 3.8, we obtain ΔΔGU* values that are in
reasonable agreement with the three state unfolding data given in Table 3-1 in the
main text.
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Figure 3-22: Plots generated using the two state fitting method for WT, Cys 135, and Val 136 . Left: For each
CaM variant a single set of raw data (θMRE) and fits from equations for θfit, θf, and θu. Right: The averaged
fraction folded plots (1-Fcalc) from three replicated melts.
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Figure 3-23: Plots generated using the two state fitting method for Tyr 138, Glu 139, and Glu 140. Left: For
each CaM variant a single set of raw data (θMRE) and fits from equations for θfit, θf, and θu. Right: The
averaged fraction folded plots (1-Fcalc) from three replicated melts.
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Figure 3-24: Plots generated using the two state fitting method for Val 142, Ala 147, and CaM1-134. Left: For
each CaM variant a single set of raw data (θMRE) and fits from equations for θfit, θf, and θu. Right: The
averaged fraction folded plots (1-Fcalc) from three replicated melts.
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Table 3-10: Average values for the thermodynamic parameters determined from the two state fits of Fcalc.
Q
ΔTM and ΔΔGU are values relative to the Cys 135 control.
CaM
Variant

TM
(°C)

ΔTM
(°C)

ΔH
-1
(kcal mol )

ΔGU(25)
-1
(kcal mol )

ΔΔGU(25)
-1
(kcal mol )

WT

46.0 ± 0.1

---

41.9 ± 1.1

2.74 ± 0.08

---

CaM1-134

48.7 ± 0.3

---

48.5 ± 5.7

3.54 ± 0.43

---

135

44.1 ± 0.2

---

31.5 ± 2.2

1.88 ± 0.15

---

136

50.6 ± 0.6

+6.5

24.3 ± 0.3

1.91 ± 0.05

+0.03

-0.71

40.1 ± 0.6

-4.0

40.9 ± 0.3

1.95 ± 0.09

+0.07

0.44

46.8 ± 1.7

+2.7

24.5 ± 2.7

1.70 ± 0.31

-0.18

-0.29

40.8 ± 0.7

-3.3

29.5 ± 1.8

1.47 ± 0.08

-0.41

0.36

42.7 ± 0.4

-1.4

30.7 ± 2.0

1.70 ± 0.09

-0.18

0.15

41.8 ± 0.8

-2.3

35.9 ± 2.0

1.90 ± 0.18

+0.02

0.25

Cys
Val

Q

S

Tyr

S

138
S
Glu 139
S
Glu 140
S
Val 142
S
Ala 147

* Calculated from ΔTM using equation 3.8 in Section 3.3.4
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ΔΔGU*
-1
(kcal mol )

80

Three State Fit of Apo CaM Data
In this model, the protein undergoes two transitions: F®I and I®U, where
F, I, and U are the folded, intermediate, and unfolded states, respectively. This fit
is more intuitive for CaM as the N- and C-terminal domains behave almost
independently and have different melting temperatures.278, 280, 281 The equations
used here are adopted from Sorensen et al.281 The folded, intermediate, and
unfolded baselines were fit to 𝜃- = 𝑚- 𝑇 + 𝑏- , 𝜃4 = 𝑚4 𝑇 + 𝑏4 , and 𝜃3 = 𝑚3 𝑇 + 𝑏3 ,
respectively. In this case, 𝑚4 was constrained to the average of 𝑚- and 𝑚3 as
previously described.281 The full data set was then fit to
𝜃-45 = (𝜃- ) 𝐹- + (𝜃4 )(𝐹4 ) + (𝜃3 )(𝐹3 )
𝐹3 =

WX WY
DEWX EWX WY

𝐹4 =

WX
DEWX EWX WY

(3.4)
𝐹- = 1 − 𝐹4 − 𝐹3

𝐾[ = 𝑒 LP]^ /#_
𝛥𝐺[ 𝑇 = 𝛥𝐻[ 1 −

(3.5)
(3.6)

_
_ J^

+ 𝛥𝐶G^

𝑇 − 𝑇"^ − 𝑇

𝐿𝑛

_
_ J^

(3.7)

where K1 and K2 are the equilibrium constants for the transitions F®I and I®U,
respectively. 𝐹- , 𝐹4 , and 𝐹3 are the calculated fractions of the total population that
the folded, intermediate, and unfolded states make up at any given temperature.
The heat capacity 𝛥𝐶G^ for each transition is set to zero in accordance with
previous analyses of CaM unfolding.281 𝛥𝐻[ and 𝑇"^ are adjustable parameters for
each transition. The RMSD between the observed θMRE and 𝜃-45 (equation 3.4) was
minimized against these adjustable parameters. A weighted fraction folded value
𝐹-∗ = 𝐹- + 𝑛𝐹4 was generated to account for the contributions of both C- and N173

terminal unfolding to the overall unfolding transition. Here, 𝑛 is a weighting factor
held constant to 𝑛 = 0.5 to reflect the weighted contribution of 𝑚4 in 𝜃-45 . A weighted
average melting temperature of the two transitions (TM*) is generated by finding 𝑇
such that 𝛥𝐺D (𝑇) + 𝛥𝐺f (𝑇) = 0. TM* corresponds to the midpoint of the
𝐹-∗ unfolding curve. ΔGU(25) for the total transition of F®U was calculated as a
sum of ΔG1(298.15) and ΔG2(298.15). Plots for each mutant and control are shown
in Figures 3-22 through 3-25. Comparison of the fits from the two state (Ff) and the
three state (Ff*) fitting methods is shown in Figures 3-29 and 3-30.
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Figure 3-26: Plots generated using the three state fitting method for WT, Cys 135, and Val 136. Left: For each
CaM variant a single set of raw data (θMRE) and fits generated from θfit, θf, and θu. Right: The averaged Ff
(purple), Fi (green), and Fu (blue) plots from the three replicates.
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Figure 3-27: Plots generated using the three state fitting method for Tyr 138, Glu 139, and Glu 140. Left: For
each CaM variant a single set of raw data (θMRE) and fits generated from θfit, θf, and θu. Right: The averaged
Ff (purple), Fi (green), and Fu (blue) plots from the three replicates.
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Figure 3-28: Plots generated using the three state fitting method for Val 142 and Ala 147. Left: For each CaM
variant a single set of raw data (θMRE) and fits generated from θfit, θf, and θu. Right: The averaged Ff (purple),
Fi (green), and Fu (blue) plots from the three replicates.
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and Glu 139. Bottom: WT, Glu 140, Val 142, and Ala 147.
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Figure 3-31: Apo CaM structures. Overlay of C-terminal helix of 1CFD NMR structure with corresponding
helix in chainR of 1QX5 crystal structure showing alignment of residues 118-148. Twisting about the 114117 segment prevents simultaneous alignment of the rest of the CaM sequence. Residues 81-101 in chainD
of 1QX5 structure make intermolecular contacts similar to the intramolecular contacts of residues 81-101
in 1CFD. Left Inset: All eight chains in 1QX5 structure aligned, showing identical folds. Right Inset: Cterminal helices of 1CFD and 1QX5 structures.

Table 3-11: Distances and angles for hydrogen bonds at sites of thioamide substitution in apo CaM
structures from PDB entries 1CFD and 1QX5. 1QX5 distances are averages of distances in all 8 chains. X
denotes site of thioamide insertion. Hydrogen bonding partners can be seen in Figures 3-32 through 3-34.
X

X

C=X--N Dist. (Å)

C=X--N Angle (º)

N --O=C Dist. (Å)

Residue

1CFD

1QX5

1CFD

1QX5

1CFD

1QX5

1CFD

1QX5

Val

S

136

3.4

3.1

137

151

---

---

---

---

Tyr

S

138

2.6

3.1

165

157

---

2.8*

---

123*

139

3.4

3.0

145

144

3.3*

---

130*

---

140

3.4

3.0

150

147

---

---

---

---

3.3

3.0

145

158

2.6

3.0

165

156

142

3.3

3.3

160

152

3.4

3.0

150

147

147

---

---

---

---

3.4

3.2

150

115

Glu

S

Glu

S

Phe

S

Val

S

Ala

S

141

*Asn137 sidechain forms hydrogen bonds with either Tyr138 or Glu139.
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N --O=C Angle (º)

Figure 3-32: Hydrogen bonding of Val
in another chain.

S

136.

S

In the 1QX5 structure, Val136 accepts a hydrogen bond from Ile

S

S

S

100

Figure 3-33: Hydrogen bonding of Glu 139, Val 142, Ala 147. The 1CFD structure shows the potential stabilizing
S
hydrogen bond from the N-H of the Glu 139 thioamide to the sidechain carbonyl of Asn137.
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S

S

Figure 3-34: Hydrogen bonding of Tyr 138 and Phe 141. 1QX5 structure shows the potential stabilizing
S
hydrogen bond from the N-H of the Tyr 138 thioamide to the sidechain carbonyl of Asn137.
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3.3.4 – Analysis of GB1 Thioproteins
Sample Preparation for CD
Dried peptides were dissolved in 500 μL ligation Buffer (200 mM Na2HPO4,
6 M GnHCl, pH 7.0) and dialyzed against 2 L 20 mM Na2HPO4, pH 7.0. The dialysis
buffer was exchanged for fresh buffer twice over a period of 24 hours. After
dialysis, samples were concentrated to 300-400 uL, using Amicon Ultra centrifugal
filter units (3 kDa MWCO).

Concentration Determination of GB1
The absorbance for each GB1 sample was measured at 274 nm and Beer’s
law was used to determine the concentration of each sample by using extinction
coefficients of ε274 = 9567 M-1 cm-1 and ε274 = 19736 M-1 cm-1 for the GB1 Oxo and
GB1 thioamide proteins, respectively.

CD Wavelength Measurements
Each sample (300 μL) was added to a 1 mm path length Helma Analytics
110-QS CD cuvette and loaded into a Jasco J-1500 CD Spectrometer. CD
wavelength scans were taken at 25 °C by scanning at a 1 nm step between 350
nm and 190 nm with a bandwidth of 1 nm and an averaging time of 8 s per
measurement. Blank spectra were obtained by measuring the CD signal of the
relevant buffer in each cuvette with an averaging time of 2 s. The raw signal (θd,
mDeg) from each sample was background subtracted against the blank buffer
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spectrum and converted to molar residue ellipticity (θMRE) using equation 3.1. The
resulting averaged scans for each GB1 variant are shown in Figure 3-10.

CD Thermal Melts
Thermal denaturation was performed by monitoring θd at 220 nm over a
temperature range of 5 to 95 °C. The temperature increase was set to 0.2 °C per
min with an equilibration time of 10 s. Measurements were made with an averaging
time of 8 s per sample and a bandwidth of 1 nm.

Two-State Fitting of GB1 Thermal Melts
The two state fitting procedure described in the above CaM section was
used to fit all GB1 melting profiles with a few minor changes. The linear folded and
unfolded baselines for GB1 Oxo were fit from 5 to 60 °C and 90 to 95 °C,
respectively. The thioprotein folded and unfolded baselines were fit from 5 to 50
°C and 85 to 95 °C, respectively. These changes reflect the elevated melting
temperature observed in GB1 compared to CaM. Changes in free energy of
unfolding between GB1 Oxo and the thioprotein variants were calculated using
equation 3.8 as described by Becktel et al and previously used in GB1 studies.292,
301

𝛥𝛥𝐺 =

P_J ∙PQhih

(3.8)

_J,hih

Here, ΔHoxo and TM, oxo are values for GB1 Oxo that are obtained from the two state
fits discussed above. ΔTM is the difference in melting temperatures between GB1
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Oxo and a particular thioprotein analogue. These calculations are made under the
assumption that a single amino acid change only provides a small perturbation to
the system and that the structural and functional characteristics of the system
largely remain intact.301
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Figure 3-35: Plots generated using the two state fitting method for GB1 Oxo and Leu 5. Left: For each GB1
variant, a single set of raw data (θMRE) and fits from equations for θfit, θf, and θu. Right: The averaged fraction
folded plots (1-Fcalc) from two replicated melts.
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Figure 3-36: Plots generated using the two state fitting method for Ile 6 and Leu 7. Left: For each GB1
variant, a single set of raw data (θMRE) and fits from equations for θfit, θf, and θu. Right: The averaged fraction
folded plots (1-Fcalc) from two replicated melts.

Table 3-12: Distances and angles for hydrogen bonds at sites of thioamide substitution in GB1 from PDB
entry 2QMT. X denotes site of thioamide insertion.
X

X

Residue

C=X--N Dist. (Å)

C=X--N Angle (º)

N --O=C Dist. (Å)

N --O=C Angle (º).

S

3

154

2.8

152

3

175

2.8

147

3.1

134

2.8

177

Leu
Ile

S

5

6

Leu

S

7
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CHAPTER 4:
IMPROVED FMOC DEPROTECTION CONDITIONS FOR THE SYNTHESIS OF
THIOAMIDE CONTAINING PEPTIDES AND PROTEINS
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Reprinted (adapted) with permission from (Christopher R. Walters, D. Miklos
Szantai-Kis, Taylor M. Barrett, Eileen M. Hoang, and E. James Petersson) the
Thieme Publishing Group; Synlett (DOI: 10.1055/s-0036-1589027). Copyright
(2017) Thieme Publishing Group.
Section 4.1 – Introduction
As described in Section 3.1, thioamide substitutions in the backbone of
peptides and proteins have been leveraged in many biophysical studies due to
their distinct physiochemical properties as compared to their native oxoamide
counterpart. 220, 221, 232, 234, 235, 237, 266-269 For these and other types of applications,
site-specific incorporation of thioamides into peptides is required. This is generally
achieved by synthesizing thioamide precursor monomers that can then be
incorporated into peptides using fluorenylmethyloxycarbonyl (Fmoc)-based solid
phase peptide synthesis (SPPS). The activated precursors can be synthesized
from Fmoc protected amino acids in three steps (Figure 4-1) based on a
nitrobenzyltriazolide (Nbt) route developed by Shalaby et al.296
Thioamides are generally compatible with the reagents used in SPPS
including bases, activators, cleavage additives and trifluoroacetic acid (TFA).
However, there are three side reactions that can often occur with thioamide
containing peptides. First, prolonged exposure to high TFA concentrations during
cleavage of the peptide from resin can lead to an Edman degradation-type reaction
resulting in backbone cleavage at the n+1 position.302 Therefore, one must
consider a tradeoff between complete removal of acid-labile protecting groups and
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degradation of the thiopeptide (especially in long peptides) when determining the
duration of TFA exposure. Second, our laboratory as well as Mukherjee et al.
reported that thioamide precursors can react with residual amounts of water during
coupling, leading to the exchange of sulfur for oxygen.222, 266 The use of anhydrous
CH2Cl2 greatly reduced the formation of the undesired oxoamide. Last,
epimerization can occur at the α-carbon of the thioamino acid (pKa ~13).303-307
Prolonged exposure to base during Fmoc deprotection can catalyze this
epimerization reaction. Recently, it was reported that lowering the concentration of
piperidine and shortening Fmoc deprotection times to 1 minute resulted in less
epimerization of thioamides.308 However, since the half-life of the Fmoc group
under these conditions is 20-45 seconds, this approach significantly decreases the
yield of isolated protein.309
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Figure 4-1: Scheme for the synthesis of Fmoc-Tyr (tBu)-NBt using the route from Shalaby et al. Thioamino
acid NBt derivatives can be used directly in a thioacylation reaction for incorporation of backbone
thioamides in SPPS.
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A 20% (v/v) solution of piperidine in dimethylformamide (DMF) is the most
commonly used solution for Fmoc deprotection in SPPS, but there are alternatives:
a 50% (v/v) solution of morpholine in DMF is considered a milder condition and is
often used for sensitive glycopeptides.310 In contrast, a 2% (v/v) solution of 1,8diazabicyclo[5.4.0]-undec-7-ene (DBU) is considered a harsher deprotection
condition.311 Unlike piperidine or morpholine, DBU is a non-nucleophilic base and
is not able to scavenge the reactive dibenzofulvene group resulting from the Fmoc
deprotection.311 Therefore, either a nucleophile needs to be added as a scavenger,
or reaction times must be kept short and the resin washed extensively after
deprotection.
Here, I demonstrate that for the synthesis of thiopeptides, the use of 2%
(v/v) DBU in DMF as an Fmoc deprotection solution is superior to 20% (v/v)
piperidine in DMF. I, in conjunction with colleague Taylor Barrett, synthesized
several thiopeptides with both of the aforementioned deprotection solutions and
observed that peptides synthesized with 2% DBU typically exhibited a lower
percentage of epimerization than those synthesized with 20% piperidine.
Additionally, we typically observe a higher isolated yield and increased purity of
thiopeptide using 2% DBU as a deprotection reagent. Thus, DBU deprotections
are generally superior to piperidine deprotections for backbone thioamides.
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Section 4.2 – Results and Discussion
I designed a set of model peptides containing a mixture of non-polar (Phe
and Ala) and polar (Lys and Glu) amino acids (Table 4-1). For each sequence, 7methoxycoumarin-4-yl-alanine (Mcm or μ) was installed as the first amino acid on
2-chlorotrityl resin. This chromophore has an absorption maximum at 325 nm and
allows for facile tracking of the peptides by analytical HPLC. Thioamides also have
a shifted absorption maximum (272 nm) relative to oxoamides (215 nm), which can
be used to characterize the thiopeptides. To discriminate between genuine Lthiaomino acid peptides and their D-epimers, we synthesized both L- and Dthionitrobenzyltriazolide monomers (Fmoc-alaS-NBt and Fmoc-pheS-NBt, using
the lower-case letter convention for D-amino acids) for inclusion into the model
peptides. The retention times for the authentic D-thioamino acid peptides were
used as standards for each of the first four sets of thiopeptides. Additionally, a
separate assay was performed to assess how each condition affected yield. In
these experiments, 7-methoxycoumarin-4-acetic acid (Mca) was added to each
peptide sample to a final concentration of 500 μM, representing the maximum
theoretical yield of peptide in each HPLC sample. The integration value of this
standard peak was compared to the integration of the product peak in each
chromatogram (at 325 nm) to calculate the yield.
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Figure 4-2: General scheme for deprotection reactions on thiopeptides. DBU leads to a decrease in
epimerization as observed by analytical HPLC.

I began my analysis with peptide 4-1, which contained a thioamide linkage
at the central Phe. Treatment with 20% piperidine (v/v) in DMF for 20 minutes lead
to epimerization of 16%, as calculated by the ratio of peak integrations (at 325 nm)
for the L- and D-epimers. The identical masses of the L- and D-product peaks were
confirmed by matrix assisted laser desorption ionization mass spectrometry
(MALDI-MS). To test DBU deprotection conditions, the same peptide was
synthesized and elongated up to the thioamino acid position using standard SPPS
with 20% piperidine deprotections. After the thioacylation reaction, the peptide was
treated with 2% v/v DBU in DMF (2 mL) for 2 minutes before draining and washing
the resin and then repeating the process twice more. Each subsequent
deprotection was done using these conditions. It should be noted that a scavenger
was not used in the deprotection solution, but no characterizable byproducts
containing the mass of a dibenzofulvene adduct were observed. The
aforementioned deprotection conditions lead to only 3% epimerization,
significantly decreasing the amount of D-byproduct observed in comparison to the
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piperidine deprotections. In addition, the yield was increased from 30% to 36%
when DBU was used (Table 4-1). Oxoamide controls for the L- and D-peptides
were also synthesized using piperidine as the deprotection reagent and no
epimerization was observed for these peptides (Figure 4-5).

Table 4-1: Comparison of yield and percent epimerization between peptides synthesized with either DBU
or piperidine.

4-1

%
%
%
Epimerization
Purity
Yield
S
KAF AKμ (4-1) – Piperidine
16.1
56.2
29.9
S
KAF AKμ (4-1) – DBU
9.1
61.6
35.9
S
F AKAKμ (4-2) – Piperidine
1.0
89.0
44.3
S
F AKAKμ (4-2) – DBU
0.0
88.5
51.3
S
FA KAKμ (4-3) – Piperidine
3.2
68.5
44.0
S
FA KAKμ (4-3) – DBU
1.0
67.3
44.7
S
b
b
b
FAKA Kμ (4-4) – Piperidine/DBU
n/d
n/d
n/d
S
FAE AKμ (4-5) – Piperidine
5.6
71.5
18.2
S
FAE AKμ (4-5) – DBU
1.0
71.6
22.7
S
c
CVNY EEFVQMMTAK (4-6) - Piperidine
49.9
14.9
n/d
S
c
CVNY EEFVQMMTAK (4-6) - DBU
9.3
22.0
n/d
S
c
CVNYEEF VQMMTAK (4-7) - Piperidine
28.1
37.0
n/d
S
c
CVNYEEF VQMMTAK (4-7) - DBU
7.0
28.6
n/d
Graph: Example chromatogram for epimer quantification and yield determination. L- and D- denote epimers
S
S
S
of 4-1, KAF AKμ and KAf AKμ, respectively, # denotes KAAKμ, the product of failed F coupling.
^ denotes Mca standard used to quantify yield.
a
Peptides in one-letter code. Superscript S denotes thioamino acids. μ = 7-Methoxycoumarin-4-yl-alanine;
b
c
L- and D- epimers were not resolvable on analytical HPLC; No external standard added for yield
quantification.
Peptide

a
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Encouraged by these results, we synthesized four additional peptide series
(2-5) with L- and D-thioamino acids. Series 4-2 changes the sequence to put the
PheS linkage at the N-terminus of the peptide, allowing us to quantify the
epimerization effects from a single deprotection reaction. Only 1% epimerization
was detected with piperidine; epimerization was undetectable with DBU
conditions. This result indicates that the initial deprotection step may not have a
significant effect and implies that the thioamino acid is vulnerable to epimerization
at each subsequent deprotection step. The epimerization of thiopeptides may also
depend upon local sequence or the identity of the thioamino acid. Therefore, we
synthesized peptides 4-3 and 4-4 with AlaS at each Ala position within the same
sequence as peptide 4-2. We detected 3% epimerization with piperidine and 1%
epimerization with DBU for peptide 4-3. This is in agreement with the expected
additive effects of multiple piperidine treatments. Unfortunately, the L- and Depimers of peptide 4-4 were not separable by analytical HPLC. This highlights the
need for Fmoc removal conditions that minimize epimerization of thioamino acid
positions, as epimerization byproducts may not always be chromatographically
distinguishable from the desired product.
The peptides synthesized thus far contained non-polar thioamino acids,
therefore we synthesized peptide 4-5 containing a GluS linkage to verify that
epimerization can be suppressed independent of sidechain identity (although %
epimerization may vary depending on amino acid identity). In agreement with the
effects discussed in peptides 4-1 to 4-3, DBU treatments for peptide 4-5 decreased
epimerization from 6% to 1%. The peak area percentage was calculated for
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peptides 4-1 to 4-3 and 4-5 in order to quantify the effects of DBU deprotections
on the purity of the products. In each case, the purity of the desired L-peptide was
similar across methods, with the exception of peptide 4-1, where purity was
increased using the DBU method (Figure 4-3). In samples containing the Mca
standard discussed above, the yield of desired L-product was either maintained or
increased through use of DBU, with the most significant increases in yield
observed in peptides 4-1 and 4-2 (29.9% to 35.9% and 44.3% to 51.3%,
respectively). Taken together, these results indicate that in sequences where there
are several deprotections after the thioamide installation, it is beneficial to use DBU
as a deprotection method to reduce epimerization and even increase yield and
purity of the desired L-thiopeptide product.
To extend these results to a longer, more sequence diverse system, I
synthesized a peptide derived from the C-terminus of the calcium-binding protein
calmodulin (CaM).272 I have described the synthesis and characterization of
CaM135-148-Cys135 including many thioamide substitutions recently(see Section
3.2)256, and I wished to see what improvements could be made by using DBU
deprotection conditions. I established two target sites at N-terminal and central
positions within the 14-mer peptide (CaM135-148-Cys135TyrS138 and CaM135-148Cys135PheS141, 4-6-L and 4-7-L respectively). Each peptide was synthesized on a
50 μmol scale on 2-chlorotrityl resin with either piperidine or DBU deprotection
conditions. Thiopeptide products were detected by their characteristic absorbance
at 272 nm and percent epimerization calculated for each peptide based on the
retention times of an authentic D-thioamino acid peptide (CaM135-148195

Cys135pheS141, 4-7-D) and MALDI-MS analysis of the peaks from analytical HPLC
chromatograms (4-6 and 4-7). In each of the CaM thiopeptides, the epimerization
with piperidine is more exaggerated than with any of the model peptides discussed
thus far (50% and 28% for 4-6 and 4-7, respectively). As expected, DBU
deprotection decreased the observed epimerization percentages for peptides 4-6
and 4-7 to 9% and 7%, respectively. These results highlight the positional and
sequence variability in the amount of epimerization observed with piperidine-based
Fmoc removal, as well as the net positive effects that DBU deprotections can have
in all cases observed here. However, by chromatographic peak area percentage
analysis, DBU does appear to decrease the overall purity in 4-7 as it may lead to
additional byproducts that we were unable to assign by MALDI-MS analysis. I hope
to further improve our methodology by using an additive during Fmoc-deprotection
in order to decrease the formation of undesired byproducts. Nevertheless, DBU
deprotections did lead to a 7% increase in peak area percentage for 4-6.
Finally, we compared our DBU protocol to the protocol used in Mukherjee
et al., which also reported reduced epimerization during thiopeptide synthesis.308
Peptide 4-1 was synthesized up to the coupling of PheS3, and then the resin was
split. For one half of the resin, the peptide was elongated using 2 x 1 minute Fmoc
deprotections with 10% piperidine, as in Mukherjee et al. For the other half of the
resin, the peptide was elongated using our procedure of 3 x 2 minute deprotections
with 2% DBU. We observed similar purity (63% vs. 61% with DBU), but a higher
degree of epimerization (7% vs. 1% with DBU) in the synthesis using 10%
piperidine. I also synthesized the longer peptide 4-7 using the same split-resin
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approach for direct comparison of the two methods. Here, I observed somewhat
lower purity (14% vs. 17% with DBU) with significantly higher epimerization (23%
vs. 2% with DBU) in the synthesis using 10% piperidine. Thus, we find that
although the two methods give peptides of comparable overall purity, the lower
levels of epimerization seen with DBU represent a significant advantage for our
method, as peptide epimers may not always be separable by HPLC (as seen for
peptide 4-4).
With the preparation of each backbone thiopeptide system, we have
demonstrated reduction of epimerization at the thioamino acid α-carbon by
performing Fmoc deprotection reactions with DBU in the place of piperidine.
Although only four different amino acids were tested (AlaS, PheS, GluS, and TyrS),
the positional and sequence variability with which this effect is demonstrated
provides strong evidence that this result is general. Furthermore, we demonstrated
that in at least one sidechain thioamide case, the use of DBU as the deprotection
reagent was superior to piperidine or morpholine (work discussed elsewhere by D.
Miklos Szantai-Kis). While we have not yet observed a piperidine adduct in a
backbone thioamide, it may occur at sterically-accessible sites such as GlyS
residues. Such adducts would presumably not be stable, but could lead to Edmantype degradation, as well as hydrolysis of the peptide backbone or oxoamide
formation by reaction with water under the acidic resin cleavage conditions. All of
these side reactions would be avoided by using DBU for Fmoc-deprotections
during peptide synthesis. I expect that these synthetic developments will help to
improve the accessibility of thioamide containing peptides and proteins, further
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enabling the broad spectrum of biophysical and biochemistry experiments made
possible by this versatile functional group.

Section 4.3 – Materials and Methods
4.3.1 – General Information
Piperidine was purchased from AmericanBio (Natick, MA). Triisopropylsilane
(TIPS) was purchased from Santa Cruz Biotechnology, Inc (Dallas, TX). All Fmoc
protected amino acids and peptide synthesis reagents were purchased from EMD
Millipore (Billerica, MA). All other reagents and solvents were purchased from
Fisher Scientific (Waltham, MA) or Sigma-Aldrich (St. Louis, MO) unless otherwise
specified. Peptides 4-1 through 4-5 were synthesized and injected onto the
analytical HPLC by Taylor Barrett.
High resolution electrospray ionization mass spectra (ESI-HRMS) were
collected with a Waters LCT Premier XE liquid chromatograph/mass spectrometer
(Milford, MA). Low resolution electrospray ionization mass spectra (ESI-LRMS)
were obtained on a Waters Acquity Ultra Performance LC connected to a single
quadrupole detector (SQD) mass spectrometer. UV-Vis absorption spectra were
acquired on a Hewlett-Packard 8452A diode array spectrophotometer (Agilent
Technologies, Santa Clara, CA). Nuclear magnetic resonance (NMR) spectra were
obtained on a Bruker DRX 500 MHz, Bruker DRX 600 MHz and Bruker AVIII
500MHz instruments (Billerica, MA). Matrix assisted laser desorption/ionization
with time-of-flight detector (MALDI-TOF) mass spectra were acquired on a Bruker
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Ultraflex III instrument (Billerica, MA). Analytical HPLC was performed on an
Agilent 1100 Series HPLC system (Santa Clara, CA). HPLC columns were
purchased from or Phenomenex (Torrence, CA).

4.3.2 – Synthesis and Epimerization Analysis of Thiopeptides
Synthesis of Thioamino Acid Precursors (Fmoc-AaS-NBt)
All

L-

and

D-thioamino

acid

precursors

were

synthesized

as

Fmoc-

thionitrobenzotriazolide monomers (Fmoc-AaS-NBt) by starting with commercially
available Fmoc protected amino acids and using a route modified from Shalaby et
al.217 Each thioamino acid precursor used in our studies has been previously
synthesized and characterized296, with the exception of Fmoc-alaS-NBt and FmocpheS-NBt (lower case naming convention denotes D-amino acids), which were
synthesized using the same routes as their L-counterparts and are detailed below.

(9H-fluoren-9-yl)methyl(R)-(1-((2-amino-5-nitrophenyl)amino)-1-oxo-3phenylpropan-2-yl)carbamate (4-8). Fmoc-phe-OH (1.29 mmol, 500 mg) was
dissolved in 15 mL of tetrahydrofuran (THF) and stirred under argon. The solution
was then cooled to -10 °C in a 1:3 NaCl: ice bath. To this solution, 2 equivalents
of N-methylmorpholine (2.58 mmol, 0.284 mL) was slowly added in dropwise. Next,
1.1 equivalents of isobutyl chloroformate (1.42mmol, 0.186mL) was slowly added
in dropwise. The reaction was then stirred at -10 °C for 15 minutes. Then, 1.1
equivalents of 4-nitro-o-phenylenediamine (1.42 mmol, 217.50 mg) was added to
the reaction. The reaction was then stirred for 2 hours at -10 °C and taken out of
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the ice bath to be stirred at room temperature (RT) overnight under argon. The
resulting reaction mixture formed a thick, yellow precipitate. The reaction was then
removed from argon and the solvent was removed under reduced pressure. The
yellow solid that formed was dissolved in N,N-dimethylformamide (DMF, 20 mL)
and added to 100mL of saturated aqueous potassium chloride solution in order to
precipitate the desired product out of solution. This precipitate was removed from
solution by vacuum filtration with a Büchner funnel and washed with cold water
and diethyl ether. The solid was then allowed to air dry for two hours before being
dried under vacuum overnight. Compound 4-8 (1.13 mmol, 589 mg) was obtained
in a crude yield of 87.4% and used, crudely, in the following thionation reaction.

(9H-fluoren-9-yl)methyl(R)-(1-((2-amino-5-nitrophenyl)amino)-3-phenyl-1thioxopropan-2-yl)carbamate (4-9). Sodium carbonate (1.13 mmol, 119.8 mg)
and phosphorus pentasulfide (1.13 mmol, 501.7 mg) were added to 20 mL of THF
in an oven-dried round bottom flask and allowed to stir under argon at room
temperature until the phosphorus pentasulfide was completely dissolved (30
minutes). Then the solution was cooled to 0°C in an ice bath and 4-8 (1.13 mmol,
589 mg) was dissolved in minimal THF (10mL) and added to the reaction. The
reaction was then monitored by thin layer chromatography (TLC) with a mobile
phase of 2:3 ethyl acetate:hexanes. After 1.5 hours, the starting material was
mostly consumed and a small amount of byproduct had been formed, therefore
the reaction was judged to be at completion. The reaction was condensed to dark
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yellow oil by rotary evaporation. This oil was then dissolved in minimal ethyl
acetate and was loaded onto silica plug (bed volume approximately 400 mL in ethyl
acetate) to remove the phosphorus pentasulfide. The column was run in DCM, and
then the crude product was eluted in neat ethyl acetate as a bright yellow band.
This solution was dried by rotary evaporation and redissolved in 1:1 ethyl
acetate:hexanes (3 mL). This mixture was purified by flash chromatography on
silica with a running solvent of 1:1 ethyl acetate:hexanes. Product eluted as a
yellow solution and solvent was removed under reduced pressure. The resulting
yellow solid was washed with dichloromethane and chloroform, then dried under
high vacuum overnight. The product was obtained at a 54.2% (0.612 mmol, 329.6
mg) yield and used in the following step after characterization by 1H NMR. 1H NMR
(500 MHz, CDCl3): δ 9.07 (s, 1H), 7.90 (dd, J = 9.0, 2.6 Hz, 1H), 7.73 (dd, J = 10.6,
7.5 Hz, 2H), 7.58 (s, 1H), 7.48 (d, J = 7.5 Hz, 1H), 7.41 – 7.32 (m, 3H), 7.30 – 7.17
(m, 9H), 6.48 (d, J = 9.0 Hz, 1H), 5.78 (s, 1H), 4.86 (s, 1H), 4.10 (dt, J = 16.7, 8.3
Hz, 5H), 3.21 (d, J = 9.2 Hz, 0H), 1.59 (s, 1H), 1.36 – 1.04 (m, 1H).

(9H-fluoren-9-yl)methyl(R)-(1-(6-nitro-1H-benzo[d][1,2,3]triazol-1-yl)-3phenyl-1-thioxopropan-2-yl)carbamate (4-10). Compound 4-9 (0.612 mmol, 330
mg) was dissolved in glacial acetic acid diluted with 5% water (10 mL) and allowed
to stir while cooling to 0°C in an ice bath. After 5 minutes, 1.25 equivalents of
NaNO2 (0.765 mmol, 52.8 mg) was added slowly to the reaction. After thirty
minutes, no starting material remained by TLC and the reaction became thick with
201

an orange precipitate. Cold Milli-Q water (100 mL) was added to the reaction to
precipitate the remaining product and the resulting orange precipitate was filtered
on a Büchner funnel, washed with additional cold Milli-Q water, dried on a watch
glass overnight, and lyophilized to remove access acetic acid. The crude yield of
the reaction was 84.0% (0.514 mmol, 256 mg) and was used directly in solid phase
peptide synthesis without further purification. 1H NMR (500 MHz, Chloroform-d,
major rotamer only) δ 9.61 (s, 1H), 8.44 (d, J = 8.9 Hz, 1H), 8.29 (d, J = 8.9 Hz,
1H), 7.74 (d, J = 7.6 Hz, 2H), 7.52 (t, J = 6.9 Hz, 2H), 7.38 (t, J = 7.6 Hz, 2H), 7.28
(q, J = 8.0 Hz, 2H), 7.23 – 7.13 (m, 5H), 6.56 (d, J = 7.4 Hz, 1H), 5.66 (d, J = 9.3
Hz, 1H), 4.46 – 4.35 (m, 1H), 4.33 (t, J = 9.0 Hz, 1H), 3.40 (dd, J = 14.0, 5.4 Hz,
1H), 3.10 (dd, J = 13.8, 8.0 Hz, 1H). ESI+-HRMS: calculated for C30H23N5O4S+:
550.1549; found [M+H]+: 550.1550.

Synthesis and Purification of Fmoc-alaS-NBt Precursor
Starting with Fmoc-ala-OH (3.21mmol, 1.00g), (9H-fluoren-9-yl)methyl(R)(1-(6-nitro-1H-benzo[d][1,2,3]triazol-1-yl)-1-thioxopropan-2-yl)carbamate

(4-11)

was synthesized as described elsewhere298. Compound 4-11 was obtained in
26.6% yield (0.942 mmol, 446 mg) after three steps. 1H NMR (500 MHz,
Chloroform-d, major rotamer only) δ 9.68 – 9.62 (m, 1H), 8.47 – 8.41 (m, 1H), 8.30
(d, J = 8.9 Hz, 1H), 7.76 (d, J = 7.6 Hz, 2H), 7.62 (t, J = 6.9 Hz, 2H), 7.40 (t, J =
6.2 Hz, 2H), 7.35 – 7.28 (m, 2H), 6.26 (h, J = 6.8 Hz, 1H), 5.77 (d, J = 9.0 Hz, 1H),
4.57 – 4.32 (m, 2H), 4.22 (t, J = 6.9 Hz, 1H), 1.69 (d, J = 6.6 Hz, 3H). ESI+-HRMS:
calculated for C24H19N5O4S+: 474.1236; found [M+H]+: 474.1248.
202

Synthesis of Thiopeptides with Piperidine Deprotections
SPPS of thiopeptides 4-1 through 4-7 was performed on 2-chlorotrityl resin
(100-200 mesh, 10 μmol scale) in 6 mL fritted syringes. The resin was swelled in
DMF (6 mL, 30 minutes) while stirring. The syringe was then drained and to it was
added

Fmoc-β-(7-methoxy-coumarin-4-yl)-alanine

(Fmoc-Mcm-OH,

2

equivalents) and DIPEA (4 equivalents) in DMF (2 mL). This initial loading reaction
stirred for 30 minutes at room temperature (RT) before being drained, washed with
DMF (2 x 4 mL) and repeated. Fmoc removal was performed by adding to the resin
a solution of 20 % v/v piperidine in DMF (2 mL total volume) and stirring for 20
minutes at RT. The vessel was then drained and the resin washed with DMF,
followed by DCM (1 x 4 mL DMF, 2 x 4 mL DCM, then 2 mL DMF). The peptide
was then elongated up to the thioamide position using standard SPPS protocols
by adding 5 equivalents of amino acid, HBTU, and 10 equivalents of DIPEA in DMF
(2 mL) and stirring each coupling for 45 minutes at RT. Prior to the thioamide
coupling, the resin was washed with dry DCM (obtained by drying over 4 Å
molecular sieves, washed 2 x 4 mL). Fmoc-AaS-NBt (2 equiv.) was then added to
the vessel with DIPEA (2 equiv.) in DCM (2 mL) and the reaction was stirred at RT
for 30 minutes. The vessel was then drained and the resin washed with dry DCM
(2 x 4 mL) before the thioamide coupling was repeated. At completion of the
second coupling, the resin was washed with DCM then DMF (2 x 4 mL) and Fmoc
deprotection via piperidine treatment proceeded as described above. Standard
SPPS was used to add the remaining amino acids. After the last Fmoc group was
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removed, the resin was washed with DMF, followed by DCM (2 x 4 mL each). A
cleavage cocktail was prepared with 12:6:1:1 DCM:TFA:TIPS:H2O. This was
added to the resin and allowed to stir at RT for 30 minutes before being drained
and collected. DCM (3 mL) was added to the resin to wash out any remaining
peptide and the collected solution was dried to a colorless oil by rotary evaporation.
The crude peptide product was then precipitated by adding cold diethyl ether (12
mL) and vortexing vigorously. The resulting precipitate was dried and stored under
argon at -20 °C until HPLC analysis proceeded. The oxo controls for peptide 4-1
were synthesized by standard SPPS described above without any special coupling
conditions for the oxo Fmoc-Phe-OH.

Synthesis of Thiopeptides with DBU Deprotections
SPPS for thiopeptides 4-1 through 4-7 proceeded as described above until
deprotection following thioamide installation. After thioamide coupling was
complete for each peptide, subsequent Fmoc deprotections were done using the
alternative base DBU. For each deprotection the resin was treated with 2 % v/v
DBU in DMF (2 mL total volume) for 2 minutes while stirring at RT. The vessel was
then drained and the resin washed with DMF and DCM (1 x 4 mL DMF, 1 x 4 mL
DCM, then 2 mL DMF). This procedure was repeated twice before proceeding to
the next amino acid coupling reaction. At peptide completion, cleavage and
precipitation proceeded as described in the above section.
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Synthesis of Thiopeptides 4-1 and 4-7 with 10% Piperidine Deprotections
Peptides 4-1 and 4-7 were synthesized as described in the previous section
with the following differences. After thioamide coupling, the resin was split into two
equal portions (10 μmol each for 4-1, 25 μmol each for 4-7). This will ensure that
the starting material is identical for direct comparison between 2% DBU and
shortened 10% piperidine deprotections. One of the aliquots had the remaining
Fmoc deprotections performed with 2% DBU in DMF as described in the previous
section (3 x 2 mL, 2 minutes per deprotection). The other aliquot had the remaining
deprotections performed with 10% piperidine in DMF with shortened deprotection
times (2 x 2 mL, 30 seconds per deprotection) as outlined in Mukherjee et al.223
Table 4-2: Peptide Purification/Characterization Methods and Retention Time.
Retention
Peptide
Gradient
Time
S

KAF AKμ-OH (4-1-L)

Column

2

18.2 min

Phenomenex Luna C8

KAf AKμ-OH (4-1-D)

2

21.0 min

Phenomenex Luna C8

KAFAKμ-OH (4-1-Oxo)

2

16.6 min

Phenomenex Luna C8

2

16.0 min

Phenomenex Luna C8

2

18.7 min

Phenomenex Luna C8

2

17.2 min

Phenomenex Luna C8

S

S

F AKAKμ-OH (4-2-L)
S

f AKAKμ-OH (4-2-D)
S

FA KAKμ-OH (4-3-L)
S

Fa KAKμ-OH (4-3-D)

2

18.6 min

Phenomenex Luna C8

S

2

16.3 min

Phenomenex Luna C8

S

2

16.4 min

Phenomenex Luna C8

2

18.2 min

Phenomenex Luna C8

2

19.2 min

Phenomenex Luna C8

3

33.7 min

Phenomenex Luna C8

3

29.0 min

Phenomenex Luna C8

3

32.4 min

Phenomenex Luna C8

3

28.8 min

Phenomenex Luna C8

FAKA Kμ-OH (4-4-L)
FAKa Kμ-OH (4-4-D)
S

FAE AKμ-OH (4-5-L)
S

FAe AKμ-OH (4-5-D)
S

CVNY EEFVQMMTAK-OH (4-6-L)
S

CVNy EEFVQMMTAK-OH (4-6-D)
S

CVNYEEF VQMMTAK-OH (4-7-L)
S

CVNYEEf VQMMTAK-OH (4-7-D)
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Table 4-3: HPLC Gradients for small molecule/peptide purification and characterization.
Time
No.
%B
No.
Time (min) %B
(min)
2

0:00
2
3
0:00
2
5:00
2
5:00
2
10:00
20
10:00
20
35:00
35
40:00
40
38:00
100
43:00
100
40:00
100
48:00
100
42:00
2
50:00
2
Solvent A: 0.1% trifluoroacetic acid in water; Solvent B: 0.1% trifluoroacetic acid in acetonitrile

Table 4-4: MALDI-TOF MS Characterization of Purified Peptides.
[M + H]

Peptide

+

Calculated

Found

825.39

825.76

KAf AKμ-OH (4-1-D)

825.39

825.70

KAFAKμ-OH (4-1-Oxo)

809.41

810.26

825.39

825.82

825.39

825.74

825.39

826.48

S

KAF AKμ-OH (4-1-L)
S

S

F AKAKμ-OH (4-2-L)
S

f AKAKμ-OH (4-2-D)
S

FA KAKμ-OH (4-3-L)
S

Fa KAKμ-OH (4-3-D)

825.39

826.01

S

825.39

826.01

S

825.39

825.94

826.84

827.04

826.84

827.00

1709.72

1709.53

1709.72

1709.50

1709.72

1709.87

1709.72

1709.94

FAKA Kμ-OH (4-4-L)
FAKa Kμ-OH (4-4-D)
S

FAE AKμ-OH (4-5-L)
S

FAe AKμ-OH (4-5-D)
S

CVNY EEFVQMMTAK-OH (4-6-L)
S

CVNy EEFVQMMTAK-OH (4-6-D)
S

CVNYEEF VQMMTAK-OH (4-7-L)
S

CVNYEEf VQMMTAK-OH (4-7-D)
μ = 7-methoxycoumarinylalanine
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Analytical HPLC Peptides 4-1 through 4-5
Stock solutions of all the peptides were made by dissolving the solid peptide
precipitate in 50% (v/v) CH3CN in H2O (with 0.1% TFA) and vortexing to fully
dissolve the peptide. Next, 100 μL of the stock solution were diluted to 1 mL total
volume with water containing 0.1% TFA. Peptide samples were analyzed by
reverse phase HPLC using gradient 2 on a Phenomenex Luna C8 column with a
flow rate of 1 mL/min. The absorbance was monitored at 214 nm (amide bond),
272 nm (thioamide bond), and 325 nm (methoxycoumarin) and peaks were
analyzed by MALDI MS to confirm their identity (See Table 4-4). Integration values
for peak area percentage and yield determination were calculated using the
HPCORE ChemStation software from Agilent Technologies. Percent epimerization
was calculated by dividing the peak area (325 nm) of the L-thiopeptide by the total
peak area of the observed L- and D-thiopeptides.
For quantification of peptide yields, 7-methoxycoumarin-4-acetic acid (Mca)
can be used as an internal standard for each peptide sample. A stock of Mca was
made in 1 mL of 1:1 CH3CN:H2O with dropwise DMSO added until all Mca
solubilized. The concentration was determined by diluting the sample by a factor
of 2000 in Milli-Q water and measuring the absorbance at 324 nm (ε=11,820 M-1
cm-1; stock concentration was 22.1 mM). A 1 mL HPLC sample was then prepared
by adding 50 μL of stock peptide solution (2 mL stock volume; described above)
to a 500 μM solution of Mca in Milli-Q H2O containing 0.1% TFA. The maximum
theoretical concentration of peptide in solution should be 500 μM and is
represented by the Mca added to each sample. Samples were prepared in
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triplicate and yield was calculated by dividing the peptide product peak integration
(325 nm) by the Mca standard peak integration (325 nm).

Peptide 1 (PheS, Piperidine)
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Figure 4-3: Analytical HPLC of peptide 4-1 showing Phe spectra at 272 nm (thioamide absorbance, left) and
325 nm (Mcm absorbance, right). The L-epimer (L) and D-epimer (D) are denoted for each spectrum. The
peak marked with (#) corresponds to peptide product where thiophenylalanine was not coupled.
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Figure 4-4: Analytical HPLC of peptide 4-1 showing phe spectra at 272 nm (thioamide absorbance, left) and
325 nm (Mcm absorbance, right). The L-epimer (L) and D-epimer (D) are denoted for each spectrum. The
peak marked with (#) corresponds to peptide product where thiophenylalanine was not coupled.
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Figure 4-5: Analytical HPLC of peptide 4-1 (oxo) showing spectra at 325 nm (Mcm absorbance). The Lepimer (L) and D-epimer (D) are denoted for each spectrum. No epimerization was observed for either the
L- or D-oxo amino acid standards.
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Peptide 1 (PheS, 10% Piperidine)

Peptide 1 (PheS, 10% Piperidine)
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Figure 4-6: Analytical HPLC of peptide 4-1 from direct comparison of 2% DBU to 10% piperidine
S
deprotections. Chromatograms of the Phe spectra at 272 nm (thioamide absorbance, left) and 325 nm
(Mcm absorbance, right). The L-epimer (L) and D-epimer (D) are denoted for each spectrum. The peak
marked with (#) corresponds to peptide product where thiophenylalanine was not coupled. Retention times
differ from Figure 4-3 due to changes in HPLC instrumentation however, relative retention time shifts
between #, L, and D are consistent.
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Peptide 2 (PheS, Piperidine)
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Figure 4-7: Analytical HPLC of peptide 4-2 showing Phe spectra at 272 nm (thioamide absorbance, left) and
325 nm (Mcm absorbance, right). The L-epimer (L) and D-epimer (D) are denoted for each spectrum. The
peak marked with (#) corresponds to peptide product where thiophenylalanine was not coupled.
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Figure 4-8: Analytical HPLC of peptide 4-2 showing phe spectra at 272 nm (thioamide absorbance, left) and
325 nm (Mcm absorbance, right). The L-epimer (L) and D-epimer (D) are denoted for each spectrum. The
peak marked with (#) corresponds to peptide product where thiophenylalanine was not coupled.
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Peptide 3 (AlaS, Piperidine)
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Figure 4-9: Analytical HPLC of peptide 4-3 showing Ala spectra at 272 nm (thioamide absorbance, left) and
325 nm (Mcm absorbance, right). The L-epimer (L) and D-epimer (D) are denoted for each spectrum. The
peak marked with (#) corresponds to peptide product where thioalanine was not coupled.
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Figure 4-10: Analytical HPLC of peptide 4-3 showing ala spectra at 272 nm (thioamide absorbance, left) and
325 nm (Mcm absorbance, right). The L-epimer (L) and D-epimer (D) are denoted for each spectrum. The
peak marked with (#) corresponds to peptide product where thioalanine was not coupled.
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Figure 4-11: Analytical HPLC of peptide 4-4 showing Ala spectra at 272 nm (thioamide absorbance, left)
and 325 nm (Mcm absorbance, right). The L-epimer (L) and D-epimer (D) are denoted for each spectrum,
although they cannot be separated for this peptide. The peak marked with (#) corresponds to peptide
product where thioalanine was not coupled.
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Figure 4-12: Analytical HPLC of peptide 4-4 showing ala spectra at 272 nm (thioamide absorbance, left) and
325 nm (Mcm absorbance, right). The L-epimer (L) and D-epimer (D) are denoted for each spectrum,
although they cannot be separated for this peptide. The peak marked with (#) corresponds to peptide
product where thioalanine was not coupled.
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Figure 4-13: Analytical HPLC of peptide 4-5 showing Glu spectra at 272 nm (thioamide absorbance, left)
and 325 nm (Mcm absorbance, right). The L-epimer (L) and D-epimer (D) are denoted for each spectrum.
The peak marked with (#) corresponds to peptide product where thioglutamate was not coupled. Some
conversion of the thiopeptide to oxopeptide is observed (denoted by “O”) as a byproduct of prolonged TFA
exposure during cleavage from the 2-chlorotrityl resin.
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Figure 4-14: Analytical HPLC of peptides 4-1 through 4-5 containing the internal Mca standard (Piperidine,
left; DBU, right). The L-epimer (L) and internal Mca standard (^) are denoted for each spectrum.

219

Table 4-5: Peak area and integration values for the MCA assay used to quantify peptide yields.

Peptide 4-1 Piperidine Peak Area
MCA Peak Area
Peptide 4-1 Piperidine % Yield
Peptide 4-1 DBU Peak Area
MCA Peak Area
Peptide 4-1 DBU % Yield
Peptide 4-2 Piperidine Peak Area
MCA Peak Area
Peptide 4-2 Piperidine % Yield
Peptide 4-2 DBU Peak Area
MCA Peak Area
Peptide 4-2 DBU % Yield
Peptide 4-3 Piperidine Peak Area
MCA Peak Area
Peptide 4-3 Piperidine % Yield
Peptide 4-3 DBU Peak Area
MCA Peak Area
Peptide 4-3 DBU % Yield
Peptide 4-5 Piperidine Peak Area
MCA Peak Area
Peptide 4-5 Piperidine % Yield
Peptide 4-5 DBU Peak Area
MCA Peak Area
Peptide 4-5 DBU % Yield

Trial 1
9171.8
30679.8
29.9
11008.1
30888.1
35.6
13795.1
31730.6
43.5
15826.5
31478.0
50.3
15119.9
31879.6
47.4
13585.3
30547.3
44.5
5573.9
30473.7
18.3
6951.6
30477.2
22.8

Trial 2
9069.7
30563.2
29.7
10851.2
30286.8
35.8
14006.5
30989.6
45.2
16119.3
30749.3
52.4
12930.9
30879.1
41.9
13747.5
30827.3
44.6
5612.5
30581.9
18.4
6971.3
30456.8
22.9
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Trial 3
9048.9
30131.0
30.0
11045.3
30427.9
36.3
13968.3
31594.8
44.2
15740.6
30728.3
51.2
13185.9
30868.7
42.7
13787.7
30651.5
45.0
5574.4
31179.6
17.9
6970.6
30999.1
22.5

Average
9096.8
30458.0
29.9
10968.2
30534.3
35.9
13923.3
31438.3
44.3
15895.5
30985.2
51.3
13745.6
31209.1
44.0
13706.8
30675.4
44.7
5586.9
30745.1
18.2
6964.5
30644.4
22.7

Std. Dev.
65.8
289.1
0.2
103.0
314.4
0.3
112.7
394.5
0.9
198.5
426.9
1.1
1197.0
580.7
3.0
107.2
141.5
0.3
22.1
380.2
0.3
11.2
307.4
0.2

Analytical HPLC of Thiopeptides 4-6 and 4-7
Stock solutions of all the peptides were made by dissolving the solid peptide
precipitate in 50% (v/v) CH3CN in H2O (with 0.1% TFA) and vortexing to fully
dissolve the peptide. Next, 100 μL of the stock solution was diluted to 1 mL total
volume with water containing 0.1% TFA. Peptide samples were analyzed using
reverse-phase HPLC at a flow rate of 1 mL/min using gradient 3. The absorbance
was monitored at 214 nm (amide bond) and 272 nm (thioamide bond) and peaks
were analyzed by MALDI MS to confirm their identity (See Table 4-4). Integration
values for peak area percentage were calculated using the HPCORE ChemStation
software from Agilent Technologies. As there is no Mcm present in this peptide,
Mca could not be used as an internal standard to quantify yield. Percent
epimerization was calculated by dividing the peak area (272 nm) of the Lthiopeptide by the total peak area of the observed L- and D-thiopeptides.
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Figure 4-15: Analytical HPLC of peptide 4-6 showing Tyr spectra at 272 nm (thioamide absorbance, left)
and 215 nm (amide absorbance, right). The L-epimer (L) and D-epimer (D) are denoted for each spectrum.
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Figure 4-16: Top and Middle: Analytical HPLC of peptide 4-7 showing Phe and phe spectra at 272 nm
(thioamide absorbance, left) and 215 nm (amide absorbance, right). The L-epimer (L) and D-epimer (D) are
S
denoted for each spectrum. Bottom: The authentic phe peptide 4-7 was synthesized as a standard using
both the piperidine (Left) and DBU (Right) deprotection conditions (spectra monitored a 272 nm shown).
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Figure 4-17: Analytical HPLC of peptide 4-7 from direct comparison of 2% DBU to 10% piperidine
S
deprotections. Chromatograms showing Phe spectra at 272 nm (thioamide absorbance, left) and 215 nm
(amide absorbance, right). The L-epimer (L) and D-epimer (D) are denoted for each spectrum. The peak
labeled “T” is thioanisole from the TFA deprotection cocktail. Small changes in retention time due to
changes in HPLC instrumentation as compared to Figure 4-16.
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CHAPTER 5:
DITHIOAMIDE PROTEIN SEMISYNTHESIS FOR THERMODYNAMIC
ANALYSIS AND FLUORESCENCE QUENCHING STUDIES
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Section 5.1- Introduction
Incorporation of multiple thioamides within a single protein may confer
advantages over their single thioamide counterparts in biophysical studies. This is
especially true in their capacity as fluorescence quenchers; dithioamides show
increased fluorescence quenching relative to monothioamide analogs in model 6mer peptides containing Pro, Ala, and Gly.298 Furthermore, additive stabilization or
destabilization of protein secondary and tertiary structure may be possible with
dithioamide substitutions, based upon the observations made with single
thioamide substitutions in prior studies (see Chapter 3).256 Yet the solid phase
synthesis of sequence-diverse dithioamide peptides and their stability during TFA
cleavage from resin, HPLC purification, and NCL, remains essentially untested.222
In order to identify conditions for dithiopeptide synthesis and compatibility with
NCL, I used a previously established CaM NCL semi-synthetic scheme (See
Section 3.2).256 This section describes the syntheses of six distinct dithioamide
containing peptides and proteins with varying thioamide positioning (See Figure 51). Each of these syntheses was achieved without any additional complications
with respect to single thioamide ligations. Thioamide substitution positions were
chosen to assess if dithioamide containing CaM variants (dithioCaM, CaMSS) can
fold properly when accommodating multiple backbone substitutions. Furthermore,
using CD thermal denaturation experiments, I determined the impact that these
substitutions have on the thermostability of CaM. Sites for thioamide incorporation
were chosen to assess if the stabilizing effects observed in single thioamide
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substitutions can be additive. Additionally, I investigated whether a destabilizing
mutation can be negated by a predicted stabilizing mutation.
The second part of this work focuses on the study of the fluorescence
quenching properties dithioamides have in a dynamic protein system such as CaM.
These experiments employ a previously described CaM-peptide binding assay that
utilizes a peptide (denoted ‘FRRIAR’) derived from an olfactory cyclic nucleotide
gated ion channel.132 In the modified system described herein, the peptide contains
a tryptophan fluorophore (denoted as WRRIAR), which can be quenched by
thioamides.235 Taken together, these studies of dithioproteins will inform the usage
of next-generation, multiply thioamidated peptides and proteins for use as
enhanced fluorescence quenchers and structural modulators.

HS
O

+ H 2N

S

S

RS

Figure 5-1: Dithioamide substitutions in CaM. Top: NCL scheme for the semi-synthesis of dithioCaM
following the same general procedure outlined in Section 3.2. Bottom: Table describing the sequences of
dithioamide substitutions and the corresponding single thioamide effects observed in Section 3.2.
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Section 5.2- Synthesis and CD Characterization of Dithioamide Containing
Calmodulin (CaMSS)
In my initial designs, I was interested in placing the thioamides in positions
which, relative to one another, may provide the highest potential for degradation
during SPPS extension and cleavage. For example, placing the thioamide at the i
and i + 1 position may lead to an increase in Edman-like degradation of the
thioamide, thereby leading to truncated peptide products (See Figure 5-2).312
Additionally, i and i + 1 sites may also lead to enhanced n à π* interactions, which
may be observed by near-UV absorption studies such as CD and
spectrophotometry, even within the context of an α-helix.313 I have previously
studied the structural and thermodynamic impacts of single thioamide substitutions
in the context of the C-terminal loop and helix of CaM. With rationale for how the
CaM fold accommodates each single thioamide, this same portion of CaM provides
an established platform by which to explore multiply thioamidated proteins. The
placement of two thioamides within the helix may change the periodicity of the
helix, and allow for complementary inclusion of previously unaccommodated
thioamide substitutions. Thus, I began my studies by synthesizing the two
dithioamide

peptides

CaM135-148-Cys135TyrS138ValS142

and

CaM135-148-

Cys135PheS141ValS142 by manual SPPS using modified thioamide coupling
procedures from Section 3.2 and DBU deprotections as discussed in 4.2. It should
be noted that the use of DBU as an alternative Fmoc deprotection reagent is
especially advantageous for peptides containing two or more thioamides. This is
due to the suppression of multiple epimerization reactions (at each thioamide α228

carbon), thereby eliminating the formation of a multitude of byproducts. After two
rounds of HPLC purification, pure CaM135-148-Cys135TyrS138ValS142 (5-1) and
CaM135-148-Cys135PheS141ValS142 (5-2) were each obtained in 1.2% isolated yields
(1.5 mg each).
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Figure 5-2: Proposed mechanism of Edman degradation-like backbone cleavage of i and i+1 dithiopeptides
under acidic conditions.

These dithiopeptides were each used in a ligation with CaM1-134-MES in the
presence of denaturant (Gdn) and thiophenol as the catalyst. The reactions were
monitored by MALDI-MS for formation of CaM1-148-Cys135TyrS138ValS142 and CaM1S
S
148-Cys135Phe 141Val 142.

Each ligation generated no observable thio- to oxo-amide

exchange or degradation products other than the typical CaM1-134-OH hydrolysis
byproduct previously observed in these syntheses (see Section 3.3). To remove
this byproduct, the crude reaction was subjected to anion exchange purification by
FPLC, followed by Cys capture and release purification using thiopropyl sepharose
resin as before.256 The site of the ligation (Cys135) is a glutamine residue in the
native CaM sequence and in past preparations, I have alkylated this Cys with
iodoacetamide to create a nearly isosteric Gln mimic (denoted “CysQ”). The
dithioproteins were therefore treated with 100 mM iodoacetamide in capping buffer
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(20 mM Tris, 0.5 mM TCEP, pH 8.3) and only singly alkylated proteins were
detected by MALDI, with no observable thioamide sulfur modifications in
agreement with past preparations of CaM thioproteins (CaMS). CaM1-148CysQ135TyrS138ValS142 and CaM1-148-CysQ135PheS141ValS142 were obtained in
isolated yields of 5.1% and 5.9%, respectively. Although these yields are lower
than previously reported syntheses of CaMS (typically 10-20% yield), this
methodology certainly provides evidence that dithioproteins can be synthesized
using NCL and our newly developed SPPS protocols.314 The low yield for these
constructs may be due in part to poor solubility of the protein after lyophilization.
Nonetheless, these CaM dithioproteins were obtained in quantities sufficient to
acquire CD spectra of the Ca2+-bound and Ca2+-free structures. Each of the
spectra show significantly diminished helicity when compared to a CysQ control
protein, in agreement with the destabilization observed for each monothioamide
substitution (Figure 5-3). Unfortunately, each of these constructs were prone to
aggregation, as observed previously for the PheS141 single thioamide mutant.
Therefore, we were unable to effectively monitor the thermal unfolding transitions
of these dithioamide constructs.
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Figure 5-3: CD wavelength scans of initial dithioamide CaM constructs (Phe 141/Val 142 and Tyr 138/Val
Q
tested for compatibility with NCL. Each protein shows significantly reduced MRE compared to Cys .

S

142)

With the preliminary success of the synthesis of CaMSS, I turned my
attention to other constructs that may be more amenable to CD studies in order to
learn more about the effects of dithioamide substitutions in a helix-loop-helix motif
(see Figure 5-1). The first thioamide positions, ValS136 and GluS139, were chosen to
assess if single stabilizing mutations can work synergistically to provide greater
gains in thermostability for the protein. Surprisingly, the MRE of both the holo and
apo forms of the protein were significantly reduced relative to the CysQ and single
thioamide ValS136 and GluS139 controls. Melting temperature (TM*) and free energy
of unfolding (ΔGU) were determined by performing CD thermal melts monitoring
the helicity of the protein via the CD signal at 222 nm as temperature was
increased. As previously noted, holo CaM constructs do not unfold completely (TM
> 80 °C) during thermal denaturation and all holo CaMSS proteins discussed here
also do not unfold in the temperature range studied (5 to 95 °C). However, in
agreement with the CD wavelength scans, apo CaM ValS136/GluS139 showed
thermodynamic parameters that indicate destabilization compared to the CysQ
231

control (ΔTM = -2.9 °C, ΔΔGU = -1.1 kcal mol-1). Although this is a counterintuitive
result, this destabilization may indicate that the remodeling of the loop-helix
hydrogen bonding network by ValS136 alters the structural dynamics of the helix. A
change in the periodicity of the helix could, hypothetically, lead to poorer
accommodation of the GluS139 thioamide sulfur by shrinking the hydrogen bond
distance with the next helical turn (C=X--N distance is 3.4 Å), although higher
resolution studies to support this hypothesis have not yet been performed.276
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Figure 5-4: CD wavelength scans for dithioproteins each containing at least one predictively stabilizing
mutation. Single thioamide protein wavelength scans are also shown for direct comparison. A significantly
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increased πàπ* single (centered at 270 nm) is observed in the Val 136/Tyr 138 protein (blue).
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Figure 5-5: CD wavelength scans of each CaM protein (holo and apo) plotted with their respective single
thioamide scans from Section 3.2. Increased absorbance at 270 nm (thioamide CD signature) is observed
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for both Val 136/Val 142 and Val 136/Tyr 138 proteins.
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With the intriguing, non-additive effects of the thioamide substitutions in
CaM ValS136/GluS139, I wished to determine whether stabilizing effects of the ValS136
mutation could be maintained with a second thioamide (ValS142), which was
previously found to be a near neutral mutation (TM comparable to the CysQ control).
However, I was again surprised to find that this CaMSS construct showed a
decrease in MRE signal compared to each single thioamide control in the CD
wavelength scans. However, CaM ValS136/ValS142 showed a similar melting
temperature to the CysQ control (see Table 5-1), yet underwent a significantly less
cooperative unfolding transition (ΔΔGU = -1.0 kcal mol-1). The stabilization provided
to CaM by ValS136 (ΔTM = +3.1 °C) appears to have negated the slight perturbation
observed in ValS142 (ΔTM = -1.5 °C), yet the two effects are not a sum of these
individual values. Taken together, these two CaMSS proteins indicate that the effect
multiple thioamides have on the thermostability and structural elements of a protein
may be difficult to predict from the effects of single thioamides. Nevertheless, I
continued my exploration of dithioamide substitutions in this region by combining
one of the two singly stabilizing mutations (ValS136 or GluS139) with the destabilizing
mutation TyrS138.
Based on the results achieved in the ValS136/ValS142 protein, I hypothesized
that one of the stabilizing mutations may be able to rescue some of the protein
structure and thermostability that is compromised by TyrS138. For CaM
TyrS138/GluS139, some of the global thermostability was recovered with respect to
the TyrS138 single mutant (ΔTM = + 4.0 °C relative to TyrS138), however, it does not
return the protein to the levels of thermostability of CysQ (ΔTM = -2.2 °C, ΔΔGU = 234

1.3 kcal mol-1). Curiously, there still appears to be significant structural perturbation
when examining the CD wavelength scans; CaM TyrS138/GluS139 shows significant
reduction in helical signature at 208 and 222 nm in both the holo and apo forms of
the protein. In fact, the Apo form shows a MRE value at 222 nm that is consistent
with the destabilizing TyrS138 single mutation. These results are again difficult to
interpret, but it is most likely that together, the two thioamide mutations are driving
the protein towards an alternative fold where some of destabilizing character of the
TyrS138 can be recovered. However, the dithioamide protein shows distinct
structural properties that do not completely agree with what would be expected
from the net effects of both the previously published single mutations.
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Figure 5-6: Left: Holo dithioCaM MRE values plotted as a function of temperature. All dithioproteins have
TM values greater than 80 °C, in agreement with oxo and single thioamide controls. Right: Transformed apo
thermal melts plotted as fraction folded (Ff*) fits that include a weighted contribution from the
intermediate state as described in Section 3.2. Melting curves were obtained by measuring the θ222
at 1 °C increments in 10 mM Tris, pH 7.5 with either 0.5 mM EDTA (apo) or 2 mM CaCl2 (holo).
Transformation of raw CD signal to MRE values and three-state fitting procedures were performed
as described in Section 3.3.
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When performing the same set of experiments for CaM ValS136/TyrS138, I
encountered an even more surprising result; the CD signature for CaM
ValS136/TyrS138 matches identically to that of the ValS136 monothioamide protein. In
addition, CaM ValS136/TyrS138 is more thermally stable during CD thermal melts
when compared to the oxo control CysQ135 (ΔTM = 3.1 °C, ΔΔGU = 2.2 kcal mol-1)
and shows a more cooperative transition during unfolding than that of either the
TyrS138 or ValS136 thermal melting profiles (See Figure 5-6). To ensure that both
thioamides were present in the protein and unmodified during iodoacetamide
treatment, a trypsin digest was performed, followed by MALDI-TOF tandem
MS/MS fragmentation analysis of the resulting tryptic dithioamide peptide. To my
satisfaction, both thioamides are present in the fragmentation analysis (See
Figures 5-11 and 5-12, and Table 5-6). The hypothesized hydrogen bond that
ValS136 makes with the side-chain of GluS140 could change the periodicity of the Cterminal helix, as with the ValS136/GluS139 mutant. However, in this case, the sulfur
atom may be more readily accommodated into the inter-strand space due to an
expansion in the first turn of the helix (TyrS138 sulfur accommodation normally
forbidden; C=O--N distance of 2.6 Å). With the TyrS138 no longer being structurally
perturbing in this conformation, the thioamide N-H may participate in a hydrogen
bonding within the helix, thereby leading to increased stabilization.
Although the structural and thermodynamic effects of dithioamide
substitutions within CaM are not necessarily intuitive, TyrS138/GluS139 and
ValS136/TyrS138 provide effects that can be rationalized within the context of the CaM
C-terminal domain. I am currently in pursuit of high-resolution studies of both
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mono- and di-thioamide CaM through a combination of NMR and crystallography
to provide more context for the effects, especially within the multiply thionated
proteins discussed here.
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Figure 5-7: Individual fraction folded (Ff*) plots for CaM thermal melts (from Figure 5-5) showing
Q
corresponding single thioamide thermal melts and the Cys oxo and wild type controls (from Section 3.2).
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Table 5-1: Thermodynamic values for CaM variants compared to their single thioamide congeners from
Section 3.2.
a

CaM Variant

TM1
(°C)

WT

(kcal mol )

TM2
(°C)

43.5 ± 0.6

33.1 ± 0.8

Q
135

38.9 ± 0.8

ValS 136
TyrS138

b

c

ΔΔGU

(kcal mol )

ΔTm*
(°C)

48.6 ± 0.6

60.5 ± 0.7

46.8 ± 0.3

---

6.4 ± 0.2

---

30.2 ± 0.9

48.8 ± 0.7

61.7 ± 0.8

45.5 ± 0.4

---

5.9 ± 0.1

---

39.6 ± 0.5

36.7 ± 0.6

55.3 ± 0.8

52.0 ± 0.5

48.6 ± 0.7

3.1

6.5 ± 0.1

0.6

34.7 ± 0.8

39.7 ± 0.7

43.0 ± 0.9

51.1 ± 1.0

39.3 ± 0.8

-6.2

4.1 ± 0.2

-1.8

Glu 139

40.7 ± 0.7

40.1 ± 0.4

51.9 ± 0.6

53.9 ± 0.9

47.0 ± 0.1

1.6

6.4 ± 0.1

0.5

ValS142

36.4 ± 0.6

35.5 ± 0.8

48.4 ± 0.8

62.9 ± 0.9

44.0 ± 0.7

-1.5

5.8 ± 0.2

-0.1

ValS 136 /TyrS138

43.0 ± 0.1

48.0 ± 1.7

53.0 ± 0.6

62.1 ± 1.6

48.6 ± 0.2

3.1

8.1 ± 0.3

2.2

/Glu 139

37.4 ± 1.0

36.0 ± 1.5

46.4 ± 0.8

50.5 ± 2.7

42.6 ± 0.1

-2.9

4.8 ± 0.2

-1.1

ValS 136 /ValS142

43.8 ± 0.5

32.9 ± 0.7

47.0 ± 0.7

42.9 ± 0.2

45.6 ± 0.6

0.1

4.9 ± 0.1

-1.0

TyrS 138 /GluS139

38.8 ± 0.0

36.3 ± 1.9

47.6 ± 0.1

43.4 ± 2.0

43.6 ± 0.2

-2.2

4.6 ± 0.1

-1.3

Oxo

S

S

Val

136

S

-1

ΔH2

d

TM*
(°C)

Cys

ΔH1

-1

ΔGU

-1
(kcal mol ) (kcal mol )
-1

Section 5.3 – Dynamic Fluorescence Quenching of Tryptophan in CaMSS
Calcium bound CaM is known to bind several peptide partners derived from
various regulatory domains
in the literature.315 Upon binding these
ΔTm* discussed
ΔGU
ΔΔG
U
TM*
CaM Variant
(kcal
(kcal
peptide sequences,
a structural change to produce a distinct
(°C) CaM
(°C)undergoes
-1
-1
mol )
mol )
2+
2+
conformation
from±that
the Ca
0.4 of --5.9 -bound
± 0.1 or
---Ca -free form. Our lab has previously
CysQ Oxo45.5
135
S
48.6 ±sequences
0.7 3.1 of
6.5a± 0.1
0.6(denoted “FRRIAR”) taken from an
136
used Val
derivatized
peptide
S
Tyr 138 39.3 ± 0.8 -6.2 4.1 ± 0.2 -1.8
olfactoryS cyclic
nucleotide gated ion channel as a model system for studying
Glu 139 47.0 ± 0.1 1.6 6.4 ± 0.1 0.5
S
44.0 ± 0.7fluorescence
-1.5 5.8 ± 0.2
-0.1 phenomena in CaM.132 In these
Val 142
distance
dependent
quenching
S
S
48.6 ± 0.2 3.1 8.2 ± 0.6 2.3
Val 136/Tyr 138
S
experiments,
S
S F RRIAR was used as a stoichiometric reporter for FRET quenching
41.9
Val 136/Glu 139 ± 0.4 -3.6 4.6 ± 0.6 -1.3
S
S
38.0
± 0.0 sites
-7.5 within
3.0 ± tyrosine-free
0.0 -2.9
ofVal
Cnf
placed
at various
CaM. In the following studies, we
/Val 142
136
S
S
41.6 ± 1.2 -3.9 3.2 ± 0.1 -2.7
Tyr 138/Glu 139

have used the inverse of this assay to place the thioamide within the context of the
folded protein to observe quenching of an external fluorophore in a FRRIAR-like
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peptide. Although Cnf is an attractive probe for FRET based quenching
experiments, it cannot be used in CaM sequences that contain Tyr (all CaMS and
CaMSS proteins contain a Tyr and position 99 and 138), due to the spectral overlap
between Cnf emission and Tyr excitation. Therefore, a FRRIAR derivative
containing an N-terminal fluorescent tryptophan residue (denoted WRRIAR) will
be used as the fluorescent probe. The objective of these studies is threefold: (1)
to establish that thioCaM and dithioCaM proteins are able to bind the peptide and
undergo similar conformational changes observed in the WT controls, (2) to
observe thioamides as fluorescence quenchers while embedded within folded
secondary and tertiary elements of protein structure, and (3) to provide additional
evidence of increased fluorescence quenching by dithioamides relative to their
monothioamide counterparts.
The fluorescence experiments described in this section were designed by
Chris Walters and John Ferrie and the fluorescence measurements were taken by
John Ferrie, to be reported in total elsewhere. In order to qualitatively determine
each CaMSS protein’s ability to bind WRRIAR, two ratios of CaMSS to WRRIAR
were prepared (2:1 and 0.5:1 CaMSS:WRRIAR), with a 1 μM concentration of
WRRIAR (125 μL final volume). The same ratiometric measurements were made
with the single thioamide mutants ValS136, TyrS138, Glu139, and ValS142, to verify the
potential additive quenching in dithioamide proteins. Fluorescence measurements
with WRRIAR peptides were also performed on WT CaM and a CysQ135 oxoamide
control protein to determine the maximum Trp fluorescence of CaM-bound
WRRIAR. The concentrations of each protein used in these experiments were
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determined by a FluoroProfile® (Sigma-Aldrich, St. Louis, MO) assay using a series
of WT dilutions as standards. Excitation of tryptophan was performed at 295 nm
and emission spectra were collected from 305 nm to 450 nm. A large peak
centered at ~320 nm was detected in the buffer-only background spectra and can
be attributed to the Raman scattering of the buffer. This peak is subtracted from
all fluorescence spectra acquired for protein samples. Each experiment was
replicated three times to ensure the precision of the data collected.
The measurements collected were analyzed by John Ferrie (to be described
in detail elsewhere) and based off of fits to each spectrum, the percent quenching
of Trp and percent of peptide bound can be obtained for each CaM protein at each
WRRIAR ratio. Quenching efficiency is calculated as the percent quenching
divided by the percent peptide bound for each construct and ratiometric
measurement. The ValS136/ValS142 CaM construct demonstrates the best example
of the additive contributions each thioamide has on the quenching of Trp (see
Figure 5-8). For each CaM:WRRIAR ratio, the single thioamide constructs ValS136
and ValS142 provide Trp quenching in single contributions approximately equal to
the total Trp quenching observed for the ValS136/ValS142. Fitting of the raw
fluorescence spectra enables deconvolution of the amount of CaM-bound
WRRIAR and free WRRIAR in solution. For ValS136/ValS142, this analysis indicates
that 100 % of WRRIAR is bound at the 2:1 CaMSS:WRRIAR ratio. This is greater
than the percent of WRRIAR bound for either of the single thioamide mutants and
demonstrates similar binding capacity to that of the WT protein. Similar effects are
demonstrated for the ValS136/Tyr138 protein, where, although the percent of
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WRRIAR bound is not at WT levels for each ratiometric measurement, the CaMSS
protein still shows higher quantities of peptide bound than its single thioamide
counterparts at a 2:1 ratio of CaMSS to WRRIAR. Additionally, this dithioCaM
construct restores much of the quenching efficiency lost in the single TyrS138
mutant. More importantly, these results agree with the CD analysis that the
stabilizing nature of the ValS136 mutation can act to recover the destabilizing TyrS138
effects, even in the functional outcome of model protein-protein interactions with
WRRIAR peptide binding. Both ValS136/GluS139 and TyrS138/GluS139 show a drastic
increase in quenching efficiency, even though each construct appears to bind the
peptide in lower quantities than each of their single thioamide controls. Although
quantitative thermodynamic analysis was only performed on the calcium-free
forms of these constructs, these peptide binding results are intuitive as these two
CaMSS variants are significantly destabilized when compared to the CysQ135
control.

241

ValS136/ValS142 WRRIAR Binding

% Peptide Bound

WT
CysQ oxo
ValS136

1.0

ValS142
ValS136/ValS142

0.5

WT
CysQ oxo
ValS136

100
75

ValS142
50

ValS136/ValS142

25

0
2.

0
2.

5

5
0.

0.

0

0.0

Ratio of CaM:WRRIAR

Ratio of CaM:WRRIAR

ValS136/TyrS138 Trp Quenching

ValS136/TyrS138 WRRIAR Binding

% Peptide Bound

WT
CysQ oxo
ValS136

1.0

TyrS138
ValS136/TyrS138

0.5

WT
CysQ oxo
ValS136

100
75

TyrS138
50

ValS136/TyrS138

25

0
2.

0
2.

5

5
0.

0.

0

0.0

Ratio of CaM:WRRIAR

Ratio of CaM:WRRIAR

ValS136/GluS139 Trp Quenching

ValS136/GluS139 WRRIAR Binding
% Peptide Bound

WT
CysQ oxo
ValS136

1.0

GluS139
ValS136/GluS139

0.5

0.0

WT
CysQ oxo
ValS136

100
75

GluS139
50

ValS136/GluS139

25

5

0
2.

0
2.

0.

5
0.

0

Ratio of CaM:WRRIAR

TyrS138/GluS139 Trp Quenching

TyrS138/GluS139 WRRIAR Binding
WT
CysQ oxo
TyrS138

1.0

GluS139
TyrS138/GluS139

0.5

% Peptide Bound

Ratio of CaM:WRRIAR

0.0

WT
CysQ oxo
TyrS138

100
75

GluS139

50

TyrS138/GluS139

25

5

0
2.

0
2.

Ratio of CaM:WRRIAR

0.

5

0
0.

Quenching Efficiency

Quenching Efficiency

Quenching Efficiency

Quenching Efficiency

ValS136/ValS142 Trp Quenching

Ratio of CaM:WRRIAR

Figure 5-8: Individual plots of CaM-WRRIAR binding experiments. Left: Efficiency of Trp quenching (percent
Trp quenched divided by percent peptide bound) by each thioamide and dithioamide CaM construct. Right:
Percent of WRRIAR bound to each protein at varying stoichiometric ratios of CaM:WRRIAR, as extracted
from the fit.
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Ca2+-Bound CaM

Ca2+-WRRIAR-Bound CaM

WRRIAR

TyrS138

ValS136

Trp

GluS139

Trp

ValS142
316

Figure 5-9: Calcium bound CaM binding a WRRIAR-like peptide modeled from PDB accession 1SY9. The
expressed fragment of the protein is shown in blue, while the synthetic portion containing thioamide
2+
modifications in red. The green helix represents the bound WRRIAR peptide. The Ca -bound CaM structure
287
is taken from PDB entry 1UP5. Inset: Thioamide substitutions modeled into the C-terminal helix of CaM
showing their potential spatial relationship to the Trp fluorophore in the bound WRRIAR peptide.

Discussion and Conclusion
In this work, I have undertaken the initial steps towards understanding how
to best utilize dithioamide substitutions in a full-length protein. The CD studies
performed show that multiple thioamide substitutions within the same protein
domain can have unexpected effects, such as the net stabilization observed when
combining ValS136 (a stabilizing mutation) and TyrS138 (a massively destabilizing
mutation). Although definitive rules cannot be parsed out from these pilot studies,
it does appear that within the same helix (ValS136/GluS139 and TyrS138/GluS139), two
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thioamide mutations cannot be incorporated without perturbing the structure and
thermostability of the protein. However, as with ValS136/ValS142 and ValS136/Tyr138
proteins, thioamide substitutions in the loop preceding the helix (ValS136) can work
synergistically with thioamides embedded within the helix (TyrS138 and GluS139; see
Figures 3-31 through 3-33).
These dithioamide CaM variants were tested as fluorescence quenchers to
monitor protein-peptide interactions with varying success. Most notably, the two
most thermostable CaMSS variants (ValS136/ValS142 and ValS136/Tyr138) bound the
fluorescent WRRIAR peptide in greater amounts than their single thioamide
cognates, and showed an increased amount of Trp quenching. To our knowledge,
these fluorescence studies show the first semisynthetic dithioprotein capable of
performing native or near-native folding. Certainly, further high-resolution analyses
must be done to directly observe the site-specific changes induced by multiply
thioamidated CaM constructs. These experiments are paramount to maximizing
the utility of the thioamide as a spectroscopic probe or modulator of the structure
and function of protein targets.
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Section 5.4 - Materials and Methods
5.4.1- General Information
Fmoc protected amino acids and peptide coupling reagents as well 2chlorotrityl resin were purchased from EMD Millipore (Billerica, MA, USA).
Piperidine was purchased from American Bioanalytical (Natick, MA, USA).
Triisopropylsilane (TIPS) was purchased from Santa Cruz Biotechnology, Inc
(Dallas, TX, USA). Isopropyl β-D-1-thiogalactopyranoside (IPTG) was purchased
from LabScientific, Inc (Highlands, NJ, USA). Protease inhibitor tablets were
purchased from Roche Boehringer Mannheim (Indianapolis, IN, USA). Sodium 2mercaptoethanelsulfonate (MES•Na) was purchased from TCI America (Portland,
OR, USA). FPLC purification of proteins was performed on an ÄKTA system with
HiTrap Q columns (GE Healthcare Bio-Sciences, Pittsburgh, PA, USA), while
peptide HPLC was performed on a Varian Prostar system (currently Agilent
Technologies, Santa Clara, CA, USA) for CaM. Thiopropyl sepharose 6b resin was
also purchased from GE Healthcare (Princeton, NJ, USA). Cuvettes for CD
spectroscopy were purchased from Hellma Analytics USA (Plainview, NY, USA).
All other reagents, solvents, and materials were purchased from either Fisher
Scientific (Pittsburgh, PA, USA) or Sigma-Aldrich (St. Louis, MO, USA) unless
otherwise specified. Matrix assisted laser desorption/ionization mass spectrometry
(MALDI) was performed on a Bruker Ultraflex III mass spectrometer (Billerica, MA).
Common abbreviations for all other chemicals are as follows: 2-(1H-benzotriazol1-yl)-1,1,3,3-tetramethyluronium

hexafluorophosphate
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(HBTU),

N,N-

diisopropylethylamine (DIPEA), trifluoroacetic acid (TFA), 1,2-ethanedithiol (EDT),
1,8-diazabicyclo(5.4.0)undec-7-ene

(DBU),

4-(2-hydroxyethyl)-1-

piperazineethanesulfonic acid (HEPES), tris(2-carboxyethyl)phosphine (TCEP),
and guanidinium hydrochloride (Gdn•HCl).

5.4.2- Synthesis and Characterization of DithioCaM
Synthesis of Thioamino Acid Precursors (Fmoc-AaS-NBt)
All

thioamino

acid

precursors

were

synthesized

as

Fmoc-

thionitrobenzotriazolide monomers (Fmoc-AaS-NBt) by starting with commercially
available Fmoc protected amino acids and using a route modified from Shalaby et
al.296 Each thioamino acid precursor used in these studies has been previously
synthesized and characterized256, 296, as detailed in Section 3.4.2.

Synthesis of Thioamide Containing Peptides for NCL
SPPS of monothioamide and dithioamide peptides was performed on 2chlorotrityl resin (100-200 mesh) in 10 mL reaction vessels. The reaction scale was
50 μmol for monothioamide peptides and 100 μmol for dithioamide peptides. The
resin was swelled in DMF (6 mL, 1 hour) while stirring. The vessel was then drained
and to it was added the first amino acid (Fmoc-Lys(Boc)-OH; 5 equivalents) and
DIPEA (10 equivalents) in DMF (4 mL). This initial loading reaction stirred for 45
minutes at room temperature (RT) before being drained, washed with DMF (2 x 4
mL) and repeated. Fmoc removal prior to thioamide couplings was performed by
adding to the resin a solution of 20 % v/v piperidine in DMF (5 mL total volume)
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and stirring for 20 minutes at RT. The vessel was then drained and the resin
washed with DMF, followed by DCM (2 x 4 mL DMF, 2 x 4 mL DCM, then 4 mL
DMF). The peptide was then elongated up to the thioamide position using standard
SPPS protocols by adding 5 equivalents of amino acid and HBTU, and 10
equivalents of DIPEA in DMF (4 mL) and stirring each coupling for 45 minutes at
RT. For thioamide couplings, each Fmoc-AaS-NBt (3 equivalents) precursor was
added to the vessel with DIPEA (2 equivalents) in DCM (2 mL) and the reaction
was stirred at RT for 30 minutes. The vessel was then drained and the resin
washed with dry DCM (2 x 4 mL) before the thioamide coupling was repeated. At
completion of the second coupling, the resin was washed with DCM then DMF (2
x 4 mL) and Fmoc deprotection proceeded by adding to the resin a 2 % v/v DBU
in DMF solution (2 mL total volume). This DBU deprotection reaction was stirred
for 2 minutes at RT. Then, the vessel was drained and the resin washed with DMF
and DCM (2 x 4 mL DMF, 2 x 4 mL DCM, then 4 mL DMF). This procedure was
repeated twice more before proceeding to the next amino acid coupling reaction.
All subsequent Fmoc deprotections were performed using this DBU method.
Standard SPPS was used to add the remaining oxo amino acids, and in the case
of the dithiopeptides, the second thioamino acid coupling was done as described
above. After the last Fmoc group was removed, the resin was washed with DMF,
followed by DCM (2 x 4 mL each). A cleavage cocktail was prepared with
24:16:1:1:1 DCM:TFA:TIPS:EDT:Thioanisole (total volume of 4.3 mL). This was
added to the resin and allowed to stir at RT for 1 hour before being drained and
collected. DCM (6 mL) was added to the resin to wash out any remaining peptide
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and the collected solution was dried to a colorless oil (or yellow oil in the case of
TyrS containing peptides) by rotary evaporation. The crude peptide product was
then precipitated by adding cold diethyl ether (20 mL) and vortexing vigorously.
The resulting precipitate was dried and stored under argon at -20 °C until HPLC
analysis proceeded.

HPLC Purification of Thiopeptides
Monothioamide peptides were purified as described in Section 3.4.256
Dithioamide crude peptide samples were dissolved in 40 % acetonitrile in Milli-Q
H2O with 0.1 % TFA (10 mL final volume). 5 μL of a 0.5 M solution of TCEP Bond
Breaker™ was added to each sample to reduce any Cys disulfides that formed
during deprotection and the sample was filtered through a 0.22 μm filter. HPLC
purification was performed using a Grace VyDac C18 Preparatory column (flow
rate of 12 mL/min) and the gradients listed in Table 5-2. Collected fractions were
analyzed by MALDI-MS for the presence of the desired dithiopeptide mass (see
Table 5-3). Additionally, MALDI-TOF tandem MS/MS fragmentation experiments
and corresponding analysis was performed on each of the dithiopeptides to verify
that both thioamides were intact.
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Table 5-2: HPLC purification gradients for CaM dithiopeptides. Buffer A: Milli-Q H2O with 0.1 % TFA. Buffer
B: Acetonitrile with 0.1 % TFA.
Peptides

Time (min)

S S

Buffer A (%)

Peptides
S

Time (min)

Buffer A (%)

S

H2N-CVNYEEF V QMMTAK-OH

0

98

0

98

H2N-CVNYSEEFVSQMMTAK-OH

5:00

98

5:00

98

10:00

75

10:00

70

34:00

62

38:00

65

35:00

2

39:00

2

40:00

2

44:00

2

41:00

98

45:00

98

46:00

98

50:00

98

0

98

0

98

H2N-CVSNYEEFVSQMMTAK-OH

H2N-CV NY EEFVQMMTAK-OH

H2N-CVSNYESEFVQMMTAK-OH
S S

5:00

98

5:00

98

10:00

70

H2N-CVNY E EFVQMMTAK-OH

10:00

70

30:00

63

30:00

63

31:00

2

32:00

2

36:00

2

40:00

2

37:00

98

42:00

98

41:00

98

46:00

98

Table 5-3: MALDI-MS observed masses for dithiopeptides and corresponding isolated yields after HPLC
purification.
CaM135-148 Sequence
S

1724.74

1.2

1724.69

1724.92

1.2

S

1724.69

1723.33

8.3

1724.69

1725.19

2.2

S

1724.69

1724.54

2.2

S

1724.69

1723.49

2.5

H2N-CV NYE EFVQMMTAK-OH
S

% yield

1724.69

H2N-CV NYEEFV QMMTAK-OH
S
S
H2N-CV NY EEFVQMMTAK-OH
S

Observed
m/z

S

H2N-CVNY EEFV QMMTAK-OH
S

+

S

H2N-CVNYEEF V QMMTAK-OH
S

Calculated m/z [M+H]

H2N-CVNY E EFVQMMTAK-OH
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Synthesis, Purification, and Iodoacetamide Capping of CaM Dithioproteins
Native chemical ligation reactions were run as described in Section 3.4 with
no changes to protocol with respect to dithiopeptides. After 20 hours, reactions
were quenched by adding 2 mL of Milli-Q water and dialyzing twice against 2 L of
20 mM Tris pH 8.0 buffer (2 hours each) at room temperature in preparation for
FPLC anion exchange chromatography using the gradient outlined in Table 5-4. It
should be noted that the crude samples need to be treated with 15 μL of a 0.5 M
solution of TCEP Bond Breaker™ to reduce disulfides prior to FPLC purification.
Collected FPLC fractions were analyzed by MALDI-MS and fractions containing
product were pooled and dialyzed against 20 mM Tris, 1 mM EDTA, pH 7.5 in
preparation for thiopropyl sepharose purification. Using 0.75 g of dry thiopropyl
sepharose for each CaMSS product, CaMSS was separated from the CaM1-134-OH
hydrolysis byproduct as described in Section 3.4. The resulting pure eluent was
dialyzed against 20 mM Tris pH 8.0 buffer (2 L) for 2 hours prior to capping with
iodoacetamide. Capping reactions were run as in Section 3.4 with the exception
that fewer equivalents of iodoacetamide were used (25 mM final concentration in
each sample) to potentially avoid any thioamide alkylation. Reactions were
incubated with agitation for ten minutes and monitored by MALDI. At completion,
the reactions were dialyzed twice against water (2 L for 2 hours each) at room
temperature before being flash frozen in liquid N2 and lyophilized to a powder.
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SS

Table 5-4: Gradient used for anion exchange purification of CaM NCL products. Buffer A: 20 mM Tris, pH
8.0. Buffer B: 20 mM Tris, 1 M NaCl, pH 8.0.

Time (min)

Buffer B (%)

0:00

10

10:00

10

15:00

25

70:00

40

80:00

40

80:01

100

90:00

100

SS

Table 5-5: Synthetic yields for CaM proteins.
CaM Variant
Cys

Q

S

Percent Yield
S

135Tyr 138Val 142
S
S
Cys 135Phe 141Val 142
Q
S
S
Cys 135Val 136Val 142
Q
S
S
Cys 135Val 136Glu 139
Q
S
S
Cys 135Val 136Tyr 138
Q
S
S
Cys 135Tyr 138Glu 139

5.1 %

Q

5.9 %
3.3 %
5.1 %
2.0 %
1.9 %
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Expected [M+Na]+ = 16794
Observed [M+Na]+ = 16793

Expected [M+Na]+ = 16794
Observed [M+Na]+ = 16793

Expected [M+Na]+ = 16794
Observed [M+Na]+ = 16794

Expected [M+Na]+ = 16794
Observed [M+Na]+ = 16794

Expected [M+Na]+ = 16794
Observed [M+Na]+ = 16793

Expected [M+Na]+ = 16794
Observed [M+Na]+ = 16795

SS

Figure 5-10: MALDI-MS traces showing pure CaM proteins used for CD and fluorescence experiments.
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Trypsin Digest of ValS136/TyrS138 CaM
To ensure that the dithioamides are stable and unmodified during the entire
purification and capping process, a trypsin digestion was performed on holo CaMCysQ135ValS136/TyrS138. 200 μL of the CaM sample used for CD spectra acquisition
was incubated with 10 μL of 0.5 μg/mL sequencing grade trypsin at 37 °C for 20
hours. The reaction was then analyzed by MALDI-MS and MALDI-TOF tandem
MS/MS fragmentation. The parent mass and resulting fragmentation pattern are
consistent with the presence of both intact thioamides and a singly alkylated Cys
residue (see Figures 5-12 and 5-13 and Table 5-6).
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S

S

Figure 5-11: Top: Trypsin digest of CaM Val 136/Tyr 138 showing the mass of the desired fragment containing
Q
+
the both thioamides and the alkylated Cys (expected [M+H] = 2555.89 Da, observed 2556.22 Da) Bottom:
Tandem MS/MS fragmentation of the tryptic peptide corresponding to the sequence shown in Figure 5-13.
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Trypsin Digestion and MS/MS
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Figure 5-12: Fragmentation patterns of the H2N-EADIDGDGC
V NY EEFVQMMTAK-OH
tryptic
exact mass observed from MSMS)

Table 5-6: Expected (black) and observed (red) MS/MS fragment m/z (a-, b-, x- and y- series ions) for the
Q S
S
tryptic peptide H2N-EADIDGDGC V NY EEFVQMMTAK-OH. Nearly complete coverage of the peptide is
observed.
Sequence Observed Series

• 6167A trypsin doesn’t produce enough of the
Obs b (m/z) x (m/z) Obs x (m/z) y (m/z) Obs y (m/z) # (+1)
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Sample Fluorescence Fitting Data
Fluorescence data was collected as described in Section 5.4 and will be
described in more detail by John Ferrie elsewhere. Below is a sample spectra
(ValS136) of the raw fluorescence data and the fits used to extract the percent Trp

2.5×106

0.5:1 ValS136:WRRIAR

Fluorescence Intensity

Fluorescence Intensity

quenched and percent WRRIAR bound values.

Raw Fluorescence
Free WRRIAR
Bound WRRIAR
Fit

2.0×106
1.5×106
1.0×106
5.0×105
0.0

350

400

450

2.5×106

2:1 ValS136:WRRIAR
Raw Fluorescence
Free WRRIAR
Bound WRRIAR
Fit

2.0×106
1.5×106
1.0×106
5.0×105
0.0

Wavelength (nm)

350

400

450

Wavelength (nm)
S

Figure 5-13: Fluorescence spectra of CaM Val 136 bound to the WRRIAR peptide in samples with ratios of
S
0.5:1 (Left) and 2:1 (Right) CaM Val 136 to WRRIAR. Fits were performed by John Ferrie and populations of
free and bound WRRIAR were extracted from these fits.

CD Sample Preparation and Fitting Procedures
CD samples were prepared as in Section 3.4 and CD spectra were acquired
on samples with a final concentration between 10 and 15 μM (as determined by
BCA assay). Each holo spectra and thermal melt was acquired as a single sample
and apo spectra and thermal melt acquisition were performed in duplicate. Fitting
procedures were performed via the three-state fit method described in Section 3.4.
Initial guesses for ΔH1, ΔH2, ΤΜ1, and TM2 were taken from single thioamide thermal
melts in Section 3.4 as starting values during the minimization of the root mean
square deviation of θfit from θMRE. Representative traces of the raw data and fits,
as well as the fractional population analysis, can be seen in Figure 5-13.
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Figure 5-14: Plots generated using the three state fitting method for all CaM variants. Left: For each CaM
variant, a representative set of raw data (θMRE) and fits generated from θfit, θf, and θu. Right: The averaged
fraction folded (Ff, purple), fraction intermediate (Fi, green), and fraction unfolded (Fu, blue) plots from the
three replicates.
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CHAPTER 6:
EXPANDING THE USAGE OF L/F-AMINOACYLTRANSFERASE FOR N-TERMINAL
BIOCONJUGATION AND NATIVE CHEMICAL LIGATION REACTIONS
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Section 6.1 – Introduction
The in vitro enzymatic modification of target proteins is an important
contributor to the wide array of techniques for site-selectively incorporating
unnatural amino acids (Uaas). Specifically, enzymatic modifications to isolated
proteins can provide chemoselective and regioselective additions of Uaas in mild,
aqueous conditions. This “downstream” approach to Uaa labeling can circumvent
issues in the purification and yield of labeled proteins that are often encountered
in genetic and synthetic incorporation methods.188, 257 Methods to engineer and
expand the usage of these enzymes continue to improve and provide unique ways
to change how researchers approach structural studies and functional modulation
of proteins. One promising target for the enzymatic modification of the N-termini of
target proteins is the enzyme Leucyl/Phenylalanyl Aminoacyl Transferase (AaT)
from Escherichia Coli.197, 198, 317 In particular, this enzyme could be applied towards
three distinct labeling strategies: (1) transfer of fluorescent molecules for use in
biophysical studies of protein structure and function, (2) transfer of ‘click’ chemistry
handles for chemoselective labeling reactions, and (3) addition of thiol bearing
amino acids for use in the semisynthesis of proteins.
Endogenously, AaT functions in the N-end rule protein degradation
pathway by adding Phe or Leu to the positively charged N-terminal Lys or Arg
residues of a protein via a phenylalanyl- or leucyl-tRNA substrate that is generated
by a synthetase (aaRS).193 AaT has strict fidelity to the N-terminal residues of a
protein as it has not been observed to modify internal amino acids.317, 318 Recent
work has demonstrated that a chemoenzymatic protocol with a simple aminoacyl
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adenosine analogue of tRNA can be efficiently used as a minimalist substrate for
AaT (Figure 6-1).319 Using either enzymatic (aaRS/tRNA) or chemoenzymatic
transfer, AaT can conveniently modify the N-termini of peptides and proteins with
residues useful for NCL. For example, homocysteine (Hcs) was transferred to the
N-terminal Lys of a fragment of the protein α-synuclein, used in a NCL reaction
with a fluorescently labeled peptide to generate labeled α-synuclein, and
methylated, leaving Met at the ligation site.195 This “traceless” ligation allows for
the inclusion of a synthetic probe without the need to introduce a Cys into the
protein sequence, so that the protein may be studied in a near native state.
AaT has also been used to site-selectively introduce Uaas containing
functional groups for ‘click’ chemistry applications.317 A preliminary study exploring
the scope of Uaas containing either propargyl or azido groups that can be
transferred

by

the

enzyme

showed

that

p-azidophenylalanine

(Azf),

azidohomoalanine (Aha), or homopropargylglycine (Hpg) can be transferred from
an aminoacyl adenosine analogue (Figure 1-20).318, 320 Chemoselective labeling
reactions can then be used to label these amino acids with a functional tag, such
as biotin or fluorescent dyes.
Transfer of fluorescent dyes that require no additional ‘click’ chemistry
functionalization would allow for fewer steps after enzymatic transfer to isolate the
desired product.198 AaT has been screened against fluorescent amino acid
substrates such as acridon-2-ylalanine and β-(7-methoxy-coumarin-4-yl)-alanine
however, neither were transferred by the enzyme.318 In initial screening tests, a
naphthalene containing amino acid (L-3-(2-naphthyl)-alanine) was transferred to a
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short peptide substrate. However, no other polyaromatic amino acids have been
successfully transferred by the wild type enzyme to date.
In the following sections, I will describe how the aforementioned usages of
AaT have been rigorously tested for expansion. In initial pilot studies, the substrate
scope of the wild type (WT) enzyme was probed to establish optimal conditions for
the transfer of established, as well as novel, ‘click’ chemistry substrates and thiol
bearing amino acids. These optimized conditions were then used in applications
involving the protein calmodulin (CaM). The transfer of homocysteine by AaT was
utilized in efforts to tracelessly construct CaM from three protein fragments, two
expressed in E. coli and one synthesized by solid phase peptide synthesis (SPPS).
In a second vein of work, expansion of the substrate scope was explored.
Based upon the crystal structures obtained by Watanabe et al., a library of mutants
was generated to test for the transfer of thiol bearing and fluorescent amino acids
for use in NCL and biophysical studies, respectively.197,
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Additionally, AaT

mutants were generated with the intent to expand the scope of N-terminal amino
acids that AaT can recognize as substrates. Enabling AaT to accept N-terminal
residues other than Arg or Lys would create a versatile enzyme for
chemoenzymatic installations of NCL-capable or fluorogenic amino acids onto a
larger variety of expressed proteins. Finally, at the exhaustion of our rationally
designed mutant library, an AaT-Ice Nucleation Protein (AaT-INP) fusion was
produced for use in a surface anchored variant of the enzyme in E. coli. This AaTINP conjugate was used in attempts to develop a high-throughput screening assay
for rapid assessment of the activity of AaT mutants generated by saturation
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mutagenesis. Although each of these AaT applications and technologies are still
in development, this collection of studies has enabled a deeper understanding of
the enzyme’s applications in bioconjugation and native chemical ligation.
Section 6.2 – Transfer and Characterization of Natural and Unnatural Amino
Acid Transfer by AaT
Establishing a more complete characterization of the WT AaT enzyme’s
substrate scope and transfer properties will enable a broader usage of the enzyme
towards labeling proteins for biophysical studies. I began by examining the transfer
of aromatic ‘click’ chemistry substrates that mimic the native substrate
phenylalanine. With the report of O-propargyltyrosine (Ppy) incorporation into
proteins via Uaa mutagenesis322, and the use of this probe in our lab to
fluorescently label proteins via copper mediated ‘click’ chemistry323, I sought to
establish if this Phe-like analogue could also be transferred by the WT enzyme.
First, a small molecule adenosine donor bearing the Ppy amino acid (PpyAde) was synthesized using a modified method from Wagner et al. without
complications (see Figure 6-7).318 Next, I tested the transfer of PpY to the Nterminus of a short reporter peptide using the WT enzyme and a previously
established analytical HPLC assay. In short, the enzyme (0.1 mg/mL) and PpyAde (1 mM) molecule were incubated in the presence of Lys-Ala-Coumarin peptide
(0.1 mM; KACm, peptide 6-1, Figure 6-1) for four hours at 37 °C in aqueous
transfer buffer. KACm and Ppy-Ade were incubated without AaT as a control to
ensure that aminoacylation does not happen transiently in buffer. To establish
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standards by which to compare Ppy, Phe and Azf transfer (using Phe-Ade and AzfAde, respectively) were also tested using the WT enzyme.
After incubation, the reactions were acidified through the addition of acetic
acid and the proteins and salt were removed via acetone precipitation. The
acetone was then removed by rotary evaporation and the resulting dry peptides
dissolved in 1 mL Milli-Q H2O in preparation for analytical HPLC. Reactions were
analyzed by injecting 100 μL of sample onto a Phenomenex Jupiter C18 column
using a previously established gradient for the separation of N-terminally modified
peptides from the KACm starting material (see Section 6.5).194 Percent transfer is
represented by the peak area of the N-terminally modified peptide divided by the
total peak area (represented by the peak area of the modified peptide and the
KACm starting material) based upon absorbance of the coumarin dye in each
peptide (325 nm). In an experiment with three replicates, the average level of Nterminal modification of the KACM peptide with Ppy was calculated to be 20 %
transfer (Figure 6-1). This is much lower in comparison to peak performance of the
enzyme with the Phe-Ade (>90 % transfer) and the Azf-Ade analogue (>80 %
transfer). This may be due to the propargyl group being sterically bulkier than Phe
or Azf at the para position of the aromatic side chain. This steric bulk likely
decreases the affinity of the enzyme for the Ppy-Ade substrate, leading to much
lower efficiency of transfer by AaT. Nonetheless, these assays establish that the
Ppy amino acid can be transferred by AaT for potential labeling applications via
copper mediated ‘click’ chemistry with azide bearing biophysical probes.
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Figure 6-1: Top: Scheme for the transfer of amino acids to the N-terminus of the short reporter peptide
KACm (6-1) via aminoacylated adenosine donor molecules and AaT. Bottom: Analytical HPLC
chromatograph traces (325 nm) demonstrating transfer of Phe (6-2), Azf (6-3), and Ppy (6-4). Note: The
change in retention time of 6-1 in the Ppy chromatogram is due to the use of a new C18 column for that
assay.

In addition to exploring the permissivity of WT AaT for novel transfer
substrates, it may be advantageous to screen its activity against buffer additives
that can improve the accessibility of the N-terminal Lys or Arg amino acid on a
protein substrate. When expanding the methodology of AaT labeling to protein
targets, one must consider that the N-terminal region of the protein target may be
folded and inaccessible to AaT. Denaturants such as urea or guanidinium may
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disrupt structural elements to make the N-terminal Lys or Arg solvent accessible,
and therefore improve AaT access to the site of transfer. However, it is likely that
high concentrations of denaturant will disrupt the native fold of AaT and lead to
diminished transfer activity. Therefore, it is important to test the enzymatic activity
of AaT at increasing concentrations of denaturant to establish a range at which
these effects may improve the accessibility of the target substrate without
significantly disrupting the enzyme’s catalytic activity.
To test AaT’s activity in denaturant, I relied upon the KACm assay described
above. Here, KACm is treated with Phe-Ade and AaT in aqueous buffer with
various concentrations of urea between 0 and 8 M. I chose urea for this experiment
as it is a milder denaturant than guanidinium and it was previously shown that
guanidinium significantly impacts the activity of the enzyme.318 Through analysis
of the percent transfer of each assay, we found that the enzyme has >90 % transfer
in concentrations of urea less than 2 M, and a half maximal inhibitory concentration
(IC50) of 5.3 M urea. In contrast, at 1 M guanidinium, the same enzyme batch
showed a 19 % transfer of Phe to KACm. Although guanidinium is a stronger
denaturant than urea, it may also be acting as an inhibitor of AaT based off its
functional similarity to the Arg sidechain, one of the two N-terminal amino acid
substrates for AaT. Nonetheless, establishing a working range for urea should
enable added accessibility of the N-termini of protein substrates without
compromising transferase activity in future applications of this methodology.
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Table 6-1: Analytical HPLC Peak Area and Percent Transfer Values for Phe Transfer to KACm in Denaturant
Trial 1

Trial 2

Trial 3

Average

M
Urea

KACm
Area

Prod
Area

%
Ligated

KACm
Area

Prod
Area

%
Ligated

KACm
Area
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%
Ligated

Avg

STDEV

0
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678.3

95.9

9.3

672.5

98.6
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677.4

97.9

97.5
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22.9

621.4

96.4

23.6

580.5

96.1

28.1

766.6

96.5

96.3

0.21

0.1

22.2

597.8

96.4

18.7

576.2

96.9

24.1

701.6

96.7

96.7

0.22

0.2

26.9

653.0

96.0

20.8

688.8

97.1

48.2

565.1

92.1

95.1

2.60

0.3

27.9

582.2

95.4

24.0
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96.4
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0.4
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0.5
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6.1
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1.33

1.0

26.0
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9.9
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1.5
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Figure 6-2: Dose response inhibitory curve for the determination of the IC50 of AaT in urea. The fit was
generated using GraphPad Prism’s non-linear regression fitting using the log(inhibitor) vs. responseVariable slope (four parameter) equation.
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Section 6.3 – Rational Design of AaT Mutants for Substrate Scope Expansion
To expand the usage of AaT to new classes of substrate amino acids and
recognition elements beyond Arg or Lys, mutational screening must be performed.
The target residues for transfer are polyaromatic fluorescent amino acids (Acd and
Mcm) and β-thiol containing amino acids for NCL (penicillamine and βthiophenylalanine; see Figure 6-3). Additionally, one can envision reversing the
‘polarity’ of the enzyme, where AaT recognizes the negatively charged residues
Asp or Glu instead of positively charged residues (Lys or Arg). Moreover, πstacking interactions may also be able to initiate transfer to Phe or Trp as the Nterminal recognition elements (Figure 6-3).
The multiple structures from Tomita and coworkers allow for rational design
of mutations to AaT to enlarge the substrate binding pocket (Figure 6-4).197, 321 The
modeling of a Phe side chain into the active site shows that residues Leu67, Ile185,
Phe177, Leu170, and Phe173 may sterically block the access of larger polyaromatic
substrates.198 Additionally, Met148 and Met144 are primed to block the access of βbranched amino acids that cannot be transferred by the WT enzyme. Finally, the
negatively charged Glu156 (see Figure 6-5) residue has been noted as an important
residue for the recognition of the positively charged N-terminal substrate amino
acid (Lys or Arg) through electrostatic interactions. Mutations to this residue may
enable transfer to proteins with N-terminal Glu or Asp.
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acid targets for mutagenesis experiments. Crystal structure from PDB accession 2Z3O.
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As a proof-of-concept experiment to demonstrate that the enzyme is
tolerant to mutations at these sites, alanine substitutions were made and these
mutants were screened for activity in the transfer of Phe to KACm as in Section
6.2. Additionally, other non-alanine mutations were made towards each of the
previous goals as suggested from previous literature and unpublished
computational modeling done by Professor Jeff Saven and coworkers at the
University of Pennsylvania. Some of these mutations are previously untested, as
they lead to a loss of soluble protein during purification, presumably due to
destabilization of AaT. However, small modifications to the purification of these
mutant AaT enzymes (see Section 6.5) provided several previously inaccessible
enzyme constructs. These mutations were screened for activity with Phe-Ade and
a KACm acceptor peptide as well.
Expression yields for each of the single and double mutant AaT variants
were determined by a previously described Bradford assay modified for AaT.318 In
all cases, except for the C187A/L170A and C187A/F177A mutants, the expression of
the protein in E. coli was sufficiently high to enable preliminary KACm assay
reactions. All of the single point mutants (see Table 6-2), with the exception of
F177A and I185A transfer Phe to the KACm peptide as determined by analytical
HPLC.194 In fact, some of the mutations (C187A, L67M, and T194A) appear to be nonperturbing to the enzyme’s function with similar Phe transfer percentages to the
WT enzyme (98.8 %, 94.7%, and 83.4 % of WT activity, respectively). Mutations
that altered the activity and stability of the enzyme the most were those intended
to reduce steric bulk in the side-chain binding pocket (F177 and I185, see Figure 6269

4). Many of the mutants containing two alterations significantly lowered the
expression yield of AaT and few have the capabilities of transferring the Phe to the
KACm reporter peptide (see Table 6-2). It should be noted that M144A, F177A, and
I185A are were shown by Taki et al. to be able to transfer the fluorescent Acd amino
acid when attached to tRNA (outlined in Figure 6-3).198 Therefore, an Acd-Ade
small donor molecule was synthesized and tested with each of these mutants for
transfer to the KACm reporter peptide. However, none of the mutants showed Acd
transfer capabilities and the Acd-Ade molecule appeared to readily hydrolyze in
aqueous buffer over the reaction time course (4 hours; mass of free Acd amino
acid detected by LC-MS). The single mutants in Table 6-2 were also tested for
their capabilities to transfer β-branched amino acids such as Val or Ile. These
substrates would provide proof-of-concept data to support the notion that mutated
AaT enzymes could transfer β-thiol containing amino acids for applications in EPL.
Small molecule donors (Val-Ade and Ile-Ade) were synthesized using previously
described procedures194 and again test reactions were performed using the KACm
reporter peptide. Unfortunately, none of the mutants were capable of extending the
substrate scope to the β-branched amino acids discussed here. In a final proof-ofconcept experiment, Glu156 was mutated to a Lys residue to potentially expand
transfer to peptides bearing N-terminal Glu or Asp residues. This mutant was
tested for Phe transfer using KACm reporter cognate peptides bearing either an
N-terminal Asp or Glu (DACm and EACm, respectively). The rationally designed
AaT mutant (E156K) showed no activity towards the intended target as determined
by analytical HPLC.
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Arg
Glu156

Figure 6-5: Crystal structure of AaT showing Glu156 making electrostatic contact with a peptide substrate
321
containing an N-terminal Arg residue. PDB accession number 2Z3L.

Although many of the mutants screened could transfer the native substrate
Phe, none of the mutants presented here could transfer the intended targets for
expanding the scope of AaT. Rational design can be a tedious avenue for installing
new enzymatic functions from a WT enzyme. Directed evolution can provide a
more high-throughput method for screening enzyme mutants. Specifically, if one
can perform iterative saturation mutagenesis, where a degenerate library of
mutations is created for many sites within the protein, the enzyme can theoretically
be evolved towards any target amino acid transfer (see review by Liu).324 However,
purification protocols for recombinant expression and isolation of the AaT enzyme
are lengthy and require multiple days to prepare the enzyme freshly for KACm
assays. To eliminate the need for purification of the enzyme, we turned our
attention towards surface display technologies. Surface display uses fusion protein
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tags encoded with the enzyme of interest to translocate the enzyme to the
extracellular surface.325 Small scale cultures can be grown in in 96-well plates,
where pelleted cells can be used directly in activity assays, thereby eliminating the
need for lengthy purification protocols and large-scale (1 L) expressions. In E. coli
surface display technologies, one of the most prominent protein translocation tags
is the ice nucleation protein (INP) from Pseudomonas syringae.326-328 To test if the
AaT enzyme can be used for surface display evolution of mutant enzymes,
collaborator Professor Wilfred Chen’s lab (University of Delaware) generated a
pET24a plasmid containing an expressible AaT-INP conjugate. However, in
preliminary experiments, it was found that AaT was expressed in low levels on the
surface of cells (determined by magneitcally-activated cell sorting). Additionally,
when cells were treated with the KACm reporter peptide in the absence of any
other reagents, the peptide was modified in quantities >80%, as determined by
analytical HPLC. This modification was consistent with the transfer of Val to the
peptide N-terminus. This background modification serves as a competing reaction,
beyond which, it would be difficult to detect any activity by AaT.
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Table 6-2: Rationally designed AaT mutants with their respective expression yields and Phe transfer yields.
Mutants highlighted in red were predicted by Taki et al. to enable polyaromatic side chain transfer, such as
198
Acd.
AaT Mutant

Expression
Yield

Phe Transfer

% WT Activity

M144A

3 mg/L

x

19.8

M158A

2 mg/L

x

40.2

M158G

3 mg/L

x

5.8

C187A

3 mg/L

x

98.8

F177A

<0.5 mg/L

L67M

2 mg/L

x

94.7

L170A

0.5 mg/L

x

70.1

T194A

2.5 mg/L

x

83.4

I 185A

1.0 mg/L

C187A/M158A

4.5 mg/L

x

47.4

L170A/M158A

1.0 mg/L

x

47.1

F177A/M144A

0.5 mg/L

F177A/F173A

<0.5 mg/L

I 185A/M144A

0.5 mg/L

C187A/M144A

0.5 mg/L

x

47.4

C187A/L170A

---

C187A/F177A

---

x

52.1

C187A/I 185A

0.5 mg/L

M144A/M158A

0.75 mg/L

---

---

The rational design or directed evolution of AaT mutants for the transfer of
non-native substrates could be a promising avenue towards more ubiquitous posttranslational protein modification technology. However, none of the mutants
explored in these pilot studies are capable of transferring unnatural amino acids or
their cognates. Additionally, the initial tests in creating a high-throughput readout
for AaT enzyme evolution showed that extracellular AaT may not be stable and
small Lys-containing reporter peptides may not be viable in E. coli surface display
assays. Experiments are ongoing to improve these technologies for applications
of AaT to the transfer of new unnatural substrates.
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Section 6.4 – AaT Applications in the Semisynthesis of Calmodulin
Using both synthetase and analogue donor molecule mediated transfer,
AaT can conveniently be used to site-specifically modify the N-termini of peptides
and proteins in vitro with the goal of installing residues capable of NCL at activated
oxo- or thio-esters. This was demonstrated previously with α-synuclein, the
intrinsically disordered protein implicated in Parkinson’s disease.195, 225 In one of
these applications, a methionine surrogate, homocysteine, was transferred to a Nterminal lysine of a Cnf containing α-synuclein. This residue was then used in a
NCL reaction with a peptide containing a thioamide and a C-terminal thioester.
Subsequent methylation of the protein was selective for homocysteine, thereby
yielding a native methionine residue. The aminoacylated-tRNA substrate for AaT
was generated using a mutant methionine synthetase (L13G MetRS) that permits
the transfer of disulfide protected homocysteine to E. coli total tRNA extract. This
traceless ligation allows for the inclusion of an unnatural probe in a minimally
perturbing manner so that the protein may be studied in a near native state. To
explore the potential applications of this methodology to larger, more ordered
proteins, a three-part ligation of calmodulin (CaM) was envisioned.
CaM contains two large globular domains connected by a flexible linker
region.283 Upon binding calcium in the globular domains, the protein undergoes a
conformational change to yield a rigid trans-domain α-helix. The linker region
contains several methionine residues that could be used for traceless
homocysteine ligations, including one that is adjacent to a lysine residue, making
it a convenient system for the application of our AaT ligation method (Figure 6-6).
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To include an unnatural probe in the linker region, we have split the semi- synthesis
of CaM into three fragments (see Figure 6-6). Using protein expression systems in
E. coli, we have expressed and purified N-terminal and C-terminal fragments
suitable for use in ligation reactions (unpublished work by Dr. Anne Wagner).329
The N-terminal fragment (CaM1-71) contains a C-terminal GyrA intein and a chitinbinding domain for chitin resin purification. The fragment can be purified from cell
lysate by incubating it with chitin beads and cleaving the chitin bound intein from
CaM1-71 with sodium 2-mercaptoethanelsulfonate (MESNa) to generate a Cterminal thioester for NCL. The C-terminal fragment (CaM77-148) is generated by
expressing CaM77-148 with an N-terminal histidine tag followed by a protease
cleavage site. After Ni-NTA purification, the recombinant protein is treated with
Factor Xa protease to cleave the purification tag and yield an N-terminal lysine
(previously established by Dr. Anne Wagner). This protein is then mixed in a
transfer reaction containing a L13G MetRS, which is used to generate the HcmtRNA substrate in situ. S-(methylthio)-L-homocysteine (Hcm) is then transferred
from the Hcm-tRNA to the Lys77 residue via AaT.330 In previous applications,
transfer of Hcm to a Lys residue in α-synuclein was carried out with quantitative
conversion. However, transfer to CaM proceeds with less than 10% transfer
(approximated by FPLC purification chromatograms). Therefore, denaturant may
be necessary to expose the N-terminal lysine for transfer to CaM77-148. It was
previously determined that AaT could function in molar concentrations of urea (see
Section 6.2). To ensure that the L13G MetRS is not inhibited by urea in the reaction
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mixture, a concentration of 1 M urea was used for Hcm transfer reactions to Lys77,
providing markedly improved yields of ~30% transfer.
The small, middle fragment (Hcy72-CaM72-75-N2H3, see Figure 6-6) was
made via Fmoc solid phase peptide synthesis by using a hydrazine modified 2chlorotrityl resin to generate a C-terminal acyl hydrazide. Acyl hydrazide peptides
have previously been used to generate acyl azides in situ to enable thioester
formation for NCL reactions.165 The peptide synthesized for our scheme contained
an unprotected homocysteine residue that was used to ligate the peptide to the
CaM1-71 thioester in nearly quantitative yields. After purification, CaM1-75-N2H3 was
oxidized to the acyl azide using ten equivalents of sodium nitrite followed by
treatment with 4-mercaptophenylacetic acid (MPAA) to generate a reactive aryl
thioester. CaM1-75-MPAA and Hcm76-CaM76-148 were then incubated in 6 M Gdn
and 20 mM TCEP (to reduce Hcm to the reactive homocysteine residue) at 37 °C
with shaking for 20 hours. Although both reactive species (CaM1-75-MPAA and Hcy76-CaM76-149) are present in the reaction mixture (confirmed by MALDI MS, see
Table 6-5), the Hcy72,76-CaM1-148 product was not detected. This may be due to
one of the fragments adopting a semi-stable conformation in which the reactive
moiety is not accessible. Additionally, Hcs is generally less reactive than Cys
residues, due to the formation of a six-membered ring as an intermediate
(compared to a five-membered intermediate for Cys) during the SàN acyl shift.331

276

N-terminus

Middle Fragment

C-terminus

Cl
Cl

5% N2H4
DMF

INTEIN

K
CaM77-148

H 2N

N
Cl H

RSH

AaT

Solid Phase
Peptide Synthesis
SH
O

SR

N
H

H 2N

O

O

CaM1-71-SR

O

NH 2

H 2N

Hcy72-CaM72-75-N2H3
=

H
N

10 eq. NaNO2

S
S
CH 3

S
N
H

MPAA
O

O
NH 2

CaM1-75-N2H3

Hcm76-CaM76-148
TCEP

O
N
H

K!

6 M Gdn
-15 °C, 20 min

O

S

CaM1-75-MPAA

O
H 2N

K!

SH

Hcy76-CaM76-148

CH3I

CaM Fragment Sequences
ADQLTEEQIAEFKEAFSLFDKDGDGTITTKELG
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DGNGYISAAELRHVMTNLGEKLTDEEVDEMI
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CaM without NCL
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Figure 6-6: Three-piece ligation scheme for AaT-EPL synthesis of CaM. Left: Generation of CaM1-71-SR
through thiol cleavage of the CaM1-71-GyrA fusion protein. Middle: SPPS of Hcy72-CaM72-75-N2H3 and
subsequent ligation with CaM1-71-SR to generate CaM1-75-N2H3. The central fragment can contain any
number of synthetic modifications, such as the thioamide pictured here. Right: AaT transfer of Hcm to
CaM77-148. Bottom: Generation of CaM1-75-MPAA and subsequent reaction with Hcy76-CaM76-148, followed by
alkylation of Hcy72 and Hcy76 to generate full-length CaM without any NCL artifact residues. Fragment
sequences are highlighted with their corresponding diagram colors (bottom left). The black ‘M’ represents
the Met residue resulting from the Hcm transferred by AaT.
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To test if ligation is possible between the two domains, a mutant Cys77CaM77-149 was used in a reaction with CaM1-75-MPAA. Yet, this test reaction did not
yield ligation product in buffer containing 6 M guanidinium hydrochloride. However,
in reactions with lower concentration of denaturant or no denaturant (3 or 0 M Gdn),
product formation was observed by MALDI and SDS-PAGE. With confirmation that
NCL reactions between the two domains are possible, reactions of CaM1-75-MPAA
and

Hcy76-CaM76-149 were

pursued

to

generate

Hcy72,76-CaM1-148,

and

subsequently WT CaM after alkylation of the Hcy residues with iodomethane.
However, under conditions identical to the Cys-CaM model system, no Hcy72,76CaM1-148 full-length product was observed. The reaction was then tested for pH
dependence (pH 6.8, 7.2, and 7.8) yet no product was observed in any of the
reactions. Additives such as excess MPAA or thiophenol were added in an attempt
catalyze the reaction through manipulation of the reactivity of the C-terminal
thioester. Additionally, CaCl2 or ethylenediaminetetraacetic acid (EDTA) were also
tested as reagents that could induce conformational changes in the C- and Nterminal domains, thereby driving association and promoting reactivity between
CaM1-75-MPAA and Hcy76-CaM76-149. Though tested at various concentrations,
none of these additives have shown the potential to promote the reaction to form
Hcy72,76-CaM1-148.
Currently, efforts in using two expressed protein fragments for the AaTmediated, NCL synthesis of CaM have been unsuccessful. It is possible that
reactivity between the two fragments (CaM1-75-MPAA and Hcy72-CaM76-149) could
be modified by using additional additives, such as alkyl thioesters, which may be
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less sterically hindering than their aryl thioester counterparts. If this AaT-expressed
protein ligation strategy is successful in future syntheses of CaM, it could enable
access to substitutions in the central linker region between the N- and C-terminal
domains of CaM. Inserting a thioamide in this region would enable additional
studies to corroborate the structural effects of thioamides in α-helices that are
described in chapter 3 (see Figure 6-6). Additionally, placement of fluorescent
amino acids, such as Mcm, in this region would enable fluorescence studies to
investigate the reorganization of CaM during the binding to one of its many
regulatory targets. In conclusion, future improvements to the AaT-EPL
methodology would increase the number of protein targets that could be
synthesized tracelessly by EPL. These proteins could contain any number of
unnatural amino acids to be used in biophysical studies to uncover previously
unattainable information about protein structure and function.
Section 6.5 – Materials and Methods
6.5.1 – Materials
Amino acids for use in synthesis of adenosine donor molecules were
purchased from Acros organics (New Jersey, United States), with the exception of
p-azidophenylalanine (Azf), which was purchased from Bachem (Torrance, CA).
5’-DMT-riboadenosine was purchased from ChemGenes (Wilmington, MA).
Bradford reagent assay kits were purchased from BioRad (Hercules, CA). All other
reagents were purchased from either Fisher Scientific (Waltham, MA) or Sigma
(St. Louis, MO). The CaM1-71-GyrA-CBD and CaM77-148 protein plasmids were
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previously generated by Dr. Anne Wagner. MALDI MS was taken on a Bruker
Ultraflex III instrument (Billerica, MA) and LC-MS was performed on a Waters
acquity UPLC system with a SQD single quadrupole mass analyzer with
electrospray ionization (Milford, MA).
6.5.2- Methods
Synthesis of Aminoacyl Adenosine Donor Molecules
Tert-butyloxycarbonyl (Boc) protections of each amino acid used for
adenosine donor syntheses were carried out as follows. In a 250 mL round bottom
flask, NaOH (40 mmol) is dissolved in 46 mL / 50 mL of dioxane / water and the
solution is cooled to 0 °C in an ice bath. Free, unprotected amino acid (10 mmol)
is then added to the solution. In a separate flask, di-tert-butyl dicarbonate (Boc2O,
25 mmol) is dissolved in 1 mL dioxane. Next, the Boc2O solution is slowly added
to the reaction flask containing the amino acid/NaOH solution. Reactions generally
proceed for two hours, while allowing the flask to warm to room temperature and
are monitored by TLC. At reaction completion, ethyl acetate (60 mL) is added and
the solution is acidified with HCl to a final pH of approximately 2-3. The resulting
mixture is extracted twice with ethyl acetate and the organic layer was washed with
brine, dried over MgSO4, and the solvent removed under reduced pressure.
Quantitative conversion is routinely observed and no further purification is
necessary.
Boc protected amino acids can be used directly in the synthesis of any
aminoacyl adenosine donor molecules using the scheme below and the methods
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outlined in detail in Wagner et al.194 Phe-Ade, Val-Ade, Ile-Ade, and Azf-Ade have
all been synthesized previously by Dr. Anne Wagner and others. For Opropargyltyrosine (Ppy-Ade) and acridon-2-ylalanine (Acd-Ade) derivatives, Dr.
John Warner and Itthipol Sungwienwong provided the free amino acids. Synthesis
of these molecules follows the scheme outlined for the synthesis of the Phe-Ade
molecule given in Wagner et al. without significant deviation (Figure 6-7).318 HPLC
chromatograms detailing the purification of the final Ppy-Ade and Acd-Ade
products and their corresponding masses (detected by either MALDI- or LC-MS)
can be seen in Figures 6-8 and 6-9, respectively.
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Figure 6-7: Synthesis of amino acid adenosine donors. Boc protection of a free amino acid (Aa) is followed
by activation of carboxy terminus by the addition of chloroacetonitrile to generate the activated
cyanomethylester. The N-Boc-Aa-cyanomethylester can then directly be used to esterify the 2’ or 3’ alcohol
of the 5’dimethoxytrityl (DMT) protected adenosine molecule. This is then followed by removal of the DMT
and Boc groups through treatment with trifluoroacetic acid (TFA). Abbreviations are as follows:
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triisopropylsilane (TIPS).
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Figure 6-8: HPLC chromatogram for the purification of Ppy-Ade showing absorbance at 215 nm and 260 nm.
The peaks marked with * are the 2’ and 3’ ester products of Ppy-Ade. The presence of product was verified
+
by LC-MS mass analysis (expected [M+H] = 469.59 Da, observed = 469.52 Da)
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Figure 6-9: HPLC chromatogram for the purification of Acd-Ade showing absorbance at 260 nm and 368
nm. The peaks marked with * are the 2’ and 3’ ester products of Acd-Ade. The presence of product was
+
verified by MALDI MS mass analysis (expected [M+H] = 532.53 Da, observed = 532.43 Da)
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KACm Peptide Transfer Assays
Assays were adapted from Connor et al. and Wagner et al.

317, 318, 320

In

short, the KACm peptide (0.1 mM final concentration) and Phe-Ade (1 mM final
concentration) substrates were added to a 1.5 mL Eppendorf tube containing 1x
transferase buffer (50 mM HEPES, 150 mM KCL, 10 mM MgCl2, pH 8.0). Aat was
added to the mixture last, to a final concentration of 0.1 mg/mL in the total reaction
volume of 125 μL. This reaction was mixed by pipetting and incubated at 37 °C for
four hours. The reaction was then quenched by adding 1% acetic acid (375 μL).
Next, acetone (1.5 mL) was added to the reaction and the samples were stored at
–20 °C for 1 hour to precipitate the AaT and buffer salts. The samples were then
centrifuged at 13, 200 RPM in an Eppendorf 5415R Benchtop centrifuge. The
supernatant was then added to a fresh Eppendorf tube and the acetone was
evaporated under reduced pressure. The resulting solid was redissolved in 1.2 mL
of water containing 0.1 % TFA. Analytical HPLC was then performed on an Agilent
1100 HPLC by injecting 100 μL on to a Phenomenex Jupiter C18 column and
running the gradient listed in Table 6-3 at a flow rate of 1 mL/min.
For KACm transfer assays to determine AaT’s tolerance to the denaturant
urea, the reactions were run identically as described above with increasing
concentrations of urea diluted from either an 8 M or 12 M stock of urea. The
acetone precipitation procedure described above was sufficient in removing the
urea from the reaction after completion. All AaT mutant transfer activities were
assessed through the above standard assay. For Acd-Ade, Val-Ade, Azf-Ade, and
Ppy-Ade transfer tests, each respective analogue was exchanged for Phe-Ade in
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the standard reaction and added to a final concentration of 1 mM. The Ppy-KACm
transfer product is previously undescribed, therefore the reaction was replicated
three times. An analytical HPLC trace for this product is observed in Figure 6-1.
The product peak containing Ppy-KACm has an average retention time of 14.49
min, compared to the KACm peak, which has a retention time of 12.46 min.
Table 6-3: Analytical HPLC gradient for purification of KACm reactions. Buffer A: Milli-Q H2O with 0.1 % TFA.
Buffer B: Acetonitrile with 0.1 % TFA.
Time (min)
0

Buffer A (%)
99

5:00

99

10:00

70

15:00

60

20:00

0

25:00

0

27:00

99

30:00

99

Expression of AaT and Mutant AaT Variants
Expression of AaT proteins was done as previously described318 with one
important change: after sonication, the lysed cells were centrifuged at lower
speeds (8,000 RPM) in a Sorvall SS34 centrifuge for 10 minutes at 4 °C. This
small, but important, modification led to more soluble AaT mutant protein yields,
as evidenced by SDS-PAGE analysis (see example SDS-PAGE in Figure 6-10).
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AaT C187A/M158A 13,200 RPM Centrifugation

AaT C187A/M158A 8,000 RPM Centrifugation
M E1

M E1 E2 E3 E4 E5 E6 E7 E8

E2

E3 E4 E5

E6

E7

E8

AaT

Figure 6-10: SDS-PAGE analysis of AaT C187A/M158A mutant purification. Lower centrifugation speeds (Right)
lead to more soluble protein, which can be purified by Ni-NTA affinity purification (AaT contains a His10 tag
for purification). Higher centrifugation speeds (left) show lower quantity of purified protein after Ni-NTA
resin purification. ‘M’ is a molecular weight marker and lanes marked ‘E’ correspond to Ni-NTA resin
318
elutions as described in the purification protocol from Wagner et al.

Expression and Purification of CaM77-148 and Cys77-CaM77-148
E. coli BL21-Gold cells were transformed with the pET15b-H10-CaM78-149
that encodes ampicillin (Amp) resistance. Cells were grown on LB-Agar plates with
ampicillin (100 μM) and single colonies were picked and grown in a 5 mL LB-Amp
(100 μg/mL) starter culture at 37 °C for 12 hours. A secondary culture of 1 L of
terrific broth media was inoculated with 5 mL of the starter culture and grown at 37
°C until OD600 = 0.8 at which point the culture was inoculated with 1 mL of 1 M
isopropyl β-D-1-thiogalactopyranoside (IPTG) to a final concentration of 1 mM. The
culture was then grown at 25 °C, shaking at 225 rpm for 16 hours. After incubation,
cells were pelleted at 5,000 RPM using a GS3 rotor and Sorvall RC-5 centrifuge
for 10 minutes at 4 °C. The supernatant was discarded and the pellet was
resuspended in 20 mL of lysis buffer: one Roche Boehringer Mannheim complete,
mini, EDTA-free, protease inhibitor cocktail tablet dissolved in 20 mM Tris pH 8.0.
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The resuspended cells were lysed on ice using sonication (amplitude 30, 1 second
on, 1 second off; 2 minute total cycle). The resulting solution was centrifuged at
13,000 RPM in a sorvall ss34 rotor for 20 minutes at 4 °C. The supernatant was
incubated with Nickel-NTA resin (column volume = 3-4 mL) for 1-2 h on ice. The
slurry was loaded into a fritted column and the liquid solution allowed to flow
through. The resin was washed in 3 column volumes of four wash buffers, each
with increasing imidazole content (10 mM, 25 mM, 50 mM) in 20 mM Tris pH 8.0.
Then the bound protein was eluted over 8 fractions (2 mL each) in 250 mM
Imidazole, 20 mM Tris pH 8.0. The eluent was dialyzed against Factor Xa buffer
(50 mM Tris, 100 mM NaCl, 5 mM CaCl2 pH 8.0) overnight before being treated
with 10 μL of Factor Xa Protease (Hematologics, Seattle, WA). This proteolysis
Cleavage of the H10-IEGR purification was incubated at 37 °C for 24 hours. The
resulting solution was dialyzed against 20 mM Tris pH 8.0 for 12 hours before
being filtered and purified via anion exchange chromatography on a AKTA FPLC
system. Fractions containing the mass of CaM78-149 (confirmed by MALDI-TOF
mass spectrometry) were pooled and dialyzed against water before being frozen
and lyophilized for use in AaT-Hcm transfer reactions.

Expression and Purification of CaM1-71-GyrA-CBD
CaM1-71-GyrA-CBD was transformed into BL21-Gold (DE3) E. coli cells and
grown on an LB-agar plate with ampicillin (100 μg/mL). A single colony was picked
and grown in liquid LB media (5 mL, 100 μg/mL ampicillin) with shaking (250 RPM)
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at 37 °C until saturation. The primary culture was then added to a secondary
culture of sterile Terrific Broth media299 (1 L, 100 μg/mL ampicillin) and grown at
37 °C, shaking (250 RPM) until OD600= 0.8-1.0 (3-4 h). IPTG was then added (final
concentration = 1 mM) and the temperature and shaking speed were reduced to
25 °C and 225 RPM. The culture was allowed to grow for 16 h. Cells were
harvested by centrifugation at 5,000 RPM in GS3 rotor and Sorvall RC-5 centrifuge
for 10 min at 4 °C. The supernatant was discarded and the cell pellet was
resuspended in 10 mL lysis buffer (20 mM Tris, pH 8.0) containing one broad
spectrum protease inhibitor tablet. Resuspended cells were then lysed on ice by
sonication (30 amps power, 1 second pulse, 1 second rest, 2 minute total
sonication time) and spun down at 13,000 RPM in an SS-34 rotor in a Sorvall RC5 centrifuge for 15 min at 4 °C. The supernatant was collected and incubated with
chitin beads (5 mL column volume, CV) for 1 h on ice with shaking. The slurry was
then added to a fritted column and the liquid was allowed to flow through. The
beads were washed with 10 x CV of 20 mM Tris pH 8.0. Intein cleavage buffer (20
mM Tris, 0.5 NaCl, 200 mM MESNa, pH 7.5, 10 mL) was then added to the beads
and incubated on a rotisserie at room temperature for 16 h. The column was then
drained and the flow through collected. The eluent was dialyzed against 20 mM
Tris, pH 8.0 to remove any excess MES and purified using a HiTrap Q column on
a 120 min NaCl gradient (0.1 M to 0.8 M NaCl in 20 mM Tris, pH 8.0). The protein
was pure after one round of FPLC purification (see MALDI MS in Table 6-6) and
was dialyzed against Milli-Q water overnight at 4 °C before being frozen in liquid
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nitrogen and lyophilized to white powder. The total isolated yield was ~8 mg per L
of culture.
Solid Phase Peptide Synthesis of Hcy72-CaM72-75-N2H3
2-chlorotrityl resin (100-200 mesh, 50 μmol scale) was swelled in DMF (4
mL, 30 minutes) while stirring. Treatment with hydrazine hydrate in DMF (5 % v/v)
using the protocol set forth by Zheng et al. yielded the hydrazine resin used in the
peptide synthesis described here.165 Fmoc-Lys(Boc)-OH (5 equivalents), 2-(1Hbenotriazol-1-yl)-1,1,3,3-tetramethyluronium
equivalents),

diisopropylethylamine

hexafluorophosphate

(DIPEA;

10

equivalents)

(HBTU;
in

5

N,N-

dimethylformamide (DMF; 4 mL) was added to the resin. This solution was allowed
to stir for 45 minutes at room temperature. After completion of the coupling
reaction, the vessel was drained and the resin was washed with DMF (2 x 2 mL),
then the coupling was repeated once more. After draining and washing the resin
again, the Fmoc protecting group was removed by treatment with a 20% v/v
solution of piperidine in DMF. The vessel was then drained and the resin was
washed with DMF (2 x 2 mL), dichloromethane (2 x 2 mL), and DMF again (1 x 4
mL). All subsequent Fmoc deprotections were performed using this method. All
subsequent amino acid (Fmoc-Aa-OH) coupling reactions were performed by
using a solution of Fmoc-Aa-OH (5 equivalents), 2-(1H-benotriazol-1-yl)-1,1,3,3tetramethyluronium hexafluorophosphate (HBTU; 5 equivalents), and DIPEA (10
equivalents) in DMF (2 mL), with the exception of Fmoc-Hcy(Trt)-OH, for which 3
equivalents of amino acid and HBTU are used. After the last Fmoc group was
removed, the resin was washed with DMF, followed by DCM (2 x 4 mL each). The
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resin was then dried for 30 minutes under vacuum. A cleavage cocktail (8 mL total
volume) was prepared with 90:5:5 of TFA:TIPS:H2O. This was added to the resin
and allowed to stir at RT for 1 hour before being drained and collected. DCM (3
mL) was added to the resin to wash out any remaining peptide and the collected
solution was dried under rotary evaporation. The crude peptide product was then
precipitated by adding cold diethyl ether (15 mL) and vortexing vigorously. The
precipitate was pelleted by centrifugation and the ether supernatant was
discarded. The resulting precipitate was dried and stored at -20 °C until HPLC
purification could proceed.
Table 6-4: Preparatory HPLC gradient for purification of Hcy72-CaM72-75-N2H3. Buffer A: Milli-Q H2O with 0.1
% TFA. Buffer B: Acetonitrile with 0.1 % TFA.
Time (min)
0

Buffer A (%)
98

4:00

98

25:00

60

27:00

2

32:00

2

35:00

98

37:00

98

HPLC Purification of Hcy72-CaM72-75-N2H3
The crude precipitate from above was dissolved in 50 % v/v acetonitrile in
H2O with 0.1 % TFA (10 mL). Purification was performed by reverse phase HPLC
on a Waters Sunfire Preparatory C18 column (12 mL/min flow rate) using the
binary gradient described in Table 6-4. Fractions were collected and the product
peak identified by LC-MS (see Table 6-6). The collected fractions were frozen in
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liquid N2 and lyophilized to white powder for use in CaM NCL experiments as
follows. The isolated yield of this peptide synthesis was 94.6% (23.9 mg).

Native Chemical Ligation Reaction of CaM1-71-MES with Hcy72-CaM72-75-N2H3
Ligation buffer (2 mL) was prepared fresh prior to each reaction by adding
NaH2PO4 (0.1 M), Gdn•HCl (6 M), TCEP•HCl (20 mM) and thiophenol (2% v/v) to
1.7 mL of water and adjusting the pH to 7.2, followed by the volume to 2 mL.
Ligation buffer (460 μL) was added to an eppendorf tube containing CaM1-71-MES
(17.4 mg, 2.18 μmol) and the tube was vortexed to ensure all dried protein
dissolved. This solution was then incubated at RT for 5 min to allow the more
electrophilic CaM1-134-SPh to form by transthioesterification of the MES thioester
with thiophenol. The solution containing CaM1-71-SPh was then added to an
Eppendorf tube containing Hcy72-CaM72-75-N2H3 (5 equiv) and the reaction was
incubated at 37 °C with constant shaking (600 RPM) for 20 h. The reaction was
monitored by MALDI for product formation (see Table 6-6). It should be noted that
as the reaction proceeds, significant amounts of CaM1-71-OH byproduct forms as
a result of the hydrolysis of the thioester. At reaction completion, the solution was
diluted to 2 mL with Milli-Q water and dialyzed against 20 mM Tris pH 8.0 overnight
at 4 °C in preparation for FPLC purification. FPLC purification proceeded using a
HiTrap Q column and a 120 min NaCl gradient (0.1 M to 0.8 M NaCl in 20 mM Tris,
pH 8.0). This eluent was collected in 6 x 1.5 mL fractions (product presence
confirmed by MALDI-MS). The pooled fractions were dialyzed against Milli-Q water
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at 4 °C overnight before being flash frozen with liquid nitrogen and lyophilized to a
solid. Isolated yield of Hcy72-CaM1-75-N2H3 is 33.0% (0.72 μmol).

Conversion of Hcy72-CaM1-75-N2H3 to Hcy72-CaM1-75-MPAA
The following protocol is modified from Zheng et al.165 The Eppendorf tube
containing dried Hcy72-CaM1-75-N2H3 (described above) had 400 μL of hydrazide
ligation buffer A (0.2 M NaH2PO4, 6 M Gdn, pH 3.0) added to it. This protein sample
was then cooled to -15 °C in a 1:3 NaCl:ice bath. A 0.5 M stock solution of sodium
nitrite was then prepared by dissolving 17.3 mg (0.25 mmol) in 500 μL of ligation
buffer A. This stock solution (14.4 μL, 10 equivalents) was then added to Hcy72CaM1-75-N2H3 to oxidize the acyl hydrazide to the acyl azide (Hcy72-CaM1-75-N3).
This mixture stirred for 15 minutes at -15 °C. In a separate Eppendorf tube, 24.2
mg of 4-mercaptophenylacetic acid (MPAA, 200 equivalents) were dissolved in
400 μL of hydrazide ligation buffer B (200 mM NaH2PO4, 6.0 M guanidinium
hydrochloride, pH 6.7). This mixture was then added to Hcy72-CaM1-75-N3 and the
pH was adjusted to 6.9 using 1 M NaOH. The reaction was then stirred for 2 hours
and monitored by MALDI MS. After 1 hour, the reaction was quenched with 1 mL
of water and 5 μL of TCEP BondBreaker™, before being dialyzed against 2 L of
water 2 x 2 hours at 4 °C. The resulting dialysate was flash frozen in liquid N2 and
lyophilized to a brown powder for use in the ligation reactions with Hcm76-CaM76148.
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AaT Transfer of Hcm to CaM77-148
An example set of reaction conditions, based on previously published
conditions, with small modifications were performed as follows.195 Four reactions,
each using an aliquot (1.2 mg) of CaM77-148, were intiated by mixing each reagent
listed in Table 6-5 below. Stock solutions of each reagent were prepared as
previously described. A methionine synthetase containing an L13G mutation has
been previously described to aminoacylate tRNAMet from a commercially available
E. coli total tRNA to generate the Hcm-tRNA substrate used by AaT for Hcm
transfer.330 All reagents were mixed together in a 1.5 mL Eppendorf tube, with the
freshly prepared L13G synthetase and AaT added last. A final concentration of 1 M
urea was used to make the N-terminal Lys of CaM77-148 more accessible for
transfer of Hcm. The final volume of the reaction was 0.5 mL and 1x transfer buffer
is 50 mM HEPES, 150 mM KCL, 10 mM MgCl2, pH 8.0. Reactions were incubated
for 20 hours at 37 °C before being quenched by dialyzing against 20 mM Tris pH
8.0 and purified by FPLC-anion exchange over a 120 min gradient (0.1 M to 0.8 M
NaCl in 20 mM Tris, pH 8.0). The starting material CaM78-148 and product Hcm76CaM76-148 do not completely separate during FPLC purification. Therefore, product
of the transfer reaction (Hcm76-CaM76-148) that was greater than 80% pure (by
FPLC peak area and MALDI MS confirmation) was collected with CaM78-148 as an
impurity. These FPLC fractions were then dialyzed against twice against MilliQ
water (2 L) at room temperature for 2 hours. The dialysate was then flash frozen
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in liquid N2 and lyophilized to a brown powder for use in the ligation reactions with
Hcy72-CaM1-75-MPAA.
Table 6-5: Reagents and associated reaction concentrations and volumes added to the above Hcm transfer
reaction.

Reagent

Final Concentration

Volume (μL)

2.4 mg/mL

---

10x Transfer Buffer

1x

50.0

E. coli total tRNA (10 mg/mL)

2 mg/mL

100.0

ATP (50 mM, dissolved in water)

2.5 mM

25.0

Hcm (52.8 mM, dissolved in water)

1.0 mM

9.5

L13G (1.52 mg/mL)

0.1 mg/mL

32.9

AaT (.44 mg/mL)

0.1 mg/mL

113.6

Water

---

106.5

Urea (12 M)

1M

62.5

CaM 77-148

protein

Native Chemical Ligation of Cys77-CaM77-148 to Hcy72-CaM1-75-MPAA
To test ligation conditions for Hcy based NCL reactions with Hcy72-CaM1-75MPAA, the variant Cys77-CaM77-148 was used. Here, three reaction conditions were
used: ligation buffer A (0.2 M NaH2PO4, 20 mM TCEP•HCl, pH 7.3), ligation buffer
B (0.2 M NaH2PO4, 3 M Gdn•HCl, 20 mM TCEP•HCl, pH 7.3) and ligation buffer
C (0.2 M NaH2PO4, 6 M Gdn•HCl, 1 mM EDTA, 20 mM TCEP•HCl, pH 7.3). For
each reaction, an aliquot of Hcy72-CaM1-75-MPAA (1 mg) was dissolved in one of
the above buffers (136 μL). Next, 136 μL of corresponding ligation buffer was
added to an aliquot containing three equivalents of solid Cys77-CaM77-148. The two
reactants were then mixed in a single Eppendorf tube and incubated at 37 °C for
20 hours while shaking at 500 RPM. The reactions were monitored by MALDI MS
for the formation of the full-length CaM-like product (with the noted absence of
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Met78). The correct product mass (see Table 6-6) was observed in the reactions
using ligation buffer A and B from above.
Table 6-6: CaM masses calculated for each of the fragments used for NCL reactions. The full length Hcy72,76CaM1-148 product was not observed for any reaction condition.

CaM Variant

Calculated m/z [M+H]+

Observed m/z

CaM1-71-MES

7955

7977 ([M+Na] )

Hcy72-CaM72-75-N 2H3

505.65

505.44

Hcy72-CaM1-75-N 2H3

8318

8318

Hcy72-CaM1-75-MPAA

8454

8453

CaM77-148

8277

8277

Cys77-CaM77-148

8251

8251

Hcm76-CaM76-148

8440

8440

Hcy76-CaM76-148

8394

8396

Hcy72,76-CaM1-148

16679

Not Observed

ΔMet76, Hcy72, Cys77-CaM1-148

16537

16537

+

Native Chemical Ligation of Hcm76-CaM76-148 to Hcy72-CaM1-75-MPAA
NCL reactions for Hcm76-CaM76-148 ligation to Hcy72-CaM1-75-MPAA were
performed using the identical reaction conditions and stoichiometry (1:3 of Hcy72CaM1-75-MPAA to Hcm76-CaM76-148) from buffer A and buffer B conditions (see
above). It should be noted that the buffer contains TCEP, which will reduce the
Hcm residue to the active, nucleophilic Hcy residue for NCL to proceed (this
reduction confirmed by monitoring the reaction with MALDI MS; see Table 6-6).
However, under identical reaction conditions as the above Cys77-CaM77-148 ligation,
no product was formed. An increase in pH may be necessary to form more of the
nucleophilic thiolate species on Hcy for the reaction to proceed. Therefore, the
NCL reaction was set up again using buffer B with a modified pH of 7.8. Again,
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after 20 hours, no product was observed by MALDI MS, despite the reactive
species (Hcy72-CaM1-75-MPAA and Hcy76-CaM76-148) persisting in the reaction. In
an attempt to change the conformation of CaM to potentially make the reactive
sites more accessible, the reaction using buffer B were performed again, with
either 100 mM CaCl2 or 10 mM EDTA. Again, no product was detected by MALDI
MS. In a final test, buffer B had 2% v/v thiophenol added to it and the reaction was
repeated. Thophenol may be able to serve as an added catalyst for the reaction
and to suppress the hydrolysis of Hcy72-CaM1-75-MPAA. The reaction failed to yield
full-length Hcy72,76-CaM1-148, as observed by MALDI MS.
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